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Abstract 
B cells are a group of lymphocytes that contribute to the adaptive immune 
response by producing highly specific antibodies against pathogenic antigens. In 
vivo, B cells get activated when they recognise a specific antigen on the surface of 
presenting cells through their B cell receptor. Among these cells, a population of 
macrophages at the lymph node subcapsular sinus has recently emerged as a key 
player in the presentation of antigen to B cells. Following antigenic stimulation, B 
cells process and present pathogen-derived peptides to specific CD4+ T cells, what 
induces B cell proliferation and differentiation into antibody secreting cells. 
Moreover, it was recently found that an innate-like population of T cells named 
natural killer T cells could also provide cognate help to B cells in response to lipid 
antigens. 
   
The aim of this thesis is to investigate the functional role of subcapsular 
sinus macrophages and natural killer T cells in the B cell response to infectious 
pathogens. To this end, I combined a number of innovative imaging approaches 
with the generation of a new series of transgenic mouse strains and infectious 
models. I found, in short, that virus and bacteria-induced inflammation triggers a 
temporary disruption of the subcapsular sinus macrophage organisation, resulting 
in diminished antigen capture and B cell responses to secondary infections. 
Furthermore, I unveiled a new way in which iNKT cells get activated and regulate 
germinal centre responses during respiratory viral infections. These findings are 
important as they shed light on some of the regulatory mechanisms for antigen 
encounter and B cell response during infection.   
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Chapter 1. Introduction  
1.1 The immune system: past, present and future challenges 
Despite living in an environment full of potential pathogens, on only few 
occasions do we suffer relevant infectious processes; moreover, when infection 
does happen, it is usually resolved within a few days. The reason why we are 
protected from a full range of potential microbes is because of our ability to mount 
an immune response against them. Our immune system integrates mechanisms 
from both the innate and the adaptive immunity to counteract the infection process. 
Moreover, the latter generates a phenomenon called “immune memory”, which 
allows us to stay protected from future reinfections with the same pathogens for 
years, or even for life.  
 
However, the immune response has several limitations against certain 
pathogens. For example, once HIV (human immunodeficiency virus) is acquired, 
the organism is not able to eliminate it in most cases. For years, the immune 
system of the infected patient fights against HIV and their immune system 
manages to partially control the dissemination of the virus and the harmful effects 
that the virus produces. However, in the absence of antiretroviral therapy, the host 
finally succumbs and develops AIDS (acquired immune deficiency syndrome) 
(Maartens, Celum and Lewin, 2014). Moreover, humans cannot resolve infections 
with Trypanozoma cruzi, the etiologic agent of Chagas disease. Although the 
immune system manages to raise a sufficient response to control dissemination of 
the parasite, and partially control its harmful effects, affected people may die from 
heart failure after several years (Dias, 2006). Another example is infection with 
Mycobacterium tuberculosis, the causative agent of tuberculosis, which affects 10 
million people each year. Even though the immune system efficiently controls the 
course of the infection by decreasing the bacterial load in the lung parenchyma, it 
does not manage to eradicate the pathogen. If the patient subsequently suffers 
from a condition that compromises the function of the immune system, the 
tuberculosis infection will expand rapidly (Sasindran and Torrelles, 2011). 
 
22 
Currently, we have an overall picture of the physiopathology of the immune 
response during infection. However, it is undeniable that we still have much to 
understand. For instance, not much is known about the mechanisms that 
pathogens use to evade the immune response that they themselves triggered. 
Moreover, we do not know how the immune system works during co-infections with 
different pathogens or why we are more vulnerable to contracting new infections 
when there is a previous infection on going in our bodies. Furthermore, even 
though completely new subsets of innate or innate-like lymphoid cells, such as 
ILCs (innate lymphoid cells), NK (natural killer) T cells or γδ T cells, have been 
discovered in recent years, their activation processes and roles during infection are 
still far from being understood. This lack of knowledge is reflected in our incapacity 
to create therapeutic tools that could prevent certain infectious processes or 
contribute towards the eradication of infections.  
 
We have developed successful vaccines against numerous pathogens 
causing diseases like smallpox, poliomyelitis, measles, diphtheria, tetanus and 
hepatitis B, among others. Importantly, in some cases, complete eradication of the 
disease was achieved through vaccination (Table 1.1). However, we still do not 
have vaccines against the great majority of parasitic diseases such as malaria, 
leishmaniasis or Chagas disease or for the prevention and treatment of HIV 
infection. Moreover, even though seasonal vaccines against influenza protect us 
against circulating viral strains for a few years, a universal flu vaccine has still not 
been generated. In consequence, every year around 1 million people die because 
of parasitic infections, 1 to 2 million people die of AIDS and 500,000 people die 
from influenza infection (Pica and Palese, 2013, Maartens, Celum and Lewin, 
2014, Sacks, 2014). It is therefore essential to understand how the immune system 
operates during infection to generate new therapeutic tools to protect against 
pathogenic threats.       
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Table 1.1 Estimated annual morbidity in the United States pre and post- 
vaccination era.  
 
Disease Pre-vaccine era 2010 
Smallpox 29,005 0 
Diphtheria 21,053 0 
Polio 16,316 0 
Rubella 47,745 4 
Tetanus 580 14 
Measles 530,217 61 
Mumps 162,344 982 
Hepatitis B 66,232 11,269 
Pertussis 200,752 13,506 
Chickenpox 4,085,120 449,363 
Adapted from Centres for Disease, Control and Prevention. 
 
1.2 Innate and adaptive immunity 
Immunity can generally be defined as the capacity to successfully prevent or 
overcome a pathogenic infection. This is dependent on the ability of immune cells 
to recognise foreign threats though the expression of specialised receptors. 
Depending on the type of the receptors they express, immune cells have been 
historically divided into two groups: innate immunity and adaptive immunity 
(Iwasaki and Medzhitov, 2010).  
1.2.1 Innate immunity 
The innate immune system is our first line of defence and it provides 
immediate protection against infection. The innate branch is mainly composed of 
the body surface barriers and a broad range of leukocytes. The surface barriers 
include the skin and other epithelia such as the respiratory, digestive and 
genitourinary tracts. As most infective pathogens enter the organism through these 
surfaces, these epithelia represent a protective, constitutive, efficient and common 
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physical barrier to prevent infection. If these barriers are breached, the innate 
immune system will respond by activating different mechanisms according to the 
infectious pathogen. Broadly speaking, neutrophils and macrophages are essential 
for fighting extracellular bacteria; plasmacytoid DCs (dendritic cells) and NK cells 
are important during viral infection; and mast cells, basophils and eosinophils are 
key during helminthic parasite infection. These innate immune cells participate in 
the immune response by exerting antimicrobial activity (phagocytosis of pathogens 
and production of antimicrobial peptides) and by producing chemical mediators 
(chemokines and cytokines) that recruit immune cells to sites of infection and 
orientate the course of the innate and adaptive immune response (Charles A 
Janeway et al., 2001) . 
 
All the cells of the innate branch of the immune system share a conserved 
tool to recognise microorganisms: the PRRs (pattern recognition receptors). PRRs 
are germline-encoded receptors that recognise PAMPs (pathogen associated 
molecular patterns). These PAMPs are conserved molecular sequences present in 
microorganisms, but not in the host, which are essential for their survival and 
pathogenicity. For instance, cell wall components or even genetic material can be 
detected by PRRs. PRRs can be classified in five different families: 1) TLRs (Toll-
like receptors), 2) NLRs (NOD (nucleotide binding and oligomerisation domain)-like 
receptors), 3) RLRs (RIG (retinoic acid-inducible gene)-I-like receptors), 4) CLRs 
(C-type lectin receptors) and 5) SRs (scavenger receptors) (Kumar, Kawai and 
Akira, 2011).  
 
TLRs, which are the most characterised PRRs, were first identified in 
Drosophila and so far 13 members of this family have been described in mammals. 
They are expressed on the plasmatic and endosomal membranes of the cells and 
they contain an extracellular domain in charge of recognising the PAMPs and an 
intracellular domain involved in signalling transduction. The cytoplasmic domain of 
the TLRs is similar to that expressed by the family of IL (interleukin)-1 receptors, IL-
1R and IL-18R, and is called TIR (Toll-IL-1 receptor). Signalling through TLRs upon 
recognition of their ligands recruits MyD88 (myeloid differentiation primary 
response protein 88) and/or TRIF (TIR domain-containing adaptor protein-inducing 
IFN (intereferon)-β) adaptors to the intracellular domain (Figure 1.1A). This 
25 
recruitment induces signalling through NF-κB (nuclear factor kappa-light-chain-
enhancer of activated B cells) and the production of cytokines, chemokines and 
antimicrobial molecules. Three of the most studied TLRs are TLR4, which 
recognises LPS (lipopolysaccharide) present in the surface of gram-negative 
bacteria, TLR9, which recognises microbial nucleic acids rich in unmethylated CpG 
sequences and TLR7, which recognises viral single-stranded RNAs (ribonucleic 
acids) (Kawai and Akira, 2011).  
 
NLRs are the cytoplasmic counterpart of TLRs and so far 23 members have 
been described. They recognise microbial components that have gained access to 
the cytoplasm and also cell damage signals. NLRs contain three different domains: 
a C-terminal domain able to recognise PAMPs, a central domain that binds 
nucleotides and regulates auto-oligomerisation of the receptors following activation, 
and a N-terminal effector domain, in charge of recruiting effector proteins. 
Signalling through NLRs induces auto-oligomerisation and the formation of protein 
complexes that act as scaffolds to recruit the adaptor protein ASC (apoptosis-
associated speck-like protein containing a CARD (caspase activation and 
recruitment domain)) and Caspase-1. These high molecular weight complexes 
containing NLRs, ASC and Caspase-1 are called inflammasomes. Once 
inflammasomes are assembled, Caspase-1 is activated and mediates the cleavage 
of pro-IL-1β and pro-IL-18 to their active forms. These cytokines are then released 
from the cell to mediate the initiation of the inflammatory response (Figure 1.1B) 
(Chen et al., 2009).  
 
In most cases, the innate immunity manages to eradicate the emerging 
infection. However, if not, the innate immune system will contain the infection until 
the mechanisms of the adaptive immunity are operative; a process that can take up 
to a week.  
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Figure 1.1 Schematic structures of Toll and NOD-like receptors 
(A) General structure of a TLR showing the extracellular domain containing LRRs 
(leucine rich repetitive motifs) that recognise PAMPs, a transmembrane domain 
and an intracellular domain called TIR that mediates TLR signalling. TLR activation 
induces recruitment of the adaptor molecules MyD88 and/or TRIF. (B) Structure of 
a NOD like receptor containing a C-terminal domain containing LRRs that 
recognise PAMPs, a central NBD (nucleotide binding domain) that mediates 
receptor oligomerisation and the N-terminal effector domain that recruits the ASC 
adaptor and Caspase-1 to form the inflammasome after activation. The assembly 
of the inflammasome induces the cleavage of pro-IL-1β and pro-IL-18 to active IL-
1β and IL-18.   
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1.2.2 Adaptive immunity 
The adaptive immune system is our second line of defence and unlike innate 
immunity, it is highly specific and generates immune memory, providing long-
lasting protection from future re-infections with the same pathogen. The cells that 
carry out the adaptive immune response are the white blood cells known as 
lymphocytes, of which there are two main types: B cells and T cells. B cells 
mediate the humoral response and T cells lead the cell-mediated response. In 
humoral immunity, B cells produce specific antibodies against infectious pathogens 
to inactivate them and mediate their clearance. In contrast, in cell-mediated 
immunity, T cells produce inflammatory cytokines and enable the destruction of 
infected cells (Iwasaki and Medzhitov, 2010).  
 
B cells and T cells express pathogen-specific receptors generated de novo 
during the lifetime of the host. These receptors, known as the BCR (B cell receptor) 
and the TCR (T cell receptor), recognise particular motifs present in the pathogens 
known as antigens. While B cells recognise antigens in their native form, T cells 
recognise antigen-derived peptides in the context of MHC (major histocompatibility 
complex) molecules in the surface of other immune cells (Janeway et al., 2001).  
 
The BCR comprises a membrane-bound Ig (immunoglobulin), which 
associates with the signalling components Igα and Igβ  (also known as CD79A and 
CD79B) to form a BCR complex. Four proteins constitute the membrane-bound Ig: 
two identical copies of a heavy chain and two identical copies of a light chain, all 
covalently linked through disulphide bonds. The Ig domains closest to the N-
terminal, from both heavy and light chains, are known as the variable regions (VH 
and VL respectively). Both VH and VL contribute to the antigen-binding region, which 
defines the binding specificity of the BCR. The remaining immunoglobulin domains 
of the heavy and light chains are known as the constant regions (CH and CL 
respectively) (Figure 1.2A). There are two different types of light chains called 
kappa (κ) and lambda (λ) and five different types of heavy chains γ, δ, α, µ and ε 
that define the different classes of immunoglobulins: IgG, IgD, IgA, IgM and IgE 
(Harwood and Batista, 2009).  
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The TCR is formed by two different protein chains anchored to the 
membrane. There are two main different varieties of TCR: one is formed by an α 
and a β chain (TCR αβ), present in most T cells, and one by a γ and a δ chain 
(TCR γδ) present in a minor population of T cells known as γδ T cells. The TCR 
chains also contain variable regions (Vα and Vβ or Vγ and Vδ) that determine the 
antigen-binding site, and constant regions (Cα and Cβ or Cγ and Cδ), which are 
conserved in the different individual T cells. The TCR chains are bound by 
disulphide bonds. The TCR is associated with the CD3 complex, which controls 
signal transduction after antigen recognition and assembly of the TCR. The CD3 
complex is formed by a CD3ε chain in a heterodimer with CD3γ or CD3δ 
associated, along with the TCR, with a fourth component known as the ζ chain 
(Wucherpfennig et al., 2010) (Figure 1.2B).  
 
 Importantly, both the BCR and TCR are not genetically pre-determined as 
are PRRs, rather, they arise by random rearrangement of genetic segments; a 
mechanism that allows a small number of genes to generate a vast number of 
antigen receptors uniquely expressed on each individual lymphocyte (Iwasaki and 
Medzhitov, 2010). 
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Figure 1.2 Structures of a BCR and a TCRαβ complex 
Schematic diagrams of a BCR and a TCRαβ complex. (A) The BCR is composed 
by a membrane-bound Ig and the signalling components Igα  and Igβ. The 
membrane-bound Ig contains two identical heavy chains and two identical light 
chains bound by disulphide bonds. (B) The TCRαβ is composed by two different 
chains named TCRα and TCRβ bound by disulphide bonds and the signalling 
complex CD3. Both the BCR and TCR have variable regions controlling antigen 
recognition, and constant regions that remain conserved among the different 
lymphocytes. 
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As thousands of antigens exist in the microbial world, we need many different 
B cell and T cell clones to recognise them. This implies that only 1 out of 105 or 106 
lymphocytes in our body will be specific for a certain antigen (Moon et al., 2007). 
This strategy gives rise to two different problems: firstly, the probability that such a 
reduced number of lymphocytes would encounter a specific antigen in the body just 
by random search is quite remote, and secondly, that even if the encounter 
happened, this reduced number of lymphocytes would not be able to mediate an 
efficient antimicrobial response against millions of microorganisms and infected 
cells. Interestingly, adaptive immunity has managed to solve these central 
problems by restricting the area of antigen encounter and developing fast 
proliferation of specific lymphocytes. In order to encounter specific antigens, naïve 
lymphocytes do not have to patrol for antigens around the whole organism but only 
in specialised regions called secondary lymphoid organs, to which all the 
pathogens that have crossed the natural barriers of our body are drained. Moreover, 
the B cells and T cells that recognise these antigens undergo a process called 
clonal expansion that rapidly generates thousands of lymphocytes with identical 
antigen specificity. Once expanded, most of the specific lymphocytes will mediate 
effector functions to clear the pathogen and infected cells and a minor fraction will 
differentiate into memory cells to mediate a fast response against future 
reinfections with the same pathogen. These factors together; the recirculation of B 
and T cells though secondary lymphoid organs in search of antigen, the clonal 
expansion and the development of immune memory, make adaptive immunity a 
unique and effective system to control and clear pathogens during infection and 
avoid future challenges with similar pathogens (Janeway et al., 2001). 
 
The activation of the adaptive immune system is highly reliant on innate 
immunity. During an infection, DCs and macrophages are in charge of presenting 
pathogens to B cells and T cells through a process known as antigen presentation. 
DCs, which are mainly located in the body surface barriers such as the skin and 
other epithelia, capture pathogens in the periphery and migrate to secondary 
lymphoid organs (Randolph, Angeli and Swartz, 2005). Once there, they present 
captured pathogens to specific B cells and T cells to mediate their activation. 
Moreover, as explained later in more detail, a population of macrophages in the 
border of secondary lymphoid organs also mediates the retention of pathogens and 
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their presentation to specific B cells (Carrasco and Batista, 2007, Junt et al., 2007, 
Phan et al., 2007). Therefore, innate immunity is not only foremost in containing the 
nascent infection but also in control of activating the specific mechanisms of 
adaptive immunity. 
 
1.2.3 Innate-like lymphocytes: the inbetweeners 
Interestingly, not all B cells and T cells behave according to the simplified 
schema mentioned above. There are some subsets of lymphocytes known as 
innate B cells and T cells that bear certain characteristics resembling those of 
innate immunity. Unlike conventional lymphocytes, innate B cells and T cells 
possess a relatively restricted repertoire of antigen receptors and are enriched in 
mucosal tissues, where pathogens are first encountered. Moreover, they rapidly 
respond after infection by secreting natural antibodies, cytokines and cytotoxic 
effectors (Lanier, 2013).   
   
B cells with “innate-like” functions include B-1 cells, localised at epithelial 
barriers and peritoneal and pleural cavities, and marginal zone B cells, which are a 
sessile population found exclusively in the spleen. They differ from the conventional 
B cells because of a more restricted BCR repertoire strongly biased towards the 
recognition of pathogen-associated repetitive antigens. Moreover, they express 
high levels of TLRs, allowing them to be activated by a broad array of microbial 
ligands, and they can respond independently of co-stimulatory signals, in a manner 
reminiscent of innate immune cells. These B cell populations make so-called 
natural antibodies that recognise conserved features of bacterial carbohydrates 
and phospholipids. Although natural antibodies often have a lower affinity than 
antibodies generated by conventional B cells, they can protect the host against 
bacterial pathogens soon after infection (Cerutti, Cols and Puga, 2013).  
 
T cell populations also include subsets with innate-like properties: NKT cells, 
γδ T cells and MAIT (mucosa-associated invariant T) cells. NKT cells express a αβ 
TCR that preferentially uses a single TCRα gene and a very restricted set of TCRβ 
genes. Unlike conventional T cells, which recognise peptide antigens bound to 
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MHC molecules, NKT cells recognise lipids displayed on CD1d molecules. NKT 
cells produce cytokines more rapidly than conventional naïve T cells and do not 
possess memory after their encounter with an antigen (Brennan, Brigl and Brenner, 
2013). MAIT cells also have restricted TCR chain usage and they recognise 
riboflavin metabolites from bacteria and fungi presented on the MHC-related 
molecule MR1 (Kjer-Nielsen et al., 2012). MAIT cells are preferentially localised in 
mucosal tissues and respond to microbial infection by rapidly producing cytokines 
and cytotoxic effectors (Kurioka et al., 2015). γδ T cells constitute another 
population of T cells with innate properties. These T cells, express an atypical TCR 
composed of two chains, TCRγ and TCRδ, which differ from the TCRα and TCRβ 
chains comprising the canonical TCR. They have a very limited receptor repertoire: 
all peripheral γδ T cells express the same TCRγ chain combined with TCRδ chains 
that differ depending on the tissue localisation. γδ T cells can recognise a wide 
range of antigens, from phospho-antigens to molecules expressed on stressed 
cells, although the ligands for most γδ T cells remain elusive. When activated, γδ T 
cells display rapid secretion of cytokines and cytolytic activity, in part due to their 
pre-activated phenotype (Vantourout and Hayday, 2013). In the case of MAIT cells 
and γδ T cells, it is not clear if they can induce immunological memory.  
 
More than two thousand years have passed since Thucydides first wrote 
about immunity in reference to patients who had survived the plague of Athens and 
who could nurse the sick people without contracting the illness a second time 
(Habs, 1982). Yet we are still attempting today to fully understand the complexity of 
our immune system. Expanding our knowledge in this field is key for the 
development of better vaccines to protect us against potential pathogenic threats. 
Most currently available vaccines have been empirically designed. However, in 
most cases the success of these vaccines has been associated with the induction 
of high-titres of antibodies in vaccinated people (Siegrist, 2008). Therefore, to 
improve the rational design of future vaccines it is essential to understand how B 
cells, the immune cells producing these antibodies, work in vivo during pathogenic 
challenges. During my thesis I have focussed on discovering how different cells 
from the innate immune system assist B cells to develop a robust response during 
infection.  
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1.3 B cell ontogeny and distribution 
B cells, as with other cells of the immune system, originate in the bone 
marrow from a common precursor. During development, B cells acquire their 
antigen receptor, the BCR, which is necessary for the recognition of potential 
pathogens. As each B cell expresses a particular BCR with a unique specificity, the 
B cell repertoire of each individual allows the mounting of an adaptive immune 
response to the thousands of different antigens present in the environment.  
 
1.3.1 B cell development 
B cells originate in the bone marrow from HSCs (hematopoietic stem cells). 
These HSCs generate two different progenitors: a myeloid progenitor, that gives 
rise to myeloid cells, such as DCs and macrophages, and a CLP (common 
lymphoid progenitor) that gives rise to B cells and T cells (Kondo, Weissman and 
Akashi, 1997). The development of B cells starts in the bone marrow but the 
maturation process culminates in the spleen. B cell development occurs through 
several stages, each stage representing a change in the genome content of the 
antibody loci. In the VH region there are three groups of genetic segments termed V 
(variable), D (diverse) and J (joining) that randomly recombine in a process known 
as VDJ recombination to produce a unique variable domain in the immunoglobulin 
of each individual B cell. Similar rearrangements occur in the VL region, except that 
there are only two groups of genetic segments involved: V and J (Brack et al., 
1978). Both VDJ and VJ recombination are dependent on RAGs (recombination 
activating genes), which collaborate in the insertion of DNA (deoxyribonucleic acid) 
double-strand breaks at consensus sequences to allow gene segment shuffling and 
re-joining (Schatz, Oettinger and Baltimore, 1989, Agrawal and Schatz, 1997). The 
random rearrangement of gene segments in the heavy and light chain loci ensures 
combinatorial diversity of the antigen receptor. 
     
The different stages of B cell development are shown in Figure 1.3. In short, 
commitment to the B cell fate begins at the pre-pro-B cells stage. These cells 
express B220 but are still CD19 negative (Coffman, 1983). Eventually, 
development progresses to the pro-B cell stage, where the heavy chain is 
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rearranged. The VH region is assembled by joining together a single copy from 
each of the V, D and J gene segments from the many found at the heavy chain 
locus (Brack et al., 1978). A correctly assembled VH exon is co-transcribed with CH 
gene segments to form a complete heavy chain. The heavy chain can pair up with 
a surrogate light chain and the Igα and Igβ proteins to form a pre-BCR complex. 
Expression of the pre-BCR is a hallmark of the pre-B cell stage and provides the 
first crucial checkpoint for B cell development. Cells expressing a non-functional 
pre-BCR will be eliminated. Signalling competent pre-BCRs will instead trigger cell 
division and inhibit any further rearrangement of the heavy chain locus on the 
homologous chromosome, a process known as allelic exclusion (Löffert et al., 
1996). Pre-BCR signalling is also important for the initiation for the assembly of the 
light chain. The VL exon is generated by joining together a single V and single J 
segment from the many ones found at the light chain loci. A correctly assembled VL 
exon can be co-transcribed with a CL exon to form a complete light chain, which 
can replace the surrogate one to form a functional BCR (Arakawa, Takeda and 
Takemori, 1996). Cµ is the first CH to be used for the assembly of the heavy chain, 
thus the first BCR expressed by immature B cells is termed IgM. The requirement 
for the signalling competence of IgM provides the second checkpoint in B cell 
development. Tonic BCR signalling is required as proof of functionality and for 
allelic exclusion at the light chain locus. However, very low or strong intensity 
signalling in the B cells induces anergy, a state of long-lasting unresponsiveness, 
or clonal deletion, cell death by apoptosis. This process ensures that only 
functional and non-auto reactive B cells leave the bone marrow to the spleen 
(Nemazee and Buerki, 1989, Goodnow, 1992, Wardemann et al., 2003).  
 
Once in the spleen, immature B cells express a second BCR termed IgD to 
complete maturation. Both IgM and IgD share the same variable region but 
different CH. Finally, naïve mature B cells will recirculate through the lymph nodes, 
spleen and bone marrow in search of cognate antigen (Loder et al., 1999). 
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Figure 1.3 B cell development 
Scheme displaying the different stages of B cell development in the bone marrow 
and the maturation process in the spleen. The rearrangement of the heavy and 
light chains and the expression of Ig in the membrane are detailed for each 
differentiation step.  
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1.3.2 B cells in secondary lymphoid organs 
Mature B cells are mainly found in secondary lymphoid organs, where all the 
pathogens that have managed to cross the natural barriers of the body are drained. 
These organs include LNs (lymph nodes), spleen, Payer’s patches and tonsils. 
Secondary lymphoid organs are essential for the capture of pathogens and to 
prevent their systemic spreading, a phenomenon that increases the likelihood of 
antigen encounter by lymphocytes. Secondary lymphoid organs possess a highly 
organised microarchitecture, which is essential for the compartmentalisation of 
numerous cellular interactions during an immune response (Scandella et al., 2008). 
Their importance in coordinating immune responses is evident from the severe 
impairment in lymphocyte activation in alymphoplastic and asplenic mice (Karrer, 
Althage and Odermatt, 1997). In my thesis I will focus on the regulation of the B cell 
response during infection in draining LNs, so I will describe their architecture here 
in more detail. 
 
LNs are specialised rounded structures strategically distributed throughout 
the lymphatic system to enable antigenic sampling of lymphatic fluid. LNs are 
protected by an external collagen capsule covering the whole organ and 
immediately below the capsule, there is a lymphatic lumen termed the subcapsular 
sinus (SCS) where all the afferent lymphatics converge (Batista and Harwood, 
2009). The ceiling and floor of the SCS are lined by LECs (lymphatic endothelial 
cells) (Ulvmar et al., 2014). Directly beneath the SCS there is a macrophage-rich 
layer of cells expressing high levels of the sialoadhesin molecule CD169, and 
which control the capture of incoming pathogens (Carrasco and Batista, 2007, Junt 
et al., 2007, Phan et al., 2007). This macrophage layer surrounds the B cell follicles 
or cortex, in which B-lymphocytes reside. These follicles are also rich in FDCs 
(follicular DCs), which are stromal cells involved in the presentation of unprocessed 
antigen and the production of the chemokine CXCL-13 (Heesters, Myers and 
Carroll, 2014). CXCL-13 controls the organisation of the follicles through interaction 
with the receptor CXCR-5 expressed by follicular B cells (Cyster et al., 2000). 
Between the different B cell follicles, we can find extensions of the lymphatic 
system known as the cortical sinus that allows the lymphatic fluid to pass between 
the follicles. These inter-follicular areas are populated by a network of spatially 
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prepositioned innate effector cells, such as NK cells, γδ T cells, NKT cells and 
innate-like CD8+ T cells that can rapidly receive inflammatory signals from CD169+ 
macrophages to initiate their activation (Kastenmüller et al., 2012) (Figure 1.4).   
 
Adjacent to the B cell follicles we find the T cell zone or paracortex, where T 
cells are mainly located. The T cell area is also rich in antigen presenting cells 
(mainly DCs), HEVs (high-endothelial venules) and a conduit network surrounded 
by FRCs (fibroblastic reticular cells). The HEV network is composed of specialised 
capillaries that continuously supply the LN with lymphocytes and antigen 
presenting cells from the periphery (HE, 1985). The FRC network is a group of 
stromal cells that produce and surround collagen-rich reticular fibres. This fibrous 
network acts as a conduit system to transport low molecular mass molecules, such 
as cytokines and chemokines, from the SCS to the T cell zones and HEVs (Gretz, 
Anderson and Shaw, 1997). Moreover, they produce high levels of the chemokines 
CCL19 and CCL21, which attract peripheral dendritic cells and B cells to the T cell 
area of the LNs through interaction with the receptor CCR7 (Ohl et al., 2003). 
Importantly, the levels of CCR7 in peripheral DCs and B cells increase after the 
encounter antigen, a process that is necessary for them to relocate to the T cell 
zone (Förster, Davalos-Misslitz and Rot, 2008) (Figure 1.4).   
 
Finally, the medulla is the innermost area of the LN and it is where the 
efferent lymphatic vessels originate. It contains both B cells and T cells organised 
in medullary cords, and is also rich in DC and macrophages. This area contains 
extra follicular plasma cells, which produce the first wave of antibodies after antigen 
encounter (Batista and Harwood, 2009)  (Figure 1.4).   
 
LNs constantly receive lymphatic fluid composed of blood plasma, 
chemokines, cytokines and antigens that have been collected from the body. 
Lymph enters the LN through the afferent lymphatic vessels and is subsequently 
filtered by the LN as it flows from the subcapsular, the cortical and the medullar 
sinuses towards the efferent lymphatic vessels. Lymphatic fluid is prevented from 
freely diffusing into the interior of the LN parenchyma by the sinus lining cells. The 
whole sinus system is interconnected and can be considered to be a unique 
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compartment, which directly links the afferent to the efferent vessels (HE, 1985, 
Lämmermann and Sixt, 2008)  (Figure 1.4).  
 
 
Figure 1.4 Schematics of a LN and mechanisms of B cell encounter of antigen 
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Cartoon representing the overall LN organisation. Lymphatic fluid enters the LNs 
through the afferent lymphatic vessels and sequentially passes through the SCS, 
the cortical sinus and the medullary sinus. It then leaves the LNs from the efferent 
lymphatics for eventual return to the general circulation. The cortical LN 
parenchyma is mainly divided into two different zones: the B cell area and the T cell 
area. (A) Soluble antigens with a molecular weight of less than 70 kDa can directly 
cross the SCS through pores where B cells can directly encounter them. (B) 
Follicular B cells recognise bigger antigens captured on the surface of SCS 
macrophages. (C) B cells entering through HEVs can recognise antigen retained 
on the surface of DCs. (D) B cells can also capture immune complexes presented 
on the surface of FDCs.   
 
1.4 B cell encounter of antigen 
During infection, B cells can rapidly detect pathogens and mount humoral 
responses to counteract them in secondary lymphoid organs. The mechanism by 
which B cells encounter antigens is dependent on their size. In the case of small 
soluble antigens, they can simply diffuse into the lymphatic tissue, where B cells 
can recognise them. However, in most cases, pathogens are bigger in size and 
presentation must be mediated by macrophages, DCs and FDCs (Batista and 
Harwood, 2009). 
1.4.1 Encountering of soluble antigen 
Once antigen has crossed the natural barriers of the body, it is rapidly 
transported to the draining LNs by the afferent lymphatic vessels. In fact, labelled 
antigen can be observed accumulating in the SCS of the LN within minutes of 
subcutaneous injection (Nossal et al., 1968). Antigens that are small enough (less 
than 70kDa) can enter the FRC system of conduits and reach the HEVs (Sixt et al., 
2005). Recently, it has been shown that this size exclusion is regulated by the 
lymphatic endothelial protein PLVAP (plasmalemma vesicle-associated protein), 
which forms diaphragms in transendothelial channels (Rantakari et al., 2015). 
Follicular B cells can extend cellular protrusions into the FRC conduits and pick up 
cognate antigens travelling within it (Roozendaal et al., 2009). However, as most B 
cells are usually located in the follicles, lymph-borne antigens might gain access to 
follicular B cells in a manner that is independent of the conduit system, which is 
predominantly present in the T cell zone.  
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Electron microscopy studies have shown the presence of pores of 
approximately 0.1 to 1 µm diameter in the SCS (CLARK, 1962, Farr, Cho and De 
Bruyn, 1980). These pores potentially allow small soluble antigens arriving through 
the lymphatic vessels to directly cross the SCS into the follicles and gain access to 
B cells. Indeed, subcutaneous injection of labelled HEL (hen egg lysosome) 
showed a rapid diffusion of HEL to the LN follicles and acquisition of antigen by 
HEL-specific B cells (Pape et al., 2007). Importantly, this process is independent of 
cell-mediated transport of antigen and does not require B cell migration. Therefore, 
small antigens, such as low-molecular weight toxins, may gain access to the B cell 
follicles directly through diffusion from pores in the SCS. However, bigger antigens 
such as viruses and bacteria are excluded from this system. This selectivity is 
extremely important, as it prevents the entry of pathogens to the LN parenchyma 
and their systemic spreading to the rest of the body (Figure 1.4A). 
 
1.4.2 Antigen presentation by SCS macrophages 
Although direct diffusion of antigen through the SCS provides one possible 
mechanism for exposing B cells to small, soluble antigens, the access of larger 
particulate antigens to the B cell follicles, such as viruses or bacteria, is limited. 
Another mechanism might therefore exist to ensure B cell access to larger antigens 
in order to develop a humoral response. In 2007, three independent studies 
described that the population of macrophages sitting on the SCS floor and in direct 
contact with the afferent lymphatic fluid on the outer side and with the B cell follicles 
on the inner side (CLARK, 1962, Farr, Cho and De Bruyn, 1980, Fossum, 1980, 
Szakal, Holmes and Tew, 1983), are essential for presentation of larger antigens to 
B cells (Carrasco and Batista, 2007, Junt et al., 2007, Phan et al., 2007). 
These studies show that soon after subcutaneous administration of antigen 
in the form of virus, bacteria or immune complexes (soluble antigens bound to 
antibodies), SCS macrophages are in control of retaining and accumulating these 
larger antigens coming through the lymphatic vessels. The mechanism by which 
these macrophages retain antigen is not clear, although it might be due to their 
high expression levels of CD169, a sialoadhesin molecule that binds the sialic 
acids present in a variety of pathogens. Moreover, SCS macrophages have limited 
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phagocytic activity, which favours the retention of unprocessed antigen on their 
surface. This low phagocytic activity is reflected in their lack or low-level expression 
of lysosomal enzymes, such as lysozyme, and phagocytosis-related receptors, 
such as mannose receptors (Phan et al., 2009). Importantly, depletion of these 
macrophages results in severely impaired antigen retention in the LNs (Junt et al., 
2007). 
The antigen retained on SCS macrophages is subsequently presented in its 
intact form to underlying follicular B cells. Antigen-specific B cells make stable cell- 
contact with these SCS macrophages and extract the antigen from their surface 
(Carrasco and Batista, 2007, Junt et al., 2007, Phan et al., 2007). After antigen 
acquisition, B cells internalise the antigen by the BCR before migrating to the B-T 
cell boundary, where they can receive specific T-cell help. Together, these studies 
provide the first clear demonstration of a role for SCS macrophages in the initiation 
of follicular B-cell responses (Figure 1.4B).  
During the writing of this thesis, an article in eLife revealed that SIGN-R1+ 
(Specific Icam-3 grabbing nonintegrin-related 1) macrophages positioned in the 
interfollicular areas are able to capture the HIV-envelope glycoprotein gp-120 from 
the lymphatic fluid and present it to specific B cells. In contrast, non-glycosylated 
antigens were not captured by these macrophages, revealing a specialised LN 
antigen delivery system for pathogen- derived glycoproteins to B cells (Park et al., 
2015). Whether, this new mechanism of antigen encounter contributes to the 
humoral response to glycoprotein-bearing pathogens remains to be elucidated.  
 
1.4.3 Antigen presentation mediated by DCs 
B cells enter the LNs through the HEVs present in the T cell area. 
Interestingly, this area is also occupied by DCs that have collected antigen from the 
periphery and have migrated to the LNs after antigenic challenge. As DCs are 
considered the most efficient cell type to present antigen to T cells (Itano et al., 
2003, Dudziak et al., 2007), it is possible that these DCs would be also able to play 
a key role in antigen presentation to B cells.  
In fact, it was shown by several groups that antigen-loaded DCs located 
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around HEVs can present intact antigen to B cells that are exiting the HEVs 
(Wykes et al., 1998, Colino, Shen and Snapper, 2002, Qi et al., 2006). Intravital 
microscopy studies showed that after administration of antigen-loaded DCs to mice, 
antigen-specific B cells exiting the HEVs show decreased motility and an increase 
residency time around DCs, where they can survey their antigenic contents (Qi et 
al., 2006). Furthermore, DCs are able to display unprocessed antigens on their 
surface due to the internalisation and recycling of antigen into non-degradative 
compartments, a process that is mediated by FcγRIIB and DC-SIGN (DC-specific 
Intercellular adhesion molecule-3-grabbing non-integrin) (Kwon et al., 2002, 
Bergtold et al., 2005). This phenomenon allows B cells to recognise antigens on 
the surface of DCs on their native conformation. The DC-mediated presentation of 
antigen to B cells in the paracortex provides a favourable environment for the 
following interaction between B cells and T cells to complete B cell activation 
(Figure 1.4C).  
 
1.4.4 Antigen presentation mediated by FDCs 
Historically, FDCs have been considered to be the cells that are mainly 
responsible for antigen presentation to B cells due to their localisation in the B cell 
follicles and their ability to retain unprocessed antigens on their surface (Tpw, 
Phipps and Mandel, 1980, Schwickert et al., 2007). FDCs mediate the retention of 
antigens in the form of immune complexes bound to proteins from the complement 
system. FDCs retain these immune complexes through the expression of Fc 
receptors that bind to the constant fragment of antibodies and complement 
receptors, which recognise the complement proteins bound to the antibodies 
(Heesters, Myers and Carroll, 2014). Despite the ability of FDCs to present 
unprocessed antigen, the importance of this pathway for the activation of naive B 
cells during the initiation of primary immune responses is not clear. This is due to 
the requirement of existing antibodies against specific pathogens to form these 
immune complexes. However, the pre-existence of natural antibodies produced by 
innate B cells might help with the rapid formation of immune complexes and the 
presentation of microbial antigens on the surface of FDCs (Heesters, Myers and 
Carroll, 2014). Immune complexes have a high-molecular weight; therefore they 
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cannot get access to the FDCs by simple diffusion through the SCS or by the 
conduit system. Instead, non-specific B cells can transport these immune 
complexes from the SCS to the FDCs through the binding to the complement 
proteins of the immune complexes (Phan et al., 2007) (Figure 1.4D). 
All these diverse mechanisms of antigen-presentation to B cells provide an 
important flexibility in the initiation of the B cell response to pathogens during an 
infection. Moreover, and as I will show in chapter 3, the fact that antigen 
presentation to B cells is mainly cell-mediated and not simply by diffusion of 
antigen, implies an extensive regulation of this process.   
 
1.5 B cell immunity 
The main function of B cells is to produce pathogen-specific antibodies to 
counteract nascent infections. The first step in the B cell activation process consists 
of the recognition of antigens through the BCR on the surface of macrophages, 
DCs or FDCs as explained in the previous section. However, recognition of antigen 
is not enough to induce proliferation and differentiation of B cells into antibody-
secreting cells. For this to happen, B cells need to receive a second activation 
signal from T cells. In the case of peptidic antigens, this help is provided by TfH 
(follicular helper) cells and in the case of lipidic antigens the help is provided by 
NKT cells.    
1.5.1 Signal 1: Antigen recognition 
Antigen recognition by B cells induces the activation of intracellular 
signalling cascades and endocytosis of the antigen, which will be then processed 
into antigen-derived molecules and presented on the surface of B cells. Signalling 
through the BCR is initiated by the crosslinking of BCR molecules by the antigen. 
This BCR aggregation induces the activation of the Src tyrosine kinase Lyn, which 
phosphorylates the Igα and Igβ chains of the BCR. This phosphorylation induces 
the recruitment of Syk kinase to the BCR, which then recruits PLC (phospholipase 
C) γ2 and the GEF (guanine nucleotide exchange factor) Vav to form the 
signalosome complex. The assembly of the signalosome is completed when PI3K 
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(phosphoinositide 3-kinase) is recruited to the BCR by the positive co-receptor 
CD19 and the B cell adaptor protein BCAP (Harwood and Batista, 2009, Castello et 
al., 2013). All these molecules trigger the most important signalling cascades 
involved in B cell activation. Vav activates the Rho GTPase Rac, which induces the 
activation of MAPK (mitogen-activated protein kinase) signalling. PI3K mediates 
the induction of the Akt survival pathway and PLCγ2 cleaves phospholipids from 
the membrane into IP3 (inositol triphosphate) and DAG (diacylglycerol). IP3 
induces the release of Ca2+ from the ER (endoplasmic reticulum) and the activation 
of the NFAT (nuclear factor of activated T-cells) pathway. DAG induces PKC 
(Protein Kinase C) activation, which results in the induction of the NF-κB pathway 
(Harwood and Batista, 2009). The onset of the different signalling pathways leads 
to the activation of several transcription factors and the transcription of genes 
involved in survival, proliferation and differentiation of B cells (Figure 1.5).  
 
Once the BCR is triggered, the BCR-antigen complex is internalised inside 
the cell and delivered to the endosomal compartments. These endosomes then 
fuse with lysosomes to form autolysosomes, where all the antigens are degraded 
into smaller molecules, a phenomenon known as antigen processing. This 
degradation is due to the progressive acidification of the vesicles and the 
consequent activation of catalytic enzymes that work under low pH conditions. 
Antigen-derived molecules are then loaded onto either MHCII molecules in the 
case of peptidic antigens, or onto CD1d molecules in the case of lipidic antigens, 
and presented on the B cell surface (Clark, Massenburg and Zhang, 2003). The 
antigen-derived peptides loaded on MHCII are then recognised by T cells, while 
antigen-derived lipids loaded on CD1d are recognised by iNKT cells. In the next 
section, I will focus on the classical B cell-TfH cell interaction during a B cell 
response and at the end I will discuss the recent discoveries regarding B cell-iNKT 
cell interactions. 
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Figure 1.5 BCR signalling 
Schematic depicting the early events in BCR signalling after antigen recognition. 
Antigen engagement leads to BCR crosslinking and phosphorylation of Igα and Igβ 
by the Src family kinase Lyn. This phosphorylation event initiates the formation of 
the signalosome, an assembly of intracellular signalling molecules, such as the 
kinase Syk, PLCγ2, PI3K and Vav. The signalosome allows the coordinated 
regulation of downstream cellular events, including signalling through secondary 
messengers such as calcium, the induction of gene expression and the 
internalisation of antigen for subsequent processing and presentation to T cells.  
 
1.5.2 Signal 2: T cell help  
As previously mentioned, after antigen recognition and internalisation 
through the BCR, B cells up regulate CCR7, which is the receptor for CCL19 and 
CCL21. These chemokines are present in high levels in the T cell zone, and induce 
the migration of activated B cells to the B-T cell border (Garside et al., 1998, Reif et 
al., 2002). There, they make contact with antigen-specific T cells that have been 
previously activated by migratory DCs. The B-T cell interaction is mediated by the T 
cell recognition of antigen-derived peptides in the context of MHCII in the surface of 
B cells (Amigorena et al., 1994). T cells then provide the second signal to B cells to 
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fully complete their activation. This interaction induces the expression of CD40 
ligand (CD40-L) on the surface of T cells, which binds to CD40 expressed on the B 
cells and induces their proliferation (Lanzavecchia, 1985). Moreover, the level of 
MHCII on B cells increases after antigen recognition, allowing more, and better, 
presentation of antigenic peptides to the T cells. The expression of the adhesion 
molecules ICAM-1 (intercellular adhesion molecule 1) and LFA-1 (lymphocyte 
function-associated antigen 1) also increases on the B cell surface after activation. 
These proteins interact with their respective partners on the T cells, favouring a 
close contact between these two cell types to ensure an effective collaboration. 
Other proteins also increase on the surface of B cells after antigen recognition, 
such as the co-stimulatory molecules CD80 and CD86, and ICOS, which interacts 
with CD28 and ICOS-L respectively on the surface of the T cells. All these 
interactions between B cells and T cells favour the proliferation and differentiation 
of B cells into antibody-secreting cells. Importantly, the nature of this interaction is 
not only mediated by membrane receptors but also by soluble factors. For example, 
the secretion of cytokines by T cells, such as IL-4 and IL-21, is essential for B cell 
differentiation into effector cells (Ma et al., 2012) (Figure 1.6).  
 
1.5.3 B cell fate  
Following B-T cell interactions in the B-T cell border, T cells decrease the 
expression of CCR7 and increase the expression of CXCR5, the receptor for 
CXCL13. This phenomenon induces T cell migration from the T cell zone to the B 
cell follicles. On the other hand, after B-T interaction, B cells have two different 
fates. Some migrate to the medullary conduits where they differentiate into extra 
follicular plasma cells and produce the first wave of antibodies of the humoral 
response; mainly low-affinity IgM (MacLennan and Toellner, 2003). However, most 
of the B cells are attracted back into the follicles where they continue to proliferate 
and to form structures known as GCs (germinal centres) (Victora and 
Nussenzweig, 2012). These B cells now divide every 6 hours to become 
centroblasts, which will constitute the dark zone of the GCs. On the other hand, the 
light zone of these structures is mainly composed of FDCs, TfH cells and B cells. 
When centroblasts stop proliferating they abandon the dark zone of the GC and 
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move to the light zone where they become centrocytes (Victora and Nussenzweig, 
2012). The differentiation of B cells in the GC allows for the production of 
antibodies that are more efficient in the control of pathogens during infection 
(Figure 1.6).  
 
Several key processes take place in the GCs. The genes that codify the 
heavy and light chains of the antibodies undergo a series of important modifications 
that results in the production of antibodies with higher affinity for the antigen, a 
process defined as somatic hypermutation. Moreover, the constant regions of these 
antibodies are replaced by other isotypes, a process known as class switch 
recombination. Importantly, the GC also results in the development of adaptive 
immune memory (Victora and Nussenzweig, 2012). 
 
Somatic hypermutation is the mechanism by which the genes that code for 
the variable regions of the light and heavy chains of the immunoglobulins undergo 
punctual mutations at a very high rate. As a consequence, after each cell division, 
daughter cells express different sequences in their variable regions to the original 
lymphocyte (Jacob et al., 1991). This process is initiated by the enzyme AID 
(activation induced cytidine deaminase), which is selectively expressed in B cells. 
This enzyme operates directly on the VDJ rearranged regions by removing an 
amine group from the cytidines and converting them into uracils. These uracils are 
then eliminated from the DNA and replaced by other bases by enzymes that make 
copy errors, giving rise to mutations (Muramatsu et al., 2000). As the mutations 
occur randomly, only those that increase the affinity of the BCR for the antigen will 
be selected in the GC, while all the others do not progress. After proliferation and 
mutation in the dark zone, B cells migrate to the light zone where the selection of B 
cells with high affinity immunoglobulins takes place. Centrocytes are programmed 
to die by apoptosis in a relatively short time unless they receive survival signals 
from specific TfH cells. Those B cells that have increased the affinity of their BCRs 
for the antigen will have more chance to extract antigen from FDCs and present it 
to TfH cells to receive surviving signals. Following selection, high-affinity B cells 
return to the dark zone, where they further proliferate and mutate their BCRs. 
Following several cycles of migration between dark and light zones, B cells are 
able to produce antibodies with much higher affinity that the ones initially produced 
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by extrafollicular plasma cells (Victora et al., 2010, Victora and Nussenzweig, 2012, 
Gitlin, Shulman and Nussenzweig, 2014, Gitlin et al., 2015).   
 
 
Figure 1.6 Representation of B cell response to pathogens 
Schematic depiction of the main steps involved in B cell response following antigen 
challenge in the LN. After antigen recognition by B cells in the surface of SCS 
macrophages, DCs or FDCs, antigen is internalised, processed and presented in 
the surface of MHCII (1). B cells then migrate to the B-T cell border, where they 
receive T cell help (2). B cells can either directly differentiate into extrafollicular 
plasma cells to produce the first wave of low affinity antibodies (3) or enter into 
GCs (4). Once in the GCs, B cells undergo somatic hypermutation and class switch 
recombination, resulting in affinity maturation and production of high affinity 
antibodies.      
 
In the GC there is a second important process that takes place: class switch 
recombination. During an immune challenge, the first wave of antibodies produced 
is always IgM. However, while the immune response progresses, antibodies with 
similar antigenic specificity but from different isotypes such as IgG, IgA and IgE are 
observed (Liu et al., 1996).  This is the consequence of the removal of the µ and δ 
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CH exons from the chromosome by a series of enzymes such as AID and 
endonucleases, and the association of the VH portions with another CH, such as γ, 
α or ε (Muramatsu et al., 2000). Class switch recombination is an essential part of 
the immune response and it has several advantages. For instance: a) IgG has a 
half-life in the serum of 21 days while that of IgM is only 5 days, b) the access of 
IgG to infected tissues is faster than IgM due to its lower molecular weight, c) IgG is 
the only immunoglobulin that crosses the placenta and confers immunity to the 
foetus and d) IgG but not IgM can stimulate different effector functions by binding to 
Fc receptors present on the immune cells (Vidarsson, Dekkers and Rispens, 2014).  
 
As previously mentioned, the GC is the place where adaptive immune 
memory is generated. The B cells that survived the selection process differentiate 
into 2 types of cells: the ones expressing Blimp-1 (B lymphocyte-induced 
maturation protein-1) and XBP-1 (X-box binding protein 1) differentiate into long-
lived plasma cells while the ones expressing Pax-5 (paired box 5) become memory 
B cells (Lin, Wong and Calame, 1997, Horcher, Souabni and Busslinger, 2001). 
Long-lived plasma cells migrate to the bone marrow due to the down regulation of 
CXCR5 and the up regulation of CXCR4, the receptor for CXCL12, which is highly 
expressed in the bone marrow. Long-lived plasma cells produce antibodies for 
prolonged times and maintain high levels of protective antibodies in the serum for 
several months or years (Nutt, Hodgkin and Tarlinton, 2015). On the other hand, 
memory B cells recirculate between the different lymphoid organs and they can 
also settle in these tissues. The expression of high affinity BCRs and high levels of 
MHCII by memory B cells favour their rapid response and protection against 
reinfection (Kurosaki, Kometani and Ise, 2015).   
 
1.5.4 Antibody effector functions 
The immune system has evolved in our vertebrate ancestors to produce 
highly specific antibodies to protect against infection. The survival advantage 
gained by producing these high-affinity antibodies must have been colossal, as 
their generation involves mechanisms of genetic recombination and somatic 
hypermutation. Therefore, why are antibodies so important in protecting us against 
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infection? One of their most important functions is to inhibit the infectious process 
by recognising and blocking the penetration of the cells by pathogens. Such 
antibodies are termed neutralising antibodies (Nutt, Hodgkin and Tarlinton, 2015). 
However, in most infectious processes, antibodies per se are unable to completely 
neutralise the pathogenic ability of the microorganism and to promote its clearance. 
Therefore, once they are bound to antigens and form immune complexes they can 
recruit additional effector mechanisms: the activation of the complement system 
and the induction of cellular responses by binding to the Fc receptors of innate 
immune cells (Vidarsson, Dekkers and Rispens, 2014). The activation of the 
complement system by immune complexes can induce inflammation, opsonisation 
of the pathogens, direct cytotoxic effect on the microorganisms, and potentiation of 
the B cell responses (Zipfel and Skerka, 2009). The binding of immune complexes 
to the Fc receptors of innate immune cells can also induce other effector functions:  
a) Endocytosis of opsonised microorganisms and their elimination by 
phagocytic cells such as neutrophils and macrophages (Aderem and Underhill, 
1999). 
b) ADCC (antibody-dependent cell-mediated cytotoxicity), in which the 
microorganisms that are covered with specific antibodies are destroyed by innate 
immune cells such as NK cells, granulocytes and macrophages, that secrete 
granzymes, perforins and lysosomal enzymes (Delves and Roitt, 2000)  
c) Cellular degranulation and increased production of cytokines, chemokines 
and inflammatory mediators by mastocytes, neutrophils, eosinophils and 
macrophages (Bryceson et al., 2005).  
 
Antibodies therefore not only mediate the neutralisation of the pathogens to 
avoid the infectious process but also orchestrate a collection of innate effector 
mechanisms to mediate the clearance of invading pathogens.       
 
1.5.5 Regulation of B cell immunity by NKT cells 
As explained above, B cells need two different signals to become fully 
activated; the signal through the BCR that originates on recognition of antigen and 
the signal provided by T cells after antigen internalisation, processing and 
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presentation. In the case of peptidic antigens, the second signal is provided by TfH 
cells. For lipidic antigens however, it was not known until a few years ago who was 
giving this second signal. Two different studies revealed that NKT cells could 
provide this second signal to the B cells by recognising processed lipids in the 
context of CD1d through their restricted TCR (Barral et al., 2008, Leadbetter et al., 
2008). By coupling peptidic antigens to glycosphingolipids, specific B cells 
internalise these antigens, process them and present the lipids in the context of 
CD1d. This CD1d-mediated presentation is essential to activate iNKT cells and 
induce the production of cytokines. Moreover, iNKT cells provide the help for B 
cells to proliferate and differentiate into extrafollicular plasma cells, which mediate 
the production of high titres of IgM and early class-switched antibodies (Barral et 
al., 2008, Leadbetter et al., 2008).  
 
These groups further demonstrated in 2012 that iNKT cells engage in stable 
and prolonged cognate interactions with B cells in vivo after exogenous 
administration of lipids. These prolonged interactions induced the formation of early 
GCs. Furthermore, iNKT cells up regulate CXCR5 and PD-1 (programmed cell 
death 1) after interacting with B cells and then migrate to the B cell follicles, where 
they will later localise in GCs. As these characteristics are similar to those 
observed in TfH cells, the authors defined this population of NKT cells as NKTfH 
cells. The development of NKTfH cells requires high-level expression of Bcl-6 (B 
cell lymphoma 6 protein), signalling through the co-receptor CD28 and interaction 
with B cells. NKTfH cells secrete high levels of IL-21, which contributes to B cell 
mediated formation of GCs. However, unlike T cell-dependent GCs, those driven 
by NKTfH cells induce little affinity maturation and do not generate long lived 
plasma cells (Chang et al., 2012, King et al., 2012) (Figure 1.7).          
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Figure 1.7 Differential outcomes of TfH and NKTfH cell help to B cells 
B cell presentation of pathogen-derived peptides on MHCII to TfH cells is essential 
for the generation of high-affinity antibodies and memory responses. On the other 
side, presentation of pathogen-derived lipids on CD1d to NKTfH cells is necessary 
for a strong primary IgG response.  
 
1.6  Thesis aim 
The activation of B cells during an immune response and the production of 
pathogen-specific antibodies are highly regulated processes. Therefore, many 
factors can affect and shape B cell immunity. In the present thesis I will address 
three main different questions regarding B cell response to pathogens: How is B 
cell encounter of pathogens regulated during infection? Which processes are 
involved in the processing and presentation of antigen after pathogen encounter? 
How is the B cell response to pathogens modulated by different T cell populations?  
 
In chapter 3, I will focus on the physiology of SCS macrophages during 
infection and how they regulate B cell encounter of antigen. SCS macrophages are 
important to capture pathogens entering through the lymphatic vessels and present 
them to B cells. To date, most studies have looked at the retention and 
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presentation of antigens at the initial stage of the immunisation process. However, 
infectious or inflammatory processes dramatically alter the architecture and 
function of the LNs. For instance, after local infection with LCMV (lymphocytic 
choriomeningitis virus) there is a global remodelling of the lymphoid tissue, 
involving an increase in the LN volume, in the B cell follicle size, and in the length 
of the HEV network (Kumar et al., 2010). Therefore, in chapter 3 I will look at the 
organisation of the SCS macrophage layer during infection/inflammation and 
whether an alteration in this population has an effect on the way B cells can 
respond to pathogens. 
 
In chapter 4, I will briefly analyse the potential role of autophagy, an 
indispensable process for the recycling of cell components and for the fulfilment of 
cell energy demands, on the presentation of peptides and lipids by B cells. 
Moreover, I will analyse the signals that induce the formation of autophagosomes 
(the organelles involved in the autophagy process) and the signalling pathways 
involved.  
 
Finally, in chapter 5 I will analyse the role of iNKT cells in modulating the B 
cell response during viral infection. iNKT cells have been shown to provide the 
necessary help to B cells in the presence of exogenous glycolipids (Barral et al., 
2008, Chang et al., 2012). However, iNKT cell activation can occur even in the 
absence of pathogens containing these glycolipids, by a mechanism explained in 
chapter 5. In this case, the manner in which iNKT cells become activated in vivo, 
and their ability to regulate B cell responses, remain elusive. In chapter 5, by the 
use of several transgenic models, I will dissect the mechanisms involved in iNKT 
cell activation and the role of these mechanisms in promoting humoral responses 
during viral infection.  
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Chapter 2. Materials and methods   
2.1 Materials 
2.1.1 Media 
Table 2.1 contains a complete list of all media that have been used in this 
study for the culture and maintenance of primary cells and cell lines and the growth 
of viruses and bacteria. RPMI, DMEM, Leibovitz, FCS (foetal calf serum), GlutaMax, 
HEPES (4-2-hydroxyethyl-1-piperazineethanesulfonic acid), penicillin/streptomycin 
and NEAA (non-essential amino acids) were purchased from Invitrogen, rmGM-
CSF (recombinant mouse granulocyte macrophage colony-stimulating factor) was 
generated by Cancer Research UK, β-mercaptoethanol and BSA (bovine serum 
albumin) from Sigma, NaHCO3 from Thermo, Na-Pyruvate from Lonza, DMSO 
(dimethyl sulfoxide) from Fisher Scientific, TPCK-treated trypsin from Worthington, 
Brain heart infusion broth from bioMerieux and Tryptic soy agar plates from BD.  
 
Table 2.1 List of media and their composition  
 
Medium Components 
RPMI medium 1x RPMI 1640 supplemented with 10 % FCS, 1x GlutaMAX, 
10 mM HEPES, 10 U/ml penicillin/streptomycin, 50 µM β-
mercaptoethanol 
BM (bone marrow) 
- DCs medium 
1x RPMI 1640 supplemented with 10 % FCS, 10 mM 
HEPES, 100 U/ml penicillin/streptomycin, 50 µM β-
mercaptoethanol, 1mM Na-Pyruvate, 1x NEAA, 200 U/ml 
rmGM-CSF 
Freezing medium 90 % FCS, 10 % DMSO 
DMEM medium 1x DMEM supplemented with 10% FCS and 1x GlutaMAX 
Infection medium DMEM medium supplemented with 0.3% BSA + 1 µg/ml 
TPCK-treated Trypsin 
Leibovitz medium 
(L-15) 
1x Leibovitz L-15 supplemented with 10 mM HEPES, 100 
U/ml penicillin/streptomycin and 0.075% NaHCO3.  
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Brain heart 
infusion broth  
1.75% Brain heart infusion, 1% digest of gelatine, 0.2% 
dextrose, 0.5%sodium chloride, 0.25% disodium phosphate  
Tryptic soy agar 
plates 
1.5% BactoTM tryptone, 0.5% BactoTM soytone, 0.5% sodium 
chloride, 1.5% agar and 5% sheep blood  
 
2.1.2 Antibodies and tetramers 
Table 2.2 provides a complete list of all antibodies and tetramers used in this thesis. 
It provides information about the reactivity, the clone, the conjugation, the 
manufacturer and the application. 
 
Table 2.2 List of antibodies and their application 
 
Reactivity Clone Conjugation Manufacturer  Application 
Isotype control 2A3 Non conjugated BioXCell Depletion 
IL-2  
JES6-1A12 
JES6-5H4 
Non conjugated 
Biotin 
Biolegend 
Biolegend 
ELISA capture 
ELISA detection 
CD103 2E7 PE/APC eBioscience FC 
CD138 281-2 PE Biolegend FC 
CD19 1D3 PE-Cy7 eBioscience FC 
CD1d 1B1 PE BD FC 
CD3 17A2 PE, APC-Cy7 Biolegend FC 
CD45.2 104 PerCP-Cy5.5 BD FC 
CD69 H1.2F3 PE-Cy7 BD FC 
CD8 53-6.7 PE Biolegend FC 
CD95 15A7 FITC eBioscience FC 
CXCR5 2G8 Biotin BD FC 
DX5 DX5 FITC eBioscience FC 
GL-7 GL7 A647 eBioscience FC 
Goat IgG Polyclonal A488, A647 Invitrogen FC 
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IFN-γ XMG1.2 PE-Cy7 eBioscience FC 
IgD 11-26C.2A V450 BD FC 
IL-21 mhalx21 PE eBioscience FC 
IL-4 11B11 PE eBioscience FC 
Ly6G 1A8 
PE, APC          
Non conjugated 
BD 
BioXCell 
FC 
Depletion 
MHCII M5/114.15.2 APC eBioscience FC 
MyD88 Polyclonal Non conjugated R&D FC 
NK1.1 PK136 
PE-Cy7 
Non conjugated 
eBioscience 
BioXCell 
FC 
Depletion 
PBS57- 
tetramer 
N/A APC 
NIH tetramer 
facility 
FC 
PD-1 J43 FITC eBioscience FC 
TCR β H57-597 FITC eBioscience FC 
α-Galcer-CD1d L363 PE eBioscience FC 
B220 RA3-6B2 
PE, APC, PB 
APC-Cy7, NC650 
BD 
eBioscience 
IF 
FC 
BCL-6 mGI191E PE eBioscience IF 
CD11b M1/70 
APC  
APC-Cy7, PB 
Biolegend 
BD 
IF 
FC 
CD11c 
HL3 
N418 
FITC 
PerCP-Cy5.5 
BD 
Biolegend 
IF 
FC 
Langerin 929F3.01 A647 Dendritics IF 
Lyve-1 223322 Non conjugated R&D IF 
Mac-3 M3/84 PE BD IF 
Rat IgG Polyclonal A647 Invitrogen IF 
SIGN-R1 eBio22D1 A647 eBioscience IF 
Tubulin Tub-1A2 Non conjugated Sigma IF 
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F4/80 BM8 PE, APC, PB eBioscience IF/FC 
IL-7Rα SB/199 PE BD IF/FC 
CD169 Ser-4 A488, A555, A633 Hybridoma IF/MF/FC 
CD4 RM4-5 PE, eFluor450 eBioscience IF/MF/FC 
LC3B Polyclonal Non conjugated Cell signalling IF/WB (primary) 
CD16/32 2.4G20 Non conjugated BD Neutralisation 
E-cadherin DECMA-1 Non conjugated Millipore Neutralisation 
LFA-1 M17/4 Non conjugated Abcam Neutralisation 
VLA-4 PS/2 Non conjugated Abcam Neutralisation 
Mouse IgM  Polyclonal  
Non conjugated 
AF546 
Byotinilated  
Jackson 
Invitrogen 
Southern Biotech 
Stimulation 
IF/Stimulation 
ELISA/ELISPOT 
β-Actin AC-15 Non conjugated Sigma WB (primary) 
Mouse IgG Polyclonal 
HRP 
A647 
Byotinilated 
Cell signalling 
Invitrogen 
Southern Biotech 
WB (secondary) 
IF 
ELISA/ELISPOT 
Rabbit IgG Polyclonal 
HRP 
A488 
Pierce 
Invitrogen 
WB (secondary) 
IF 
IF (Immunofluorescence), FC (flow cytometry), MF (multiphoton), WB (Western 
blot). 
 
2.1.3 Reagents 
Table 2.3 provides a complete list of reagents used in the experiments described in 
this thesis.  
 
Table 2.3 List of reagents and their application  
 
Reagent Manufacturer Application 
Chanazyne 2% Xylazine Chanelle Anaesthesia 
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IsoFlo® Isoflurane Abbott Anaesthesia 
Narketan®-10 Ketamine Vetoquinol Anaesthesia 
1,2-dioleoyl-sn-glycero-3-
phsphocholine (DOPC) 
Avanti Polar Lipids Antigen preparation 
EZ-Link-Sulfo-NHS-LC-LC-
Biotin 
Thermo Antigen preparation 
Hen egg lysozyme Sigma Antigen preparation 
N-Cap PE-biotin Avanti Polar Lipids Antigen preparation 
Ovalbumin Sigma Antigen preparation 
PierceTM Streptavidin Thermofisher Antigen preparation 
Silica beads Kisker GbR Antigen preparation 
Streptavidin polystyrene beads 
0.093 µm 
Bangs Laboratories Antigen preparation 
α-GalCer  Enzo life Sciences Antigen preparation 
Collagenase IV Worthington Cell Purification 
DNAse I Roche Cell Purification 
MACS B cell isolation kit Miltenyi Biotec Cell Purification  
MACS CD11c+ isolation kit Miltenyi Biotec Cell Purification 
MACS CD4+ T cell isolation kit Miltenyi Biotec Cell Purification 
rm IL-2 R&D  ELISA 
SIGMAFAST™ p-nitrophenyl 
phosphate tablets 
Sigma ELISA 
Extravidin-Alkaline 
Phosphatase (AP) 
Sigma ELISA/ELISPOT 
MultiScreen Filter Plates  Millipore ELISPOT 
SIGMAFAST™ BCIP®/NBT 
tablets  
Sigma ELISPOT 
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Cell stimulation cocktail plus 
protein transport inhibitor 
eBioscience FC 
Celltrace violet Invitrogen FC 
Cytometric Bead Array, Mouse 
Th1, Th2, TH17 cytokine kit 
BD FC 
DAPI Sigma FC 
Live/dead blue Invitrogen FC 
Streptavidin A450 Invitrogen FC 
Cytofix/Cytoperm solution BD FC 
Perm/Wash solution BD FC 
Bovine Serum Albumin (BSA) Sigma IF 
Fluoromount-G  Southern Biotech IF  
Goat serum Sigma IF 
OCT mounting media  VWR IF 
SNARF Invitrogen IF 
Triton X-100 Sigma IF 
CFSE Invitrogen IF/FC 
NeutrAvidin yellow-green 
0.2µm FluoSpheres  
Invitrogen IF/FC 
3-methyladenine Sigma In vitro inhibition 
Chloroquine diphosphate salt Sigma In vitro inhibition 
Wortmannin Sigma In vitro inhibition 
Diphtheria toxin Sigma In vivo inhibition 
PBS/Clodronate liposomes clodronateliposomes.org In vivo inhibition 
GM6001 Millipore In vivo inhibition 
Pertussis toxin Sigma In vivo inhibition 
Kod XtremeTM Hot Start DNA 
Polymerase 
Novagen Long Range PCR 
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Gluture (topical tissue 
adhesive) 
World Precision 
Instruments  
MF 
Platinum® SYBR® Green Invitrogen RT-PCR 
QIAshredder (50)  Qiagen RT-PCR 
RNeasy Mini/Micro Kit Qiagen RT-PCR 
SuperScript® III First-Strand 
Synthesis SuperMix 
Invitrogen RT-PCR 
DIG-high prime DNA labelling 
and detection starter kit II 
Roche Southern blot 
NEB buffer 1.1 New England Biolabs Southern blot 
Phusion® high fidelity DNA 
polymerase 
New England Biolabs Southern blot 
Proteinase K Sigma Southern blot 
Ribonuclease A from bovine 
pancreas 
Sigma Southern blot 
SacI New England Biolabs Southern blot 
Spermidine Sigma Southern blot 
Ethidium bromide Thermofisher Southern blot/PCR 
CpG (ODN 1826) Sigma Stimulation 
Interferon-α R&D Stimulation 
LPS from E. coli Sigma Stimulation 
Prostaglandin E2 Sigma Stimulation 
rm IL-4 R&D  Stimulation 
Tumour Necrosis Factor α R&D Stimulation 
Agarose Sigma Virus preparation 
Ultracentrifuge tubes  Beckman Virus preparation 
Complete protease inhibitors Roche WB 
Dual-colour protein marker Bio-Rad WB 
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ECS solution  GE Healthcare WB 
Hyperfilm MP 24 × 30 cm GE Healthcare WB 
Pre-cast 12% MiniPROTEAN 
TGX™ Gels 10 wells 
Bio-Rad WB 
PVDF membranes  Bio-Rad WB 
ICG (Indocyanine green) dye Sigma Whole body imaging 
 
2.1.4 Infectious agents 
Table 2.4 provides a list of all infectious agents used in this thesis and their origin.  
 
Table 2.4 List of infectious agents 
 
Agent Strain Origin 
Staphylococcus aureus Subsp. Aureus 
Rosenbach 
ATCC® BAA-1556 TM 
Streptococcus agalactiae Lancefield Group B, 
type Ib 
ATCC® 12401TM 
Influenza A virus Strain A/Puerto 
Rico/8/1934 H1N1 
From Caetano Reis e Sousa 
Vaccinia virus  Western Reserve From Caetano Reis e Sousa 
 
2.1.5 Buffers and solutions 
Table 2.5 provides a comprehensive list of buffers and solutions used in the 
experiments described in this thesis.  
 
Table 2.5 List of buffers and solutions 
 
Buffer Components 
Crystal violet fixing solution 1x PBS, 0.05% crystal violet, 1% formaldehyde, 
and 1% methanol  
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DNA loading 0.25% bromophenol blue, 0.25% xylene lyanol 
FF and 30% glycerol 
DNA lysis pH 8  100mM Tris-HCl, 5mM EDTA, 0.2% SDS and 
200mM NaCl  
FACS buffer 1x PBS, 1% FCS and 1% BSA 
MACS buffer 1x PBS, 0.5% FCS and 2 mM EDTA 
Maleic acid buffer pH 7.5 0.1M Maleic acid and 0.15M NaCl  
 
NaHCO3 0.1M 0.1M NaHCO3  
Paraformaldehyde 4% 4% Paraformaldehyde  
Phenol-chloroform-isoamyl 
alcohol 
25:24:1 Phenol:chloroform:isoamyl alcohol  
saturated with 10 mM Tris pH 8,1  
Pierce® Protein-free T20 
(TBS) blocking buffer 
From Thermo scientific 
Red Blood Cell lysis  1 vol. Tris-HCl pH 7.6, 9 vol. NH4Cl pH 7.2 
SDS lysis  62.5 mM Tris pH 6.8, 2% SDS, 10% glycerol 
and 50mM DTT 
Southern denaturation 1.5M NaCl and 0.5M NaOH  
Southern detection pH 9.5 0.1M Tris-HCl and 0.1M NaCl  
Southern neutralisation pH 7.4 1M Tris-HCl and 1.5M NaCl  
 
Southern stringency wash 1 2x SSC and 0.1% SDS  
 
Southern stringency wash 2 0.5x SSC and 0.1% SDS  
 
Southern wash Maleic acid buffer and 0.3% Tween 20 
 
SSC 3M NaCl and 300mM Na citrate 
Sucrose 30% 30% Sucrose  
TBE pH 8.3 1% Tris, 0.5% Boric Acid and 0.01M EDTA  
Tris Glycine SDS pH 8.6  25mM Tris, 192 mM glycine and 0.1% SDS  
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WB washing buffer 1x TBS and 0.1% Tween-20 
 
2.1.6 Cell lines 
The table 2.6 provides a comprehensive list of all cells lines used in this thesis.  
 
Table 2.6 List of cell lines  
 
 
2.1.7 Mice  
Mice listed in table 2.7 were imported from the sources indicated. A 
reference for their first description is also given. Animals were used for experiments 
at an age of 8-24 weeks and were all in a C57Bl/6 background unless stated. 
 
Table 2.7 List of mouse strains 
 
Mouse strain Description Source 
ASC (Yamamoto et al., 2004) Dr. G. Guarda 
Batf3 (Hildner et al., 2008) Dr. C. Reis e Sousa 
BCAP (Yamazaki et al., 2002) Dr. T. Kurosaki 
c-Cbl (Murphy et al., 1998) Dr. H. Gu 
Caspase-1 (Kuida et al., 1995) Dr. G. Guarda 
Cell line Species Description Source 
DF-1 chicken Immortalised cell line of 
chicken embryo fibroblasts 
Courtesy of Dr Caetano 
Reis e Sousa 
DN32.D3 mouse CD4-CD8- iNKT cell 
hybridoma 
Courtesy of Dr 
Vincenzo Cerundolo 
MDCK dog Kidney cells of a female adult 
Cocker Spaniel 
Courtesy of Dr Caetano 
Reis e Sousa 
Ser-4 rat Hybridoma expressing the 
anti-CD169 antibody Ser-4 
Courtesy of Dr Paul 
Crocker 
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CCR7 (Förster et al., 1999) Dr A. Rot and Dr D. Withers 
CD11c-Cre (Caton, Smith-Raska 
and Reizis, 2007) 
Dr. C. Reis e Sousa 
CD11c-YFP (Lindquist et al., 2004) Dr. C. Reis e Sousa 
CD169-DTR (Miyake et al., 2007) Riken Institute 
CD19-Cre (Rickert, Roes and 
Rajewsky, 1997) 
Dr R. Rickert 
CD1dflox/flox CD11c-Cre Generated by me Lymphocyte Interaction Lab 
CD1dflox/flox CD19-Cre Generated by me Lymphocyte Interaction Lab 
CD1dflox/flox Generated by me Lymphocyte Interaction Lab 
CD1dflox/flox Lyz2-Cre Generated by me Lymphocyte Interaction Lab 
CD1dflox/flox Mb1-Cre Generated by me Lymphocyte Interaction Lab 
CD1d1/2 (Mendiratta et al., 1997) Dr A. Bendelac 
CD45.1  Charles River 
Clec2 flox/flox CD11c-Cre (Acton et al., 2014) Dr C. Reis e Sousa 
FLPo (Wu et al., 2009) Cancer Research UK 
IL-21-/GFP  (Lüthje et al., 2012) Dr L. Corcoran 
IL-2Rγ  (Shultz et al., 2005) Dr D. Bonnet 
Jα18 (Griewank et al., 2007) Dr A. Bendelac 
Langerin-DTR (Kissenpfennig et al., 
2005) 
Dr C. Reis e Sousa 
LC3-GFP (Mizushima et al., 2004) Dr S. Tooze 
Lyz2-Cre (Clausen et al., 1999) Dr C. Reis e Sousa 
Mb1-Cre (Hobeika et al., 2006) Dr M. Reth 
MD4 (Goodnow et al., 1988) Jackson Laboratory 
MD4 TLR9  Crossed in the lab Lymphocyte Interaction Lab 
MyD88 (Adachi et al., 1998) Dr C. Reis e Sousa 
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MyD88 flox/flox (Hou, Reizis and 
DeFranco, 2008) 
Dr C. Reis e Sousa 
MyD88flox/flox CD11c- Cre Crossed in the lab Lymphocyte Interaction Lab 
MyD88flox/flox CD19-Cre Crossed in the lab Lymphocyte Interaction Lab 
MyD88flox/flox Lyz2-Cre Crossed in the lab Lymphocyte Interaction Lab 
MyD88/TRIF Crossed in the lab Dr C. Reis e Sousa 
OT-II (Barnden et al., 1998)  Charles Rivers 
PLCγ2 (Takata, Homma and 
Kurosaki, 1995) 
Dr T. Kurosaki 
RAG2  (Shinkai et al., 1992) Cancer Research UK 
TLR7 (Lund et al., 2004) Dr C. Reis e Sousa 
TLR9 (Hemmi et al., 2000) Dr S. Akira 
TRIF (Yamamoto et al., 2003) Dr C. Reis e Sousa 
ULK1 (Kundu et al., 2008) Dr S. Tooze 
ULK1/2 Crossed in the lab Lymphocyte Interaction Lab 
ULK2 (Cheong et al., 2011) Dr S. Tooze 
Wild-type  Charles River 
µMT (Kitamura et al., 1991) Jackson Laboratory 
 
2.2 Methods 
2.2.1 Animal maintenance and generation 
2.2.1.1 Animal breeding 
Mice were bred and maintained at the animal facility of Cancer Research 
UK. All experiments were approved by the Animal Ethics Committee of Cancer 
Research UK and the United Kingdom Home Office.  
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2.2.1.2 Generation of transgenic animals 
The generation of CD1dflox/flox animals is explained in detail in Chapter 5. For 
the generation of conditional mouse lines, CD1dflox/flox and MyD88flox/flox mice were 
crossed with animals expressing the Cre recombinase gene under the promoters of 
Mb1, CD19, CD11c and Lyz2. Genotyping of animals was performed by 
Transnetyx, Inc. 
2.2.1.3 Bone marrow and foetal liver chimaeras 
For the preparation of bone marrows, femurs and tibias of 8-12 weeks old 
wild-type and Tlr9-/- mice were harvested, cleaned of muscle and connective tissue 
and then cut at both ends under sterile conditions. The bone marrow was extracted 
by flushing through the bone ice-cold RPMI medium using a 1ml syringe and a 23G 
needle. For the preparation of foetal livers, livers were harvested from mouse 
embryos at day E14.5. Cell homogenates were generated by pressing the bone 
marrow or livers with the syringe plunge and passed through a 70µm nylon mesh 
cell strainer. Cells were washed in complete medium and either used immediately 
for transplant or frozen down in freezing medium until use. Mice of 4-6 weeks of 
age were kept on acidified water for one week prior and 3 weeks post irradiation 
treatment. 2 doses of 500 rad were given 4 hours apart to experimental animals. 24 
hours later 2x106 bone marrow cells or one-third of a liver were injected i.v. in 
recipient animals in a total volume of 200µl of PBS. 8 weeks later, blood samples 
were collected and tested by flow cytometry for B and T cells reconstitution.    
 
2.2.2 Cell Preparation, labelling and culture 
2.2.2.1 Cell preparation 
Single cells suspensions of lungs, LNs and spleens were obtained by 
pressing organs through a 70µm nylon mesh cell strainer with a plastic plunge in 
MACS buffer. When DC analysis was carried out, organs were previously 
incubated in serum-free RPMI medium supplemented with Collagenase IV (8 
µg/ml) and DNAse I (20 µg/ml) for 30 minutes at 37oC. For spleen and lungs, cell 
suspensions were further incubated with red blood cell lysis buffer for 5 minutes.  
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Purification of naive mouse B and T cells from spleen single cell 
suspensions was carried out by negative selection using a B- and a CD4+ T-cell 
purification kit respectively according to manufacturer’s instructions and resulting in 
95–98% B cell and 85-90% T cell enrichment. Purification of LN DCs was carried 
out by FACS (fluorescence-activated cell sorting) on a FACSAria (Becton 
Dickinson) using antibodies against MHCII (APC), CD11c (PerCP-Cy5.5), CD11b 
(Pacific blue) and CD103 (PE). Purification of LN iNKT cells was also performed by 
FACS using an antibody against TCRβ (FITC) and APC-conjugated CD1d-tetramer.  
 
For the generation of BM-DCs, bone marrow cells were cultured at 37ºC in 
BM-DC medium, which was replaced with fresh medium every 48 hours. On day 5, 
adherent cells were harvested using PBS 2mM EDTA and DCs were enriched 
using a CD11c+ purification kit. DCs were incubated for 16 hours with 1µg/ml CpG 
or 10-6 M PGE2 + 1000 IU/mL IFN-α + 20ng/mL TNF-α.  
2.2.2.2 Cell labelling 
For labelling, single cells suspensions (107 cells/ml) were incubated for 
10minutes at 37ºC in PBS supplemented with 1µM CFSE, 2µM SNARF or 5µM of 
Cell Trace violet (CTV) and then washed twice in complete medium. 
2.2.2.3 Cell culturing 
LN single cell suspensions and purified lymphocytes were normally cultured 
at 37ºC in RPMI medium unless differently specified. For cytokine production 
analysis, LN single cell suspensions were incubated 4 hours at 37ºC in RPMI 
medium supplemented with 1x Cell stimulation cocktail plus transport inhibitor.   
MDCK and DF-1 cells were cultured in DMEM medium at 37ºC. 
 
2.2.3 Antigen preparation 
2.2.3.1 HEL and OVA polybiotinylation  
HEL and OVA were used at a concentration of 1mg/ml and mixed for 30 
minutes at room temperature with 1 µg/ml of EZ Link Sulfo-NHS-biotin reagent. To 
remove excess free NHS-biotin, the mixture was dialysed against PBS at 4ºC.   
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2.2.3.2 Beads coating with biotinylated IgM, HEL and/or OVA 
Neutravidin or streptavidin coated beads were washed in PBS 2% BSA to 
remove any trace of azide. For B-T cell coculture, mixtures of biotinylated IgM 
(1µg/µl beads) and increasing amount of biotinylated OVA (from 0.005 to 5 µg/µl 
beads) were prepared in a total volume of 100µl of PBS 2% BSA. For immunisation, 
a mixture of biotinylated HEL (0.75 µg/µl beads) and/or biotinylated OVA (0.25 
µg/µl beads) was prepared in 100µl of PBS 2% BSA. Beads were resuspended in 
the different coating mixtures and incubated for 20 minutes at room temperature 
while shaking. Beads were then washed 3 times with PBS 2% BSA to remove any 
trace of unbound coating reagents.   
2.2.3.3 α-GalCer-liposomes preparation 
Liposomes were prepared as previously described (Barral et al., 2008). 5mg 
of DOPC, 100µg of N-Cap PE-biotin and 500µg of α-GalCer lipids were mixed and 
dried under argon and then under vacuum for 3hours. Lipids were resuspended in 
10 ml of 25mM Tris, 150mM NaCl, pH 7.0 with vigorous mixing followed by 20-25 
freeze-thaw cycles passing samples from liquid nitrogen to a 65ºC water bath in 
order to obtain a clear liposome solution. Liposomes were stored at 4ºC.   
2.2.3.4 Beads coating with α-GalCer-liposomes and HEL or anti-IgM 
For coating, 20 µl of silica microspheres were washed in PBS and incubated 
with 100µl of liposome preparation for 30 minutes at room temperature while 
shaking. Beads were then washed in FACS buffer, incubated with 20µg of 
streptavidin for 30 minutes, washed again and incubated 30 minutes more with 
either 20µg of biotinylated-HEL or biotinylated anti-IgM at room temperature. Silica 
beads were finally washed in FACS buffer and resuspended in 400µl of PBS. 
 
2.2.4 Preparation of infectious pathogens 
2.2.4.1 Bacterial culture 
Group B streptococcus and Staphylococcus aureus were sourced from 
ATCC and were rehydrated in 1ml of brain-heart infusion broth and a few drops 
were used to inoculate a tryptic soy agar plate supplemented with 5% sheep blood 
which was cultured for 24 hours at 37ºC. Single colonies were picked and amplified 
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overnight in 5ml of brain-heart Infusion broth shaking at 37ºC and then diluted 1 in 
20 in 100ml of brain-heart Infusion broth. 500µl samples were taken every 30 
minutes to measure A600 or cultured at 37ºC over night on agar plates to estimate 
number of CFU (colony forming units)/ml. For experimental studies, cultures were 
stopped at 0.8-1.0 A600, corresponding to about 109 CFU/ml. Bacteria were then 
pelleted, resuspended in PBS and injected in animals. 
2.2.4.2 Preparation of viruses 
MDCK cells were used for the amplification of PR8 influenza virus. Cells were 
grown in DMEM medium at 37ºC until confluence. Then, medium was replaced for 
infection medium and 1 PR8 viral particle/10 cells was added into the medium. 
Cells were incubated for 3-4 days at 37ºC until 100% of MDCK cells were dead. 
The medium containing the virus and dead cells was collected in a falcon and 
centrifuged at 4000 RPM for 5minutes to pellet dead cells. Supernatant was 
aliquoted and stored at -80ºC. For quantification of viral titer, MDCK cells were 
cultured in 6-well plates until 80% confluence. Cells were incubated with 200µl of 
different viral dilutions (10-3, 10-4, 10-5, 10-6, 10-7 and 10-8) in DMEM alone for 1hour 
at 37ºC 5% CO2. Then, medium was replaced for L15 medium supplemented with 
1% Agarose and 1 µg/ml TPCK Trypsin. After 3 days, the agarose was removed 
and 4ml of Crystal Violet fixing solution was added to each well for 15minutes at 
room temperature. Then, wells were washed with water and the number of plaques 
in the different dilutions was counted. The viral titer of the stock was calculated as: 
PFU (plaque forming units)/ml= Nº plaques x dilution factor. For concentration of 
viral particles, 15ml of medium containing virus was added on top of 22 ml of a 
30% sucrose solution in ultracentrifuge tubes and spun at 25.000 RPM for 2hours 
at 4ºC in a SW32Ti rotor. The pellet was resuspended in PBS and frozen at -80ºC.  
 
DF-1 cells were used for the preparation of VACV. Confluent cells were infected 
with 1 VACV particle/10 cells in DMEM medium. Cells were incubated for 3 days at 
37ºC until 100% of DF-1 cells were dead. The infection medium was collected in a 
falcon and centrifuged at 4000 RPM for 5min to pellet the dead cells. Supernatant 
was discarded and dead cells were resuspended in 1 ml of PBS. After 3 cycles of 
freezing at -80ºC and thawing, tubes were centrifuged, pellet was discarded and 
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supernatants stored at -80ºC. Inactivation of VACV was carried out under 365 nm 
long-wave UV light for 10 minutes. 
 
2.2.5 Infections and injections 
2.2.5.1 Infections 
Mice were anesthetised with isoflurane for footpad and ear infections or i.p. 
with Ketamine/Xylazine (100 mg/kg body) for intranasal infection. Anaesthetised 
mice were subcutaneously injected in the footpad with 104 PFU of vaccinia virus or 
106 CFU of Group B Streptococcus in 20µl of PBS, ear inoculated with 107 CFU of 
Staphylococcus aureus in 5µl of PBS or intranasally inoculated with 102 PFU of 
influenza virus in 20µl of PBS.  
2.2.5.2 Chemicals and antibodies administration 
For inflammation induction, mice were injected in either hind footpads or ear 
pinna with PBS, 10µg of CpG or 50µg of LPS. For depletion of macrophages, mice 
were injected in the footpads or ear pinna with 5-20µl of empty or clodronate-
loaded liposomes (ClodronateLiposome.com) or 50ng of diphtheria toxin 6 days 
before the experiment. For neutrophil depletion, mice received 500µg of anti-Ly6G 
i.p. or isotype control 24 hours before challenge and every day during the 
procedure. For NK cell depletion, mice received 500 µg of anti-NK1.1 i.p. or isotype 
control 24 hours before challenge and every day during the procedure. For the 
blockade of integrin or cadherin mediated adhesions, mice received in the footpad 
50µg of anti-LFA-1 + 50µg of anti-VLA-4 or 50µg of anti-e-cadherin respectively. 
For chemokine signalling blockade, mice were injected with 500ng of pertussis 
toxin in the footpads. For metalloproteinase blockade, mice were injected i.p. with 
GM6001 (100mg/kg) every day over the period of the experiment. To analyse the 
role of the CLEC-2-podoplanin axis, 20µg of recombinant CLEC-2 Fc (kindly 
provided by Caetano Reis e Sousa) was injected in the footpads. 
2.2.5.3 Antigen administration  
For beads administration, Alexa488-conjugated avidin microspheres of 
0.2µm diameter were loaded or not with biotinylated HEL and resuspended in 20µl 
of PBS for footpad injection. Approximately 1µl of the stock of fluorescent particles 
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(107 beads) were prepared per injection. For immunisations, 2.5µl of HEL-OVA 
beads or 1µl of HEL-α-GalCer beads were resuspended in 20µl of PBS and 
injected in the footpad of mice.  
2.2.5.4 Adoptive transfer 
5.106 B cells and/or 5.106 OT-II T cells were i.v. injected 24 hours before the 
initiation of indicated experiments. 3x106 BMDCs in 20µl of PBS were injected in 
the hind footpads of anaesthetised animals.  
 
2.2.6 B-T cell and B-NKT cell cocultures 
2.2.6.1 B and T cell Proliferation Analysis  
Purified splenic B cells from different mouse strains were labelled with 
CFSE while CD4+ T cells purified from the spleen of OT-II mice were labelled with 
Celltrace violet. B cells were cultured for 1hour at 37ºC at a density of 5x106 
cells/ml together with 2x1011 HEL-OVA-coated polystyrene beads/ml and then 
washed once in full media. B cells where then cultured together with OT-II CD4+ T 
cells both at a density of 106 cells/ml for 72 hours. Proliferation was measured by 
flow cytometry and IL-2 secretion by ELISA.   
2.2.6.2 B - NKT cell coculture  
Purified splenic B cells were cultured for 4 hours at 37ºC at a density of 
5x106 cell/ml together with 2x1011 anti-IgM-α-GalCer-coated silica beads/ml and 
then washed once in full media. B cells where then cultured together with DN32.D3 
cells both at a density of 106 cells/ml for 24 hours. IL-2 levels were measured in the 
superanatants by ELISA.   
 
2.2.7 Immunohistochemistry and confocal microscopy  
2.2.7.1 Frozen sections 
LNs were harvested from experimental animals and kept in PBS on ice 
before drying them on Wattman filter paper to remove any excess of water. Tissues 
were then placed at the centre of an OCT-filled mounting mould, which was then 
sunken for a few seconds in iso-pentane cooled over liquid nitrogen. Solidified OCT 
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was removed from the plastic mould and kept at -80ºC till sectioning. 10µm 
cryosections of LNs were cut at -20ºC using a Bright Cryostat OTF 5000 and 
placed on warm glass slides. Slides were stored at -80ºC until use. For 
immunofluorescence staining, tissue sections were thawed and dehydrated over 
silica beads for 30 minutes and then fixed for 10 minutes at room temperature with 
4% paraformaldehyde. Slides were washed in PBS and, when intracellular staining 
was required, sections were permeabilised with PBS Triton 0.3% for 5 minutes. 
Then, slides were blocked with PBS containing 10% goat serum and 1% BSA for 
30 minutes and further incubated for 1 hour at room temperature with appropriate 
antibodies diluted 1:100 in blocking buffer. Slides were then washed with PBS and 
glass coverslips were mounted onto tissue sections using Fluomount-G. Slides 
were kept in the dark at 4ºC till confocal microscopy imaging. Confocal microscopy 
images were acquired with an inverted Zeiss Axiovert LSM 780 microscope. 
Objectives used were 20x, 40x and 63x oil immersion objectives. Images were 
recorded with the same settings for control and treated LNs adjusted so that cells in 
treated LNs were clearly visible. Images were analysed using Imaris 6.3 × 64 
software (Bitplane).  
  
2.2.7.2 B cells on slides 
2x105 purified naïve B cells were set in 8-well coverslips and incubated with 
10µg/ml of labelled or unlabelled anti-IgM or 1µg/ml of CpG at 37ºC for indicated 
time points. Cells were fixed and permeabilised for 10 minutes on ice cold 
methanol, washed three times with PBS and stained for 1 hour with primary 
antibodies (1:100) at room temperature. Cells were washed three times and 
incubated for 1 hour more with secondary antibodies (1:100). Slides were finally 
washed again and glass coverslips were mounted onto them using Fluomount-G. 
Slides were kept in the dark at 4ºC till confocal microscopy imaging. Images were 
analysed using Imaris 6.3 × 64 software (Bitplane). 
 
2.2.8 Multiphoton microscopy 
Animals were injected in the hind footpads with 5µg of anti-CD169 A488 
and/or CD4 eFluor450 and sacrificed after 10 minutes. Popliteal LNs were 
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immobilised on a glass-bottom 35mm culture dish by veterinary topical tissue 
adhesive. High resolution single xy plane images were acquired with an upright 
Olympus Fluoview FV1000 MPE2 Twin multi-photon microscope using a water-
immersion 25 x 1.05 NA objective (Olympus XLPLNWMP) and a pulsed Ti:sapphire 
laser (Spectra Physics MaiTai HP DeepSee) tuned to 800nm. Collagen was 
detected as second harmonic generation signal through a bandpass filter 397-
420nm, two-photon fluorescence of eFluor450 and Alexa488 were detected using 
455-490nm and 500-540nm filters respectively. When simultaneous detection of 
eFluor450 and Alexa488 was performed, the amount of eFluor450 signal in the 
Alexa488 channel was determined with single labelled samples and removed from 
the Alexa488 channel using the channel arithmetic option in Imaris extensions. 3D 
imaging of explanted LNs was done using tiled z-stacks of 300µm depth, settings 
were chosen so that cells in treated samples were clearly visible while signal 
saturation in control samples was limited. For high resolution z-stacks, images of 
1024 x 1024 pixels with 160nm pixel size and 0.7µm z-spacing were recorded while 
increasing laser power with depth, the display was adjusted using gamma = 1.7 to 
show cells with low and high intensities in a single image. 
2.2.9 3View electron microscopy 
SBF-SEM (serial block face-scanning electron microscopy) was carried out 
using a 3View2XP (Gatan, Abingdon) mounted on a Sigma VP field emission SEM 
(Zeiss, Cambridge), and images of the block face were recorded using a low 
voltage backscatter detector (Gatan, Abingdon). Sections were cut with a thickness 
of 100nm. Typical imaging conditions in variable pressure mode (10-30 pA), used 
to reduce charging when necessary: 20-25 nm pixels (xy), 2-3 kV, 3-5 us dwell time, 
4096x4096 or 8192x8192 frame size. Typical imaging conditions in high vacuum 
mode: 21 nm pixels (xy), 1-1.3 kV, 4 us dwell time, 4096x4096 frame size. 
2.2.10 Whole body imaging 
Whole body imaging of lymphatic flow was carried out as previously 
described. 3 days after administration of CpG or PBS in the footpad, the lower half 
body fur of experimental mice was clipped. 24 hours later, 2µl of 1% indocyanine 
green dye was injected into the footpads of anaesthetised mice inside the IVIS 
Spectrum Whole Body Imaging System (Caliper Life Sciences). Image acquisition 
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and analysis was performed with Living Image 3 software (Caliper Life Sciences) 
using the following parameters: field of view 6.6, binning 8, and F-stop 2.70. 
Images were acquired every 4 seconds and sequences were mounted and 
annotated with ImageJ (NIH). 
 
2.2.11 Flow cytometry  
For flow cytometry staining of spleen and lung samples, one round of 5 
minutes incubation in red blood cell lysis buffer was performed prior to staining. LN, 
spleen and lung single-cell suspensions were then incubated with anti-mouse 
CD16/32 (1:100) diluted in FACS buffer for 20 minutes on ice to block nonspecific 
antibody binding. Cells were washed in FACS buffer and stained for 20 minutes on 
ice with the appropriate combination of antibodies, tetramers or live/dead reagents 
diluted in FACS buffer. When using biotinylated antibodies, cells suspensions were 
washed following antibody labelling and incubated for 20 minutes on ice with 
fluorescently labelled streptavidin. Cells were washed and resuspended in FACS 
buffer. For intracellular staining, surface-stained cells were fixed and permeabilised 
with Cytofix/Cytoperm for 30 minutes on ice and washed twice with Perm/Wash 
buffer. Then, cells were incubated for 30 minutes with intracellular antibodies 
(1:100) in Perm/Wash buffer and for further 30 minutes with labelled secondary 
antibodies (1:100) when required. Finally, cells were resuspended in 400µl of 
FACS buffer and data were collected on a Fortessa cytometer (BD Biosciences) 
and analysed with FlowJo (TreeStar). 
 
For the cytokine bead array measurements, the mouse Th1, Th2, Th17 CBA 
kit was used, which measures IL-2, IL-4, IL-6, IFN-γ, TNF-α, IL-17A and IL-10. 
Assay was performed according to manufacturer’s instructions. All standards and 
samples were measured in duplicate. Data were acquired on a BD™ FACS Calibur 
flow cytometer.  
 
2.2.12 RT-PCR 
Lung single cell suspensions or sorted DCs or iNKT cells from mediastinal 
LNs were lysed and mRNA was extracted using RNeasy mini or micro Kit. Between 
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104 and 105 cells were used in each condition. mRNA was reversely transcribed 
into cDNA using random hexamers from the SuperScript III first-strand system. 
cDNA was amplified using custom primer sets (Sigma) and SYBR green PCR 
master mix on a 7500 real-time PCR system (Applied Biosystems). Table 2.8 
provides a list of all DNA primers that were used in this thesis for mRNA 
quantification. The relative mRNA abundance of target genes was determined by 
means of the ΔCT method: 
 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒  𝑋  𝑚𝑅𝑁𝐴  𝑙𝑒𝑣𝑒𝑙𝑠 = 2(!!,!!!!,!)!"#$%"&!(!!,!!!!,!)!"#! 
 
CT,X= Threshold cycle for the gene of interest 
CT,R= Threshold cycle for the endogenous reference gene (cph) 
 
Table 2.8 List of primers used for RT-PCR analysis 
 
Name of target Orientation  Sequence 
A3GALT2 forward 5’-GGAACCATTTCGAGCCCTTGT-3’ 
A3GALT2 reverse 5’-GCGGCCACGGGAGATAATAG-3’ 
CPH forward 5’-ATGGTCAACCCCACCGTG-3’ 
CPH reverse 5’-TTCTTGCTGTCTTTGGAACTTTGTC-3’ 
HEXB forward 5’-GACTGGAAGGTTGGTCCAAAGAC-3’ 
HEXB reverse 5’-TACAACAGCCGCGGGAACATC-3’ 
IFN-γ forward 5’-ACTGGCAAAAGGATGGTGAC-3’ 
IFN-γ reverse 5’-TGAGCTCATTGAGAATGCTTGG-3’ 
IL-21 forward 5’-TCAGCTCCACAAGATGTAAAGGG -3’ 
IL-21 reverse 5’-GGGCCACGAGGTCAATGAT-3’ 
IL12p40 forward 5’-GGAAGCACGGCAGCAGAATA-3’ 
IL12p40 reverse 5’-AACTTGAGGGAGAAGTAGGAATGG-3’ 
NP1 forward 5’-CTCGTCGCTTATGACAAAGAAG-3’ 
NP1 reverse 5’-AGATCATCATGTGAGTCAGAC-3’ 
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2.2.13 Western blotting  
For western blot analysis, 106 primary B cells were stimulated for the 
indicated times and concentrations with anti-IgM, IL-4, CpG and LPS at 37ºC. 
When indicated, 100µM chloroquine was added to the medium 15 minutes before 
the end of incubation. After incubation, cells were pelleted and lysed with SDS lysis 
buffer and boiled for 5 minutes at 100ºC. Samples and ladders were loaded on pre-
cast 4-20% Mini-PROTEAN® TGX™ gels and ran for 35 minutes at a constant 
voltage of 200V. Proteins were transferred on PVDF membranes for 7minutes (25V, 
2.5A) using the TransBlot® Turbo™ transfer system (170-4155, Bio-Rad). 
Membranes were blocked with 5% BSA for 1 hour at room temperature and 
incubated over night at 4ºC with primary antibodies diluted in western blot washing 
buffer. Membranes were washed three times and incubated 1 hour at room 
temperature with HRP-conjugated secondary antibodies diluted in western blot 
washing buffer. Membranes were incubated with ECL solution for 1 minute at room 
temperature. Chemiluminescence was detected with Hyperfilm and developed in a 
JP-33 (Jpi) film developer. For quantifications, developed chemiluminescence films 
were scanned using a CanoScan 8800F (Canon) at a resolution of 300 dpi. Total 
fluorescence of bands was measured in ImageJ (NIH) by drawing a box-shaped 
ROI around the specific band and using the background-subtracted total 
fluorescence as a measure for band intensity. This was done for the band of 
interest and - using the same ROI – for the band of the loading control of the 
specific lane. Intensities of bands of interest were normalised to intensities of 
corresponding loading controls. All lanes were then further normalised relative to 
unstimulated samples.   
 
2.2.14 ELISA 
ELISAs (enzyme-linked immunosorbent assays) were used to quantify the 
production of cytokines and antigen-specific antibodies. To measure IL-2 
production, 96-well plates were coated over night at 4ºC with anti-mouse IL-2 
(1:125, clone JES6-1A1) in 0.1 M NaHCO3. Plates were washed with PBS 0.01% 
Tween and then blocked for 1 hour at room temperature with PBS 2.5% FCS. 
Plates were then incubated for 4 hours at room temperature with co-culture 
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supernatants or serial dilutions of recombinant mouse IL-2 as standard. Plates 
were washed with PBS 0.01% Tween and probed for 1hour at room temperature 
using a biotinylated antibody against mouse IL-2 (1:500, clone JES6-5H4) diluted in 
PBS 2.5% FCS. Plates were then washed with PBS 0.01% Tween, incubated for 
30 minutes at room temperature with streptavidin-AP (1:5000) in PBS 2.5% FCS 
and then finally washed again in PBS 0.01% Tween. To measure PR8-specific 
antibodies, plates were coated with 1µg/ml of PR8 virus in PBS over night at 4ºC, 
blocked with Pierce protein-free solution for 2 hours at room temperature and then 
incubated for further 2 hours with serial dilutions of blood serum collected at 9 days 
post-influenza infection. Plates were probed for 1 hour using biotinylated antibodies 
against mouse IgM or IgG (1:1000) diluted in Pierce buffer. All ELISA plates were 
developed using p-NitrophenylPhosphate. 405nm absorbance was detected using 
a SPECTRAmax190 plate reader (Molecular Device).  
 
2.2.15 ELISPOT 
ELISPOT (enzyme-linked immunosorbent spot) multiscreen filtration plates 
were activated with absolute ethanol, washed with PBS and coated overnight at 
4ºC with 1µg/ml of HEL or VACV diluted in PBS. Plates were subsequently blocked 
for 1 hour with complete medium and incubated for 24 hours at 37ºC with serial 
dilutions of LN single cell suspensions. Plates were washed with PBS 0.01% 
Tween and incubated for 1 hour with 1µg/ml of biotinylated anti-IgM or anti-IgG 
diluted in PBS 1% BSA. Then, plates were washed and incubated for 1 hour with 
1µg/ml streptavidin-alkaline phosphatase. Finally plates were washed and 
developed with SigmaFast BCIP/NBT. Enzymatic reactions were stopped by dH2O 
wash and dots counted manually.  
 
2.2.16 Southern blot 
2.2.16.1  DNA extraction 
Embryonic stem cells were digested in 500µl of DNA lysis buffer 
complemented with 30µl of Proteinase K (10mg/ml stock) overnight at 56°C with 
constant agitation. 500µl phenol-choloroform-isoamylalcohol were added each tube 
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under a chemical hood. After vigorous shaking, samples were spun for 5 minutes at 
maximum speed in a tabletop centrifuge. The upper layer was transferred to a new 
tube, mixed with 500µl of chloroform, shaken, and spun again. The upper phase 
was again collected, transferred into a new tube and the DNA was precipitated 
using isopropanol. After centrifugation, the supernatant was carefully removed and 
the DNA pellet was washed once with 70% ethanol. Finally, DNA was resuspended 
in dH2O and the DNA concentration was measured with a Nanodrop. 
2.2.16.2  DNA digestion 
20-30µg of DNA were digested with the restriction enzyme SacI. The 
digestion mix was prepared as described in Table 2.9. Digestions were allowed to 
proceed overnight at 37°C. The next day, 10 units of SacI were added to the 
reaction in 5µl of the same buffer for 5 more hours at 37°C.  
 
Table 2.9 Digestion mix for Southern blotting 
 
 
 
 
 
 
 
 
     
 
 
 
 
2.2.16.3 Electrophoresis and capillary transfer 
A 0.8% w/v agarose gel was prepared in TBE buffer and Ethidium Bromide 
was incorporated in the gel at 0.5µg/ml. Digested samples were diluted with 6x 
DNA loading buffer, loaded onto the gel and ran for up to 16 hours under a 
constant voltage of 20V. After migration, a picture of the gel was taken under a UV 
illuminator. This allowed to control for the efficiency of the digestion and to keep a 
record of the position of the different bands of the ladder. Gels were then submitted 
Reagent Final amount Volume (µl) 
DNA 20-30µg 10 
SacI 60 units 3 
NEB1 10x digestion buffer 1x 4 
BSA 100x 200µg/ml  0.4 
Spermidine 100mM  1mM  0.5 
RNase A 50x 400µg/ml 0.8 
dH2O  to 40µl 21.3 
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to two sequential 30 minutes rounds of incubation in Southern denaturation buffer 
with gentle agitation. Efficient denaturation resulted in a change in the colour of the 
DNA loading dye to dark blue/green. Subsequently, gels were transferred into 
Southern neutralisation buffer and incubated 45 minutes at room temperature with 
gentle agitation, after which the buffer was replaced and neutralisation continued 
for further 15 minutes. A capillary transfer was then set up on an inverted gel tray in 
a pyrex container, which was covered with two sheets of Whatman 3MM filter 
paper wetted in 10x SSC. The gel was placed upside down on top of the Whatman 
paper and two individual nylon membranes cut to the size of the gels were placed 
directly on top of the gel. The container was filled with 10x SSC and all the edges 
were covered with parafilm to prevent evaporation. Subsequently, a thick pile of 
paper towels (15-20cm) was added on top and pressure was applied by putting an 
item of about 500g on top of the stack. After overnight incubation, the set up was 
dismantled and the gel was imaged under a UV lamp to check the transfer 
efficiency. 
2.2.16.4  Probe preparation 
To generate the Southern probes, regions of interest were amplified by PCR 
from genomic DNA using the Phusion high fidelity DNA polymerase system. The 
primers used were the following and the PCR mix was prepared as shown in Table 
2.10.  
 
Forward primer: 5’CTCCAGGCACCCTTTAGCTGCTA3’ 
Reverse primer: 5’TGTTTTCTTGAATACCATTCAAGCA3’ 
 
Table 2.10 PCR mix for probe generation 
 
 
Reagent Volume (µl) 
Template DNA 1 
PhusionTM buffer 5X  4 
10 mM dNTPs 0.4 
Forward primer 10µM  1 
Reverse primer 10µM  1 
80 
PhusionTM DNA polymerase  0.2 
dH2O  12.4 
             
 
 
The PCR program used for the amplification of the probe was the one shown in 
Table 2.11:  
 
Table 2.11 PCR program for probe generation 
 
Cycle Step Temperature (oC) Time Cycles 
Initial denaturation 98 30seconds 1 
Denaturation 
Annealing 
Elongation  
98 
64 
72 
10seconds 
30seconds 
30seconds 
 
35 
Final extension 72 10minutes 1 
 
Amplification of the correct PCR products was checked by electrophoresis in 
agarose gel. PCR product were used to produce the labelled probe using the DIG 
High Prime DNA labelling and detection Starter Kit II following manufacturer’s 
instructions. Successful labelling was checked by electrophoresis, as correctly 
labelled probes migrate less than their unlabelled counterparts in agarose gels. 
Labelled probes were kept at -20°C until use. Before use, probes were denatured 
at 70°C for 30 minutes and diluted in DIG Easy Hyb solution at the required 
concentration. 
2.2.16.5  Hybridisation 
Membranes were rinsed in 6x SSC for 5 minutes. Then, the DNA was cross-
linked to the membranes by exposing the DNA-side of the membranes to UV 
source for 2 minutes at full power. Membranes were then hybridised using the DIG 
detection Starter Kit following manufacturer’s instructions. Briefly, membranes were 
pre-hybridised for 1hour at 42°C in pre-heated DIG Easy Hyb solution in a roller 
bottle of a hybridisation oven. The pre-hybridisation solution was poored off, 
replaced with the probe and membranes were hybridised overnight at 42°C. 
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2.2.16.6  Detection 
Membranes were washed 2 times for 5 minutes in Southern stringency 
wash 1 at 25°C in a hybridisation oven. Then, they were washed two times for 15 
minutes in southern stringency wash 2 at 68°C, and subsequently for 15 minutes in 
southern wash buffer at room temperature. After these various incubations, 
membranes were blocked for 30 minutes in 100ml of southern blocking buffer (from 
the DIG detection Starter Kit). The solution was then replaced with 20ml of 
southern blocking buffer complemented with 2µl of anti-DIG antibody for 30 
minutes. Membranes were washed twice for 15 minutes in southern wash buffer, 
and equilibrated for 5 minutes in southern detection buffer. Membranes were 
developed with CSPD ready-to-use solution following manufacturer’s instructions. 
Chemiluminescence was detected with Hyperflim, which was developed using a 
JP-33 (Jpi) film developer. Developed films were scanned using a CanoScan 
8800F (Canon) at a resolution of 600 dpi.  
 
2.2.17 Long-range PCR 
To screen embryonic stem cell clones, long-range PCR from genomic DNA 
was performed using the KOD XtremeTM hot start DNA polymerase system. The 
primers used were the following and the PCR mix was prepared as shown in Table 
2.12.  
Forward Primer: 5’GTTCTCTAGTGAGAGAGATGCCCATA3’ 
Reverse Primer: 5’CTACCCGTGATATTGCTGAAGAG3’ 
 
Table 2.12 PCR mix for long-range PCR 
 
Reagent Final amount Volume (µl) 
Xtreme Buffer 2x 1x 5 
dNTPs (2mM each) 0.4µM 2 
PCR grade water  0.2 
Forward Primer 10 µM 0.3µM 0.3 
Reverse Primer 10 µM  0.3µM 0.3 
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Template DNA (10 ng/µl)  2ng/µl 2 
KOD XtremeTM Hot Start 
DNA polymerase (1U/µl) 
0.02U/µl 0.2 
Total reaction volume  10 
 
The PCR program used for the amplification was the one shown in Table 
2.13. Amplification was checked by electrophoresis on agarose gel.  
 
Table 2.13 Amplification program used for long-range PCR 
 
Cycle Step Temperature (oC) Time Cycles 
Initial denaturation 94 2minutes 1 
Denaturation 
Annealing 
Elongation  
98 
60 
68 
10seconds 
30seconds 
8minutes 
 
40 
Final extension 68 10minutes 1 
 
2.2.18 Statistics 
All statistical analyses were performed using Prism (GraphPad Software), 
two-tailed t-test, and p values <0.05 were considered significant 
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Chapter 3. Inflammation-induced disruption of the 
SCS macrophage layer shuts down B cell responses 
to secondary infection   
3.1 Introduction 
The highly organised architecture of the LN is critical for mounting effective 
immune responses against pathogens. One particular facet of this organisation is 
the layer of CD169+ macrophages at the SCS floor. These macrophages are 
strategically positioned at the lymph-tissue interface to capture pathogens as they 
enter the LN. This capture not only prevents systemic dissemination of pathogens 
but also mediates the activation of innate and innate-like cells and the presentation 
of antigen to lymphocytes to initiate the humoral and cell-mediated immune 
response. 
3.1.1 SCS macrophages prevent systemic spreading of pathogens  
Several studies have shown that SCS macrophages are critical to prevent 
systemic dissemination of viruses and bacteria, such as VSV (vesicular stomatitis 
virus), VACV (vaccinia virus) and Pseudomonas Aeruginosa (Junt et al., 2007, 
Kastenmüller et al., 2012). In these studies, local depletion of SCS macrophages 
with clodronate liposomes, results in spreading of virus and bacteria to the blood, 
spleen and further LNs following local infection. Moreover, LN SCS macrophages 
function as crucial gatekeepers to the central nervous system by limiting its 
invasion following peripheral infection with neurotropic virus. This phenomenon is 
due to the ability of SCS macrophages to produce type I IFN following VSV 
infection, what limits intranodal nerves viral invasion. Therefore, local depletion of 
SCS macrophages results in paralysis and morbidity of mice due to invasion of 
VSV to the central nervous system (Iannacone et al., 2010). 
 
The ability of SCS macrophages to limit pathogen dissemination is 
dependent on B cell-expressed lymphotoxin a1b2, which maintains a protective 
SCS macrophage phenotype in the LNs. SCS macrophages from mice lacking 
lymphotoxin a1b2 selectively in B cells display an aberrant phenotype: they 
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express high levels of SIGN-R1 and F4/80 and low levels of CD169, as medullar 
macrophages do. In the absence of lymphotoxin a1b2, SCS macrophages fail to 
limit pathogen replication and produce type I IFN, allowing fatal invasion of 
pathogens to central organs (Phan et al., 2009, Moseman et al., 2012). 
 
3.1.2 SCS macrophages mediate activation of innate and innate-like cells  
Recent studies have demonstrated an active cooperation between SCS 
macrophages and lymphoid subsets closely localised in the inter-follicular areas. 
Upon arrival of microbes in the afferent lymph, the inflammasome complex is 
activated on SCS macrophages, what induces the cleavage and release of active 
IL-1 and IL-18. IL-18, together with other cytokines such as IL-12 and type I IFN, 
induces the activation of NK cells, NKT cells, γδ T cells and memory CD8+ T cells, 
which start producing high-levels of IFNγ within the first 2 to 4 hours of infection 
(Kastenmüller et al., 2012).  
 
The IFNγ produced by these cells acts back on the SCS macrophages to 
enhance their capacity for intracellular resistance to microbe replication, potentially 
through up-regulation of iNOS (inducible nitric oxide synthase) (Kastenmüller et al., 
2012). Additionally, the IFNγ production by these lymphoid populations induces the 
expression of CXCL9 by SCS macrophages. CXCL9 triggers the recruitment of LN-
resident NK cells and memory CD8+ T cells to the SCS area through interaction 
with CXCR3. Once there, NK cells and memory CD8+ T cells commit into long-
lasting interactions with SCS macrophages (Chtanova et al., 2009, Coombes et al., 
2012, Garcia et al., 2012, Sung et al., 2012, Kastenmüller et al., 2013). 
 
Furthermore, the IL-1 produced by SCS macrophages following pathogen 
recognition and inflammasome activation, mediates the recruitment of neutrophils 
from the periphery to the LNs. Once the neutrophils have reached the LN, they 
localise close to the SCS and they form highly dynamic clusters called neutrophil 
swarms. These neutrophil swarms result in localised loss of SCS macrophages and 
help to fight against extracellular pathogens (Chtanova et al., 2008, Kastenmüller et 
al., 2012). 
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The fact that the effector lymphoid cells are concentrated in close proximity 
to the SCS macrophages or re-localise close to them following infection, enhances 
the efficiency of the innate immune response and reduces the time needed for this 
response to develop in order to control lymph-born pathogens. 
 
3.1.3 SCS macrophages present antigen to lymphocytes   
SCS macrophages not only limit the systemic spreading of pathogens and 
activate innate and innate-like cells through the secretion of cytokines and 
chemokines but also mediate the presentation of antigen to cells from the adaptive 
immunity. Particulate antigens arriving through the lymphatic vessels to the SCS of 
the LN are captured by SCS macrophages. These macrophages are positioned 
such that their cell bodies are in the sinus lumen but their cellular processes extend 
into the adjacent B cell follicles. This location allows them to capture antigens from 
the SCS lumen with their cell bodies and trans-display these materials on 
processes extending into the follicles. In this way, B cells from underlying follicles 
can survey macrophage-bound antigens and cognate B cells can commit into long-
last interactions with them to extract antigen for internalisation and following 
presentation to T cells (Carrasco and Batista, 2007, Junt et al., 2007, Phan et al., 
2007). Furthermore, non-specific B cells can extract immune complexes from SCS 
macrophages by binding to the complement proteins associated with them and 
transport the immune complexes from the SCS to the FDCs to drive affinity 
maturation (Phan et al., 2007, 2009).  
 
SCS macrophages not only present intact antigens to B cells but they can 
also behave as true antigen presenting cells by up-taking, processing and 
presenting pathogen-derived lipids to NKT cells in the context of CD1d. NKT 
usually reside in the inter-follicular areas of the LNs in close contact to SCS 
macrophages even before infection (Kastenmüller et al., 2012). Following antigen 
administration, NKT cells establish long-lasting interactions with SCS macrophages 
in a CD1d-dependent manner. This interaction is required for NKT cell activation, 
cytokine production and population expansion (Barral et al., 2010). 
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Interestingly, the antigen presentation ability of SCS macrophages is not 
restricted to pathogens but they can also phagocytose dead tumour cells 
transported via the lymphatics and subsequently crosspresent tumour antigens to 
CD8+ T cells. In fact, while subcutaneous immunisation with irradiated tumour cells 
protects mice from syngeneic tumour, the activation of tumour-specific CD8+ T cell 
and subsequent antitumor immunity are severely impaired in mice where CD169+ 
macrophages were depleted (Asano et al., 2011). 
 
The strategic position of SCS macrophages at the interface between the 
lymphatic fluid entrance and the LN immune cells makes them central in the 
initiation of the immune response. They not only avoid the systemic spreading of 
infectious pathogens but they also mediate the early activation of innate and 
adaptive immune cells.   
 
3.2 Infection and inflammation disrupt SCS macrophage 
organisation in draining LNs 
The microanatomy of the LNs defines the ability of the organism to respond 
to pathogens. At the same time, the global architecture of these organs is 
extremely adaptable to environmental changes. For instance, during infection or 
inflammation, draining LNs undergo a dramatic remodelling of their structure. 
These morphological changes include an increase in LN size and B cell follicle 
volume, an expansion of the HEV network and lymphatic vasculature and a 
substantial reorganisation of antigen presenting cells, lymphoid subsets and FRC 
network. These changes are in part caused by changes in chemokine levels, 
temporary shutdown of lymphocyte egress, recruitment of new lymphocytes and 
activated DCs and clonal expansion of antigen-specific lymphocytes (Odermatt et 
al., 1991, Heikenwalder et al., 2004, Mueller et al., 2007, Junt, Scandella and 
Ludewig, 2008, Scandella et al., 2008, Kumar et al., 2010, Acton et al., 2014, 
Astarita et al., 2015). However, the effect that infection has on the organisation of 
the SCS macrophage layer is not well defined. I therefore decided to study the 
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effect that inflammation or bacterial and viral infections have on the spatiotemporal 
organisation of this central population of cells.  
3.2.1 Bacterial and viral infection interrupt the integrity of the LN barrier 
To address this question, I proceeded to visualise the distribution of SCS 
macrophages in draining LNs after localised infection with a variety of pathogens. 
Initially, I chose a Staphylococcus aureus infection model, as S. aureus is the most 
common etiological organism of skin and soft tissue infection and is often involved 
in respiratory diseases and food poisoning (David and Daum, 2010). I infected 
C57BL/6 mice in the ear skin with 106 CFU of S. aureus, and one week after, 
superficial cervical LNs were harvested from infected and non-infected mice. 
Frozen LN sections were stained with anti-B220 to stain the B cell follicles and with 
anti-CD169 to stain SCS macrophages, then examined by confocal microscopy. In 
the steady state, LNs were relatively small, B cell follicles were structurally defined 
and a continuous layer of CD169+ macrophages was observed surrounding the 
entire LN. In contrast, after bacterial infection the overall dimensions of the LNs 
increased around four-fold with a considerable enlargement of the B cell follicles 
(Figure 3.1A). Even though B cell follicles were dramatically enlarged, their defined 
structure was conserved. Surprisingly, these changes in LN and B cell follicle size 
were accompanied by an unprecedented disruption of the CD169+ macrophage 
layer in the SCS area. This disruption resulted in the loss of macrophage layer 
continuity and integrity and a retraction of these macrophages to inner follicular 
areas of the LN (Figure 3.1A).  
 
In order to quantify the extent of the macrophage layer disruption and the 
distance of macrophages to the LN border after infection, we developed, together 
with Andreas Bruckbauer, the disruption score and the distance score. For this, 
confocal images of LN sections were analysed in Imaris (Bitplane) using the build 
in tools for spot detection and surfaces as well as Matlab in combination with Imaris 
extensions. To measure the disruption score, CD169+ cells were detected as 
surfaces using a low threshold value (14 for 8 bit files, smoothing 5µm, background 
subtraction 5µm) and the number of individual surface objects within a 50µm zone 
on the edge of the follicle was counted along the SCS interface. In LNs from non-
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infected mice, macrophages form a continuous line at these low threshold settings 
and this resulted in a low number of surface objects. In contrast, disrupted 
macrophage layer in LNs from infected mice show a larger number of individual 
objects at the same threshold settings. The disruption score is the number of 
surface objects identified this way. To measure the distance of the macrophages to 
the follicle border, the position of the cells was detected using spot detection with 
background subtraction (15µm estimated diameter) and surfaces representing the 
follicles were created manually. The follicle edge was then detected as a 2D object 
using an in-lab developed Matlab script. The shortest distance of each cell to the 
edge was calculated. In brief, an increase of these two parameters, as observed 
after S. aureus infection, reflects an increase in the disruption of the macrophage 
layer and a retraction of these cells from the SCS, respectively.  
 
The next question was whether macrophage layer disruption was a general 
feature associated with bacterial infections. For this, I chose another bacterial 
infection model. GBS (group B Streptococcus) was selected in this case as it 
represents a severe infectious disease in newborn babies (Iroh Tam, Delair and 
Obaro, 2015). Mice were infected with 106 CFU of GBS in the footpad, and 4 days 
later popliteal LNs were harvested and frozen. Cryosections were stained with anti-
B220 and anti-CD169 and then examined by confocal microscopy. Similar changes 
in the LN architecture were observed in popliteal lymph nodes of infected mice, 
including increased LN and B cell follicle size and a disruption of the SCS 
macrophage layer (Figure 3.1B). This result demonstrates that the loss of 
macrophage layer integrity in draining LNs is a common feature associated with 
bacterial infections.  
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Figure 3.1 Bacterial infection disrupts SCS macrophage barrier in draining LNs 
(A) Cervical or (B) popliteal LN cryosections stained for CD169 (green) and B220 
(red) derived from mice administered with either PBS (control), (A) 106 CFU of S. 
aureus in the ear 7 days previously or (B) 106 CFU of GBS in the footpad 4 days 
previously. Scale bars, 300µm (top); 60µm (bottom). Bar charts show the 
quantification of SCS macrophage disruption and distance of macrophages to LN 
border in each condition for an individual experiment. Each dot represents the 
analysis of a distinct follicle. Mean ± s.e.m. Data are representative of at least three 
independent experiments with three mice per condition. Student t test, *p<0.05, 
****p<0.0001. 
 
Next, I analysed whether the disruption of the SCS macrophage layer was a 
process specifically related to bacterial infection or whether viral infection would 
also induce a similar phenomenon. Influenza A virus was chosen as a viral 
infection model due to its importance in the clinical setting. Influenza A virus is the 
main causative agent of influenza, commonly known as the “flu”, and complications 
with this disease can induce viral pneumonia, secondary bacterial pneumonia, 
sinus infections and worsening of previous health problems such as asthma or 
heart failure (Chowell et al., 2009, Perez-Padilla et al., 2009). Influenza constitutes 
a major threat to children, the elderly, and immunocompromised patients and 
causes 500.000 deaths per year worldwide (Waffarn and Baumgarth, 2011). Due to 
the high mutation rate of the virus, the influenza vaccine usually confers protection 
for no more than a few years and is therefore one of the most studied viruses in the 
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world, together with HIV (Impagliazzo et al., 2015). I then went on to infect mice 
intranasally with 200 PFU of influenza (strain A/Puerto Rico/8/1934 H1N1). Seven 
days later, mediastinal LNs were harvested, frozen, and cryosections stained with 
anti-B220 and anti-CD169. Confocal microscopy analysis showed a significant 
increase in B cell follicle size after infection together with a complete disruption of 
the SCS macrophage layer (Figure 3.2A) as observed during bacterial infection.  
 
To assess whether macrophage disruption was a general process 
associated with viral infections, I chose VACV (vaccinia virus) as an alternative 
infection model. The study of VACV biology has been important for the 
development of vaccines against smallpox, as immune responses generated from 
VACV infection protects a person against lethal smallpox infection (Walsh and 
Dolin, 2011). I therefore went on to infect mice with 104 PFU of VACV in the 
footpad, and after 4 days popliteal LNs were harvested and stained with anti-B220 
and anti-CD169 as before. Interestingly, VACV infection induced an increase of the 
B cell follicles and a similar disruption of the SCS macrophage layer in the draining 
popliteal LNs (Figure 3.2B). Taken together, the data above show that the 
disruption of the CD169+ macrophage layer emerges as a common feature 
associated with bacterial or viral infections. 
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Figure 3.2 Viral infection disrupts SCS macrophage barrier in draining LNs 
(A) Mediastinal or (B) popliteal LN cryosections stained for CD169 (green) and 
B220 (red) derived from mice administered with either PBS (control), (A) 102 PFU 
of influenza virus intranasal 7 days previously or (B) 104 PFU of VACV in the 
footpad 4 days previously. Scale bars, 300µm (top); 60µm (bottom). Bar charts 
show the quantification of SCS macrophage disruption and distance of 
macrophages to LN border in each condition for an individual experiment. Each dot 
represents the analysis of a distinct follicle. Mean ± s.e.m. Data are representative 
of at least three independent experiments with three mice per condition. Student t 
test, ****p<0.0001. 
 
The next question was whether macrophage disruption in the draining LNs 
was specific to the process of infection or whether merely the arrival of antigen 
could induce a similar process. To address this question, I injected 106 inert beads 
or 104 UV-inactivated PFU of VACV into the footpad of mice. After 4 days, popliteal 
LNs were harvested, cryosections were stained with anti-B220 and anti-CD169 and 
then analysed by confocal microscopy. Neither enlargement of the B cell follicles 
nor disruption of the macrophage layer was observed in either case. This result 
indicates that infection, or a process associated with it, is necessary for the 
induction of the macrophage layer disruption (Figure 3.3). 
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Figure 3.3 Inert antigens do not disrupt SCS macrophage barrier  
Popliteal LN cryosections stained for CD169 (green) and B220 (red) derived from 
mice that were injected with PBS, 104 PFU of UV-inactivated VACV or 0.2 µm inert 
beads in the footpad 4 days previously. Histograms represent CD169 fluorescence 
measured from the outer edge of the LN to the follicles. Data are representative of 
two independent experiments with two mice per condition.  
 
Due to the complexity in the calculation of the disruption and distance 
scores, for some supportive experiments the disruption of the macrophage layer 
was analysed in a simpler way: CD169 fluorescence was measured from the outer 
edge of the LN to the follicles and mean fluorescence was represented in 
histograms. In the case of LNs from non-immunised mice, there is a peak of CD169 
fluorescence in the histograms that corresponds to the continuous macrophage 
layer. In contrast, after infection/inflammation this clear peak of CD169 in the 
histogram is lost due to the loss of integrity of the macrophage layer.  
 
3.2.2 Inflammation induces temporary disruption of the macrophage layer  
 To investigate whether the disruption of the SCS macrophage layer can 
occur as a direct consequence of the inflammation associated with the infection 
process, I went on to induce inflammation in the absence of infecting pathogens. 
For this, I used the TLR9 agonist CpG and the TLR4 agonist LPS. Unmethylated 
BeadsControl UV-VACV
CD169
B220
C
D
16
9 
Fl
uo
re
sc
en
ce
0
30
60
0 100 200
Distance (µm)
93 
CpG sequences in DNA molecules are relatively common in bacterial genomes or 
viral DNA in comparison to their rare abundance in vertebrate genomes (less than 
1%). LPS is a large molecule consisting of a lipid and a polysaccharide and is 
commonly found in the outer membrane of Gram-negative bacteria. Recognition of 
CpG-rich motives in DNA by TLR9 and LPS on the cell surface by TLR4 elicits 
intracellular signalling, finally leading to pro-inflammatory response (Poltorak et al., 
1998, Hemmi et al., 2000). Mice were injected in the footpad with PBS (control), 
10µg of CpG or 50µg of LPS. Four days later, popliteal LNs were harvested and 
analysed. The overall dimensions of draining LNs were increased more than three 
times after CpG or LPS administration, presumably in part due to the expansion of 
B220+, CD3+ and B220-CD3- cell populations as revealed by flow cytometry (Figure 
3.4A). Cryosections from frozen LNs were stained with anti-B220 and anti-CD169. 
Confocal analysis revealed that TLR-mediated inflammation triggers a similar 
disruption of SCS macrophages as seen following bacterial and viral infection 
(Figure 3.4B). Furthermore, in these cases the retraction of CD169+ macrophages 
to the inner follicular areas of the LN was more evident than during infection. This 
results in a substantial increase in the disruption and distance scores compared to 
LNs from non-immunised animals. All together, these results demonstrate that the 
inflammation process per se is sufficient to induce disruption of the SCS 
macrophage layer in draining LNs. 
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Figure 3.4 CpG and LPS induce SCS macrophage disruption in draining LNs  
(A) Representative popliteal LNs harvested 4 days after footpad injection of PBS, 
10µg of CpG or 50µg of LPS. Bar charts show flow cytometry quantification of 
DAPI-, B220+, CD3+ and B220-CD3- (Lin-) cells from two independent experiments. 
Each dot represents a single mouse. (B) Popliteal LN cryosections stained for 
CD169 (green) and B220 (red) derived from mice treated as in (A). Scale bars, 
300µm (top); 60µm (bottom). Bar charts show the quantification of SCS 
macrophage disruption and distance of macrophages to LN border in each 
condition for an individual experiment. Each dot represents the analysis of a distinct 
follicle. Data are representative of at least three independent experiments with 
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three mice per condition. Mean ± s.e.m. Student t test, **p<0.01, ***p<0.001, 
****p<0.0001. 
 
 
These findings are particularly intriguing, as SCS macrophages are a 
relatively static population in the LN; indeed complete recovery of these cells after 
depletion with clodronate liposomes can take up to 5 months (Delemarre et al., 
1990). I visualised the rate at which the layer of SCS macrophages recovers after 
inflammation. Mice were injected with CpG in the footpad and popliteal LNs were 
harvested from 7 to 28 days later. Cryosections of the different time points were 
stained with anti-B220 and anti-CD169 and analysed using confocal microscopy. 
Interestingly, while considerable scattering of these macrophages was noted even 
up to three weeks after CpG administration, the compact uniform layer of CD169+ 
macrophages at the SCS was re-established by day 28 (Figure 3.5). Thus, the 
disruption of the SCS macrophages layer after inflammation is a temporary 
process.  
 
  
Figure 3.5 Disruption of the macrophage barrier is a temporary process 
Confocal microscopy analysis of popliteal LN cryosections stained for CD169 
(green) and B220 (red) after 1 to 4 weeks of footpad injection with CpG. 
Histograms represent CD169 fluorescence measured from the outer edge of the 
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LN to the follicles. Data are representative of two independent experiments with 
three mice per condition. Scale bars: 300µm (top); 60µm (bottom).  
 
3.2.3 3D analysis of the LN macrophage layer during inflammation  
To further characterise the loss of integrity in the SCS macrophage layer 
after inflammation, I employed two independent high-resolution technologies: 3D 
multiphoton microscopy and 3D electron tomography. These approaches allow 3D 
analysis of whole LNs instead of single section analysis. 
 
Firstly, I used 3D multiphoton imaging of explanted popliteal LNs from mice 
that were injected with PBS (control) or CpG in the footpad on day 0, injected in the 
footpad with labelled anti-CD169 on day 4 and sacrificed after 10 minutes of 
antibody injection. The surrounding capsule of the LN (cyan) was detected by the 
second harmonic signal generated by the collagen fibers present in this structure 
and SCS macrophages were detected by CD169 labelling. In the steady state, 
macrophages with their characteristic cytoplasmic projections were found all 
around the LN surface with a uniform organisation (Figure 3.6).  Interestingly, in 
LNs from CpG-treated mice, macrophages were found more distant from each 
other and their characteristic projections were no longer visible (Figure 3.6). A side 
view of the LNs from control mice showed a uniform layer of CD169+ macrophages 
immediately below the collagen capsule. In contrast, this uniform layer of 
macrophages was lost in LNs from CpG-treated mice and macrophages were 
found to be more retracted from the collagen capsule, supporting the previous data 
obtained by confocal microscopy of cryosections (Figure 3.6).  
 
The 3D projection obtained with this technology allowed us to quantify, with 
Andreas Bruckbauer, the density and number of CD169+ macrophages in the LNs. 
Cell numbers were quantified by detecting CD169+ cells using the spot detection 
tool in Imaris. The surface area of the LN spherical cap was measured using the 
second harmonic signal and the surface tool in Imaris, dividing by two to account 
for the outer and inner side of the 3D surface object. The macrophage density was 
calculated by dividing the cell number by the measured surface area. The total 
number of cells was estimated by assuming a spherical geometry of the lymph 
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node, estimating the surface of the sphere A, from the measured height h, and 
radius at the base a of the measured spherical cap, using A = π(a2 + h2) and 
multiplying this area by the surface density calculated before. By employing this 
method, a number of 3x104 CD169+ macrophages was calculated to be in LNs from 
control mice with a mean density of 5x10-3/µm2. Importantly, a significant decrease 
in both, number and density of CD169+ macrophages was observed in LNs from 
CpG-injected mice (Figure 3.6).  
 
 
Figure 3.6 3D multiphoton analysis of SCS macrophage disruption 
3D multiphoton microscopy of explanted popliteal LNs from animals injected in the 
footpad with either PBS or CpG (4 days) and anti-CD169 antibody (green) 10 
minutes before dissection. Second harmonic signal generated by collagen fibrils is 
shown (cyan). Scale bars, 500µm (top); 40µm (bottoms). Bar charts show the 
number and density of CD169+ macrophages in the SCS in each condition from 
three independent experiments. Each dot represents an individual LN. Mean± 
s.e.m. Student t test, **p<0.01, ****p<0.0001.   
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Secondly, together with the electron microscopy facility of CRUK and Angelo 
Castello, we used 3D electron tomography of explanted LNs. This technology 
allows the visualisation of the LN 3D structure and cellular and sub-cellular 
organisation without the need of antibody staining. 3D electron tomography 
scanning 100nm sections over a total distance of 100µm was performed on 
popliteal LNs harvested from mice after 4 days of PBS or CpG injection in the 
footpad. Macrophages have a very particular morphology and are easily identified 
due to their large size and abundant intracellular organelles (Sutton and Weiss, 
1966). In the steady state, macrophages were positioned longitudinally on the inner 
wall of the SCS, with the cell body frequently projecting into the SCS lumen and the 
nucleus located within the parenchyma (Figure 3.7). In contrast, four days after 
CpG treatment, macrophages were located deeper in the follicles with cell bodies 
retracted from the SCS (Figure 3.7). In addition, there was an expansion of the 
SCS lumen after inflammation and a large influx of dendritic cells, easily detectable 
due to their convoluted cytoplasm and the presence of dendrites (Inaba, 1992). The 
combination of electron microscopy and 3-view analysis allowed me to quantify the 
macrophages’ distance to the LN SCS, which is significantly increased during 
inflammatory conditions (Figure 3.7).  
 
 
Figure 3.7 3D electron tomography analysis of SCS macrophage disruption  
Representative Z sections (right panels) and schematics (left panels) of 3View 
electron microscopy analysis of popliteal LNs after 4 days of PBS or CpG 
administration. Yellow stars indicate macrophages. Scale bar, 5µm. Bar chart 
represents the distance of macrophages to LN SCS in an individual experiment. 
Each dot indicates a single macrophage. Mean ± s.e.m. Data are representative of 
two independent experiments with two mice per condition. Student t test, 
***p<0.001. 
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Therefore, the characteristic disruption of macrophages at the SCS is not 
simply a result of cell loss as observed by 3D multiphoton microscopy but is due, at 
least in part, to the retraction of these cells towards inner follicular areas during 
inflammation. 
 
3.2.4 Characterisation of the CD169+ population following inflammation 
CD169 is not only expressed by SCS macrophages but also by medullar 
macrophages and some DCs (Batista and Harwood, 2009, Asano et al., 2011). In 
order to confirm that the CD169+ cells in which I focussed my study were coming 
from the SCS and not from somewhere else, I performed several in situ stainings of 
popliteal LNs cryosections from mice that were previously injected with PBS or 
CpG. CD169+ cells expressed high levels of the macrophage markers Mac-3 and 
CD11b (Figure 3.8), suggesting that these cells are, in fact, macrophages. 
Moreover, if the disruption and retraction scores were calculated using CD11b or 
Mac-3 fluorescence instead of CD169, a similar increase in these parameters was 
observed following CpG-mediated inflammation (Figure 3.8). 
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Figure 3.8 Disrupted SCS macrophages express CD11b and Mac-3  
Popliteal LN cryosections from mice injected 4 days previously with PBS (control) 
or CpG in the footpad were stained for CD169 (green), CD11b (magenta) and Mac-
3 (cyan). Scale bars, 300µm (top and middle); 60µm (bottom).  Bar charts show the 
quantification of SCS macrophage disruption and distance of macrophages to LN 
border in each condition from three independent experiments with two mice per 
condition. Mean ± s.e.m. Each dot represents the analysis of a distinct follicle. 
Student t test, *p<0.05, **p<0.01, ****p<0.0001.   
 
It was recently reported that perivascular macrophages and SCS 
macrophages express high levels of CD4, which was normally used as a specific 
marker to identify T cells (Gray et al., 2012, Abtin et al., 2014). I therefore checked 
the expression of CD4 by these CD169+ macrophages in steady state conditions 
and following CpG administration using confocal and 3D multiphoton microscopy. 
In addition to CD4+ staining in the paracortex, CD169+ cells in the SCS also 
expressed CD4 (Figure 3.9A-B), in agreement with these reports. Remarkably, 
under inflammatory conditions, CD169+ cells also express high levels of CD4 
(Figure 3.9A-B). 
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Figure 3.9 Disrupted SCS macrophages express CD4  
(A) Popliteal LN cryosections from mice injected 4 days previously with PBS 
(control) or CpG in the footpad were stained for CD169 (green) and CD4 (magenta). 
Scale bars, 300µm (top and middle); 60µm (bottom). (B) Multiphoton microscopy of 
explanted popliteal LNs from animals injected in the footpad with either PBS or 
CpG (4 days) and anti-CD169 antibody (green) and anti-CD4 (magenta) 10 
minutes before dissection. Top and side views of the LNs are shown. Scale bar, 
40µm. Data are representative of two independent experiments with two mice per 
condition.     
 
To add further evidence that these CD169+ macrophages are coming from 
the SCS and not from the medulla, I stained cryosections with CD169, F4/80 and 
SIGN-R1. In the steady state, both SCS and medullary macrophages express 
CD169 while only medullary macrophages express F4/80 and SIGN-R1 (Figure 
3.10A) (Moseman et al., 2012). The disrupted CD169+ macrophage population 
observed in the SCS following inflammation was also negative for F4/80 or SIGN-
R1 (Figure 3.10A). This result strongly suggests that the disrupted macrophage 
population corresponds to SCS macrophages and not CD169+ macrophages 
migrating from the medulla during inflammatory conditions. 
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Figure 3.10 Disrupted CD169+ macrophages are not medullar cells  
Popliteal LN cryosections from mice injected 4 days previously with PBS (control) 
or CpG in the footpad were stained for CD169 (green), F4/80 (magenta) and SIGN-
R1 (cyan). Scale bars, 300µm (top and middle); 60µm (bottom). Histograms 
represent the different markers’ fluorescence measured from the outer edge to the 
LN interior on the dashed squares. Data are representative of two independent 
experiments with two mice per condition. 
 
It was previously reported that when LN architecture is perturbed during 
tissue preparation, ILCs present in the LN could acquire membrane blebs from 
CD169+ macrophages (Gray et al., 2012). To investigate whether these CD169+ 
cells observed in the SCS following inflammation were, actually, macrophages and 
not ILCs that had acquired CD169+ blebs, I performed an in situ staining of ILCs. 
Cryosections were prepared from popliteal LNs of mice previously injected with 
PBS or CpG and stained with anti-CD169 and anti-IL-7Rα. IL-7Rα is normally 
expressed by T cells, but ILCs express very high levels of this receptor, allowing 
their identification by immunohistochemistry (Gray et al., 2012). While IL-7Rα+ cells 
were observed in close association with disrupted CD169+ macrophages following 
inflammation, the markers did not co-localise with each other (Figure 3.11). This 
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result indicates that the disrupted CD169+ macrophages found in the SCS are not 
ILCs that had acquired CD169+ membrane blebs following inflammation. In 
conclusion, the cells on which I had focused my studies were SCS macrophages 
as they expressed high levels of CD169, CD11b, Mac-3 and CD4 but undetectable 
levels of F4/80, SIGN-R1 and IL-7Rα.   
 
 
 
Figure 3.11 Disrupted CD169+ macrophages are not ILCs 
Popliteal LN cryosections from mice injected 4 days previously with PBS (control) 
or CpG in the footpad were stained for CD169 (green) and IL-7Rα (magenta). 
Scale bars, 300µm (top); 20µm (bottom). Histograms represent the different 
markers’ fluorescence measured from the outer edge to the LN interior on the 
dashed square and lines. Data are representative of two independent experiments 
with two mice per condition. 
    
 
All together, the combination of different imaging techniques with various 
inflammation and infection models demonstrate that during an infectious or 
inflammation process there is a temporary loss of integrity of the SCS macrophage 
layer in the draining LNs. This disruption is the result of both, cell loss and 
retraction of these cells from the SCS to inner follicular areas. 
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3.3 DC arrival at draining LN during inflammation is necessary 
for SCS macrophage disruption 
To dissect the mechanism by which inflammation triggers the alteration of 
SCS macrophage organisation I used a series of transgenic mouse strains, 
blocking antibodies, and depleting agents to target different components of the 
immune system.   
 
3.3.1 Maintenance of the SCS macrophage layer in the steady state 
Firstly, I investigated whether the localisation of CD169+ macrophages in the 
SCS during the steady state was dependent on adhesion molecules or chemokines, 
as it is the case for other immune cells. For example, the retention of B cells in the 
marginal zone of the spleen is dependent on the integrins LFA-1/VLA-4 and their 
interaction with the ligands ICAM-1 and VCAM-1 (vascular cell adhesion protein 1), 
respectively (Lu and Cyster, 2002). The use of blocking antibodies against LFA-1 
and VLA-4 (very late antigen 4) causes a release of B cells from the marginal zone. 
During LPS-mediated inflammation, B cells move away from the marginal zone due 
to down regulation of integrin-mediated adhesion (Lu and Cyster, 2002). Moreover, 
the retention of B cells in the marginal zone is also tightly regulated by the levels of 
sphingosine 1-phosphate (S1P) and the chemokine CXCL-13. While CXCL-13 
attracts marginal zone B cells to migrate to the follicles, S1P retains B cells in the 
marginal zone (Cinamon et al., 2008). Another example of the regulated immune 
cell localisation by adhesion molecules is the retention of dendritic cells in the skin 
and epithelia through E-cadherin homotypic interactions with epithelial cells. When 
DCs detect the presence of pathogens, they down regulate E-cadherin levels so 
they can detach from the skin and epithelial cells, and migrate to draining LNs 
(Hammad and Lambrecht, 2008).  
 
In order to address the requirement of adhesion molecules by CD169+ 
macrophages to reside in the SCS under steady state conditions, I attempted to 
block these adhesion molecules using a combination of blocking antibodies. Mice 
were injected in the footpad with either i) PBS, ii) 50µg anti-LFA-1 + 50µg anti-VLA-
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4 or iii) 50µg anti-E-Cadherin (DECMA-1). After 1, 2 or 4 days, popliteal LNs were 
harvested and cryosections stained with anti-B220 and anti-CD169. Confocal 
analysis revealed that the macrophage layer was intact following the blockade of 
integrin-mediated adhesion with anti-LFA-1 and anti-VLA-4 (Figure 3.12A). This is 
in line with previous observations, where, despite the striking effect that integrin-
blocking antibodies have on marginal zone B cells, they do not affect marginal zone 
macrophages in the spleen (Lu and Cyster, 2002). In contrast, treatment with 
DECMA-1 induced partial scattering of CD169+ macrophages, but they do not 
retract to the B cell follicles (Figure 3.12B). Therefore, CD169+ macrophage 
localisation on the SCS under steady state conditions is independent of integrin-
mediated adhesion, but might require E-cadherin interaction between themselves 
and other cell types in the SCS, such as sinus lining cells. Whether E-cadherin 
levels on CD169+ macrophages are down regulated during inflammatory conditions 
is an interesting question that could be addressed in the future.  
    
I then wondered whether the retention of CD169+ macrophages in the LN 
SCS was dependent on chemokine signalling. To test this, I injected PBS (control) 
or Pertussis toxin in the footpad of mice. Pertussis toxin is an inhibitor of G protein-
coupled chemokine receptors that blocks intracellular chemokine signalling (Cyster 
and Goodnow, 1995). After 4 days, popliteal LNs were harvested and cryosections 
stained with anti-B220 and anti-CD169. Surprisingly, a single injection of Pertussis 
toxin induced a complete disruption of CD169+ macrophages in the SCS of the LNs 
(Figure 3.12C). This observation indicates that the retention of CD169+ 
macrophages in the SCS of the LNs on steady state is dependent on chemokine 
signalling. Whether changes in chemokine levels during inflammation or infection 
induces the loss of the macrophage barrier integrity needs further investigation. 
106 
 
Figure 3.12 E-cadherins and chemokines maintain macrophage layer integrity  
Popliteal LN cryosections stained for CD169 (green) and B220 (red) derived from 
mice administered in the footpad with either PBS (control) or (A) 50µg anti-LFA-1 + 
50µg anti-VLA-4 for 1, 2 or 4 days, (B) 50µg of anti-E-Cadherin for 4 days or (C) 
500ng of Pertussis toxin for 4 days. Scale bars, 300µm (top); 60µm (bottom). Data 
are representative of two independent experiments with three mice per condition.  
 
3.3.2 Role of pyroptosis on macrophage layer disruption  
 I then moved on to investigate the mechanism responsible for the disruption 
of the macrophage layer in draining LNs during inflammatory conditions. It has 
recently been reported that during Pseudomonas aeruginosa infection, SCS 
macrophages produce high levels of IL-1β and IL-18 to activate innate effector 
cells, such as CD8+ T cells, NK cells, NKT cells and γδ T cells (Kastenmüller et al., 
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2012). IL-1β and IL-18 are initially synthetised as inactive forms pro-IL-1β and pro-
IL-18, which are then cleaved to their active forms during inflammation 
(DINARELLO, 1998). This cleavage is mediated by Caspase-1, the main catalytic 
component of the inflammasome complex and by the adaptor protein ASC (van de 
Veerdonk et al., 2011). Usually, the activation of the inflammasome complex and 
the release of IL-1β and IL-18 during inflammation induces pyroptosis of the cells, 
which is a programmed cell death initiated during antimicrobial responses (Miao et 
al., 2010). I therefore wondered whether CpG-mediated inflammation would induce 
inflammasome-mediated activity on the macrophages that would lead to pyroptosis 
of these cells and depletion of them from the SCS. 
 
In order to test the impact of pyroptosis on the disruption of SCS 
macrophages during inflammation, I injected CpG in the footpad of wild type, 
Caspase1-deficient and ASC-deficient mice. After 4 days of CpG injection in the 
footpad, popliteal LNs were harvested, frozen, and cryosections stained with anti-
B220 and anti-CD169. Confocal analysis of LNs from Caspase-1 and ASC-deficient 
mice shows that the SCS macrophage layer was disrupted at a similar level as that 
observed in LNs from wild type mice (Figure 3.13). This demonstrates that 
pyroptosis, a death-related inflammatory response, might not be involved in 
disruption of SCS macrophage layer following inflammation. 
  
Figure 3.13 Macrophage layer disruption is not dependent on pyroptosis  
Popliteal LN cryosections stained for CD169 (green) and B220 (red) derived from 
wild type, Caspase-1-/- or ASC-/- mice administered in the footpad with either PBS 
(control) or 10µg of CpG 4 days previously. Scale bars, 300µm (top); 60µm 
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(bottom). Data are representative of two independent experiments with four mice 
per condition.  
 
3.3.3 Role of different immune cells on macrophage layer disruption 
  As intrinsic macrophage pyroptosis is not involved in the loss of layer 
integrity during inflammation, I next asked whether other immune cells would 
extrinsically induce this phenomenon. To start delineating this hypothesis, I took 
advantage of the CpG-mediated inflammation model and a series of mouse strains 
that are unable to respond to CpG (TLR9-deficient mice) or are impaired in TLR 
signalling due to lack of signalling adaptors (MyD88-deficient, TRIF-deficient and 
MyD88/TRIF-doubly deficient mice). Wild type mice and mice from these four 
strains were injected in the footpad with PBS or CpG and popliteal LNs were 
harvested after 4 days of injection. The overall dimensions of draining LNs were 
analysed and then LN cryosections were stained with anti-B220 and anti-CD169 to 
assess the organisation of SCS macrophages following inflammation. Mice 
deficient in either TLR9 or doubly deficient in MyD88/TRIF did not exhibit an 
increase in LN size and did not display SCS macrophage disruption as observed in 
wild type mice (Figure 3.14). This result indicates that CpG needs to signal through 
TLR9 and the adaptor proteins MyD88 and/or TRIF to induce inflammation. 
However, the TRIF adaptor is dispensable for the effect of CpG, as popliteal LNs 
were expanded and SCS macrophage layer was disrupted in TRIF-deficient mice 
(Figure 3.14). In contrast, the MyD88 adaptor is essential for this process, as 
MyD88-deficient mice do not exhibit LN expansion or SCS macrophage disruption 
during CpG-induced inflammation (later, Figure 3.17). These results are concordant 
with the notion that responses to CpG are mediated by TLR9 signalling via MyD88 
(Hemmi et al., 2003). 
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Figure 3.14 Role of TLR9 and MyD88/TRIF adaptors on macrophage disruption  
Representative popliteal LNs from wild type, Tlr9-/-, Myd88-/-Trif-/- and Trif-/- mice 
collected 4 days after footpad administration of PBS or CpG (upper panels). 
Confocal microscopy images of respective popliteal LN cryosections stained with 
mAbs to CD169 (green) and B220 (red) are shown on lower panels. Scale bars, 
300µm (top); 60µm (bottom). Histograms represent CD169 fluorescence measured 
from the outer edge of the LN to the follicles. Data are representative of two 
independent experiments with three mice per condition.  
 
 I next investigated which MyD88-expressing immune cell population is 
required for the disruption of SCS macrophages during inflammation. Animals 
selectively lacking MyD88 in individual cell types were generated by crossing mice 
carrying the MyD88flox/flox allele with others expressing Cre recombinase under the 
CD19, CD11c or Lyz2 promoters for deletion of MyD88 in B cells, DCs or 
macrophages/neutrophils respectively. I assessed the deletion efficacy of the 
MyD88-floxed allele by flow cytometry analysis of MyD88 protein levels in the 
different LN cell populations. For this, LN single cell suspensions were stained with 
anti-B220 and anti-MHCII to identify B cells, anti-CD11c and anti-MHCII to identify 
resident (CD11chi MHCIIint) and migratory (CD11cint MHCIIhi) DCs or anti-Ly6G and 
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anti-CD11b to identify neutrophils. To identify LN macrophages, I stained single 
cells suspensions with anti-B220, anti-CD3, anti NK1.1 and anti-IL-7Rα in order to 
gate out B cells, T cells, NK cells and ILCs and avoid contamination on the 
macrophage gate (Gray et al., 2012). CD169+ macrophages were recognised as 
CD169+ CD11clow and further separated into SCS (F4/80-) and medullar (F4/80+) 
macrophages (Figure 3.15).    
 
 
 
Figure 3.15 Gating strategy for the identification of LN cell populations 
Flow cytometry plots of LN single cell suspensions showing the gating strategy for 
B cells (MHCIIint B220+), migratory DCs (MHCIIhi CD11cint), resident DCs (MHCIIint 
CD11chi), neutrophils (Ly6G+ CD11b+), SCS macrophages (CD169+ CD11clow, 
B220-, CD3-, IL-7Rα-, NK1.1-, F4/80-) and medullary macrophages (CD169+ 
CD11clow, B220-, CD3-, IL-7Rα-, NK1.1-, F4/80+). Data are representative of three 
different experiments. 
 
After surface staining, LN cell suspensions were fixed, permeabilised and 
intracellularly stained for MyD88. As the staining for MyD88 is quite dim, in all 
cases MyD88-deficient LN cells were used to set up the background levels of the 
antibody (grey curve) (Figure 3.16).  
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Figure 3.16 MyD88 deletion in different immune cell populations 
Histograms display the levels of MyD88 in MyD88+/+ (blue line), Myd88-/- (grey solid) 
and Myd88flox/flox (red line) mice in the populations gated in Figure 3.15. Data are 
representative of three independent experiments with three mice per condition. 
 
 
Complete ablation of MyD88 was observed in B cells in MyD88flox/flox CD19-
Cre+ mice, while the levels of MyD88 in B cells remained unaltered in the other 
transgenic models (Figure 3.16). Moreover, complete ablation of MyD88 was 
observed in both migratory and resident DCs in MyD88flox/flox CD11c-Cre+ mice 
(Figure 3.16). Importantly in the latter animals, I observed no deletion in other LN 
cell populations, indicating that MyD88 deletion was specific for DCs, at least in 
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these organs (Figure 3.16). Surprisingly, in MyD88flox/flox Lyz2-Cre+ mice, although I 
observed full deletion of MyD88 in neutrophils, the levels of MyD88 in SCS and 
medullar macrophages were not altered (Figure 3.16), potentially due to low 
expression of lysozyme by these cell populations (Phan et al., 2009). I therefore 
restricted the analysis to the potential role of MyD88 in B cells, neutrophils and DCs 
in the disruption of SCS macrophages during inflammation. 
 
Then I moved on to inject these different transgenic animals with CpG in the 
footpad and popliteal LNs were harvested after 4 days. The overall dimensions of 
draining LNs were assessed and cryosections were immunostained with anti-B220 
and anti-CD169 for confocal microscopy analysis. In agreement with my previous 
data, LNs from wild type animals were enlarged and the macrophage layer was 
disrupted following inflammation (Figure 3.17). However, these processes were 
abrogated in MyD88-deficient animals (Figure 3.17).  
 
 
Figure 3.17 MyD88 expression on DCs is necessary for macrophage disruption 
Representative popliteal LNs from WT, Myd88-/-, Myd88flox/flox Cd19Cre+, 
Myd88flox/flox Lyz2Cre+ and Myd88flox/flox Cd11cCre+ mice collected 4 days after 
footpad administration of PBS or CpG (upper panels). Confocal microscopy images 
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of popliteal LNs cryosections stained with mAbs to CD169 (green) and B220 (red) 
(middle and lower panels). Scale bars, 300µm (middle); 60µm (bottom). Bar charts 
represent quantification of SCS macrophage disruption and distance of 
macrophages to LN border in each condition for an individual experiment. Each dot 
represents a distinct follicle. Mean ± s.e.m. Data are representative of three 
independent experiments with three mice per condition. Student t test, ***p<0.001, 
***p<0.0001.  
 
 
Interestingly, LN enlargement and disruption of the SCS layer were also 
observed in MyD88flox/flox CD19-Cre+ mice (Figure 3.17). This result demonstrates 
that MyD88-mediated signalling in B cells is not essential for the alteration of SCS 
macrophages following inflammation. I then wondered whether B cells could be 
playing an indirect role in the disruption of SCS macrophages regardless of direct 
recognition of CpG by them. To this end, I used Rag2-deficient mice, which lack 
mature lymphocytes owing to an inability to initiate V(D)J rearrangement (Shinkai et 
al., 1992). Wild type and Rag2-/- mice were injected with PBS or CpG in the footpad 
and after 4 days popliteal LNs were harvested. Cryosections were stained with anti-
B220, anti-CD169 and anti-Lyve1. Lyve-1 was used to easily differentiate the 
medullar region from the SCS, as the popliteal LNs in these animals are relatively 
small. F4/80 and SIGN-R1 could not be used in this case as SCS macrophages 
aberrantly express these markers in B cell deficient animals (Moseman et al., 
2012). Interestingly, I observed a similar disruption of the SCS macrophage layer in 
popliteal LNs of Rag2-/- mice compared to wild type animals after 4 days of CpG 
injection (Figure 3.18). This result demonstrates that SCS macrophage disruption 
does not require the presence of B cells or T cells (Figure 3.18). 
 
114 
 
Figure 3.18 Macrophage disruption does not require B and T cells 
Confocal microscopy images of popliteal LNs cryosections stained with mAbs to 
CD169 (green), Lyve-1 (magenta) and B220 (red) from WT and Rag2-/- mice 
collected 4 days after footpad administration of PBS or CpG. Scale bars, 300µm 
(top); 60µm (bottom). Histograms represent CD169 fluorescence measured from 
the outer edge of the LN to the follicles. Data are representative of two independent 
experiments with two mice per condition. 
  
 
I detected LN enlargement and SCS macrophage disruption after CpG 
administration in MyD88flox/flox Lyz2-Cre+ mice, indicating that signalling via the 
adaptor MyD88 in neutrophils is not essential for SCS macrophage disruption 
(Figure 3.17). However, while MyD88 in neutrophils themselves is not necessary 
for the effect, this does not rule out a MyD88 independent role of neutrophils in this 
process. I therefore decided to analyse macrophage disruption following 
inflammation in mice in which neutrophils were absent from the periphery. For 
neutrophil depletion, mice were injected with the commercial anti-Ly6G depleting 
antibody (Kastenmüller et al., 2012). As neutrophil turnover is relatively fast, I 
performed daily i.p. injections of this antibody in order to guarantee a complete 
ablation of this population during the time frame of the study. Effective neutrophil 
depletion in popliteal LNs was confirmed by flow cytometry (Figure 3.19A). Even 
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complete ablation of neutrophils from the periphery did not prevent the disruption of 
the macrophage layer following CpG administration (Figure 3.19B). Altogether, 
these experiments demonstrate that neutrophils are dispensable for the disruption 
of the SCS macrophage layer during CpG-mediated inflammation. 
 
 
 
Figure 3.19 Neutrophils do not mediate SCS macrophage disruption 
(A) Flow cytometry analysis of popliteal LN cell suspensions following 4 days of 
PBS (control) or CpG injection in the footpad. Mice were also injected i.p. with 
either anti-Ly6G depleting antibody or isotype control once a day over the period of 
the experiment. Neutrophils are gated as CD11b+ Ly6G+ cells. Bar chart depicts the 
numbers of neutrophils in popliteal LNs in each condition for a single experiment. 
Mean± s.e.m. Student t test, *p<0.05. (B) Confocal microscopy images of popliteal 
LN cryosections treated as in (A) and stained with mAbs to CD169 (green) and 
B220 (red). Scale bars, 300µm (top); 60µm (bottom). Histograms represent CD169 
fluorescence measured from the outer edge of the LN to the follicles. All data are 
representative of two independent experiments with three mice per condition. 
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During infection with vaccinia virus or Toxoplasma gondii, there is a 
collective migration and subsequent accumulation of NK cells in the SCS of the 
lymph nodes, where they interact with the capsule’s collagens fibres and with 
CD169+ macrophages (Coombes et al., 2012, Garcia et al., 2012). Therefore, I 
wondered whether NK cells contributed to the destruction of the SCS macrophage 
layer following inflammation. To this end, I used two different approaches in order 
to eliminate NK cells from the system: the use of transgenic Rag2-/- IL-2Rγ-/- mice, 
which do not have lymphocytes and NK cells, and the injection of an anti-NK1.1 
depleting antibody. For the first approach, I injected PBS (control) or CpG in the 
footpad of wild type and Rag2-/- IL-2Rγ-/- and tried harvesting the popliteal LNs after 
4 days. However, I could not find the popliteal LNs in Rag2-/- IL-2Rγ-/- mice. This is 
in line with previous studies reporting that these mice, besides being severely 
immunocompromised, have aberrant spleen morphology, markedly diminished LN 
cellularity and lack of some lymphoid structures (Shultz et al., 2012). Therefore, I 
moved on to the second approach, where I injected anti-NK1.1 or isotype control 
antibodies i.p. every other day during the time frame of the study. These animals 
were also administered with PBS or CpG in the footpad, and popliteal LNs were 
harvested after 4 days. NK cell depletion was assessed in popliteal LNs by flow 
cytometry using a dual staining of NK cells with anti-DX5 and anti-NK1.1. An 
almost complete ablation of NK cells was observed following antibody treatment 
(Figure 3.20A). However, NK cell depletion did not prevent SCS macrophage 
disruption after CpG injection, indicating that NK cells are also dispensable for SCS 
macrophages disruption following inflammation (Figure 3.20B). 
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Figure 3.20 NK cell depletion does not interfere with macrophage disruption 
(A) Flow cytometry analysis of popliteal LN cell suspensions following 4 days of 
PBS (control) or CpG injection in the footpad. Mice were also injected i.p. with 
either anti-NK1.1 depleting antibody or isotype control every other day over the 
period of the experiment. NK cells are gated as DX5+ NK1.1+ cells. Bar chart 
depicts the numbers of NK cells in popliteal LNs in each condition for a single 
experiment. Mean± s.e.m. (B) Confocal microscopy images of popliteal LN 
cryosections treated as in (A) and stained with mAbs to CD169 (green) and B220 
(red). Scale bars, 300µm (top); 60µm (bottom). All data are representative of two 
independent experiments with three mice per condition. 
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In the final step of this experimental thread, I moved on to analyse the role 
of DCs on the disruption of SCS macrophages. To this end, I injected CpG in the 
footpad of wild type and MyD88flox/flox CD11c-Cre+ animals and harvested popliteal 
LNs after 4 days. Flow cytometry analysis revealed a marked reduction in the 
number of migratory DCs (MHCIIhi CD11cint) in the draining LNs of MyD88flox/flox 
CD11c-Cre+ animals compared to their wild type counterparts (Figure 3.21). This 
would most probably be due to the inability of peripheral DCs to directly detect the 
presence of CpG and migrate to the draining LNs in these transgenic mice. But, 
most surprisingly, the draining LNs from MyD88flox/flox CD11c-Cre+ mice displayed a 
near-intact layer of SCS macrophages while still showing substantially enlargement 
(Figure 3.17). This phenomenon results in a marked and significant reduction in 
both disruption and distance scores in MyD88flox/flox CD11c-Cre+ mice compared to 
wild type animals (Figure 3.17). These observations are particularly striking as they 
demonstrate that the disruption of SCS macrophages during inflammation is not 
simply due to the associated enlargement of draining LNs but that it also requires 
MyD88-signalling in the DC population.  
 
 
 
Figure 3.21 DC migration is reduced in MyD88flox/floxCD11c-Cre+ mice 
Flow cytometry analysis of popliteal LN cell suspensions 4 days after PBS (control) 
or CpG injection in the footpad of wild type or Myd88flox/flox Cd11cCre+ mice. 
Migratory DCs are gated as CD11cint MHCIIhi cells. Bar charts show the numbers of 
migratory DCs in each condition for an individual experiment. Each dot represents 
a different mouse. Mean± s.e.m. Student t test, ***p<0.001. Data are representative 
of two independent experiments with three mice per condition. 
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3.3.4 DC migration regulates SCS macrophages disruption 
In order to provide additional evidence for the role of DCs on the disruption 
of SCS macrophages I used independent systems to target DCs. However, most 
mouse models that are used to deplete DCs also induce depletion of macrophages. 
For example, after injection with DT in CD11c-DTR mice, not only DCs, but also 
SCS macrophages, plasmablasts, activated T cells, NK cells and Ly-6Clow 
monocytes are depleted (van Blijswijk, Schraml and Reis e Sousa, 2013). Another 
example includes the MAFIA (Macrophages Fas-Induced Apoptosis) mice, where 
DCs as well as macrophages are depleted after administration of the reagent 
AP20187 (Burnett et al., 2004). Due to these technical limitations for depleting all 
the subsets of DCs without affecting SCS macrophages, I thought of using Batf3-/- 
mice, a mouse model were CD8+ DCs are absent, while all the other DCs subsets 
and SCS macrophages remain intact (Hildner et al., 2008). I therefore injected PBS 
or CpG in wild type and Batf3-/- mice and popliteal LNs were harvested after 4 days. 
While scattering of macrophages was still evident in Batf3-/- mice following CpG 
administration, the disruption of the layer was not as dramatic as observed in wild 
type animals (Figure 3.22). This result indicates that CD8+ DCs might play a role in 
SCS macrophage disruption and at the same time suggests that other DC subtypes, 
such as plasmocytoid, CD11b+ and Langerin+ DCs might be collectively inducing 
this disruption process. 
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Figure 3.22 Macrophage disruption is partially reduced in Batf3-/- mice 
Confocal microscopy images of popliteal LNs cryosections stained with mAbs to 
CD169 (green) and B220 (red) from WT and Batf3-/- mice collected 4 days after 
footpad administration of PBS or CpG. Scale bars, 300µm (top); 60µm (bottom). 
Data are representative of two independent experiments with three mice per 
condition.  
 
Given the importance of DCs in this process, I went on to visualise the 
distribution of these cells during CpG-induced inflammation. To this end, I injected 
PBS or CpG in the footpad of mice, and popliteal LNs were harvested after 4 days. 
Frozen sections were stained with anti-CD169 to label SCS macrophages and with 
anti-Langerin or anti-CD11c to stain DCs followed by confocal microscopy. In the 
steady state, DCs are located mainly in the paracortex and medulla (Figure 3.23A-
B), far from the SCS. In contrast, a clear accumulation of Langerin+ and CD11c+ 
DCs were observed interspersed between the SCS macrophages after 
inflammation (Figure 3.23A-B). The levels of CD11c, Langerin and CD169 
fluorescence were measured across the LN sections and plotted together in 
histograms. While the mean fluorescence peaks of CD11c and Langerin are far 
from the CD169 peak in steady state conditions, during inflammation clear peaks 
for both CD11c and Langerin are observed before that of CD169 (Figure 3.23A-B). 
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B220
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These results indicate that during inflammation there is a clear accumulation of 
migratory DCs in the SCS. 
 
 
Figure 3.23 DCs accumulate in the SCS following inflammation 
(A and B) Confocal microscopy images of popliteal LN sections stained with mAbs 
to CD169 (green) and (A) langerin (magenta) or (B) CD11c (magenta) derived from 
mice that were injected with PBS or CpG 4 days previously. Scale bars, 300µm 
(top); 60µm (bottom). Histograms represent CD169, langerin and CD11c 
fluorescence measured from the outer edge of the LN to the inner areas. Stars 
indicate DCs at the SCS. Data are representative of three independent 
experiments with two mice per condition. 
 
 I further confirmed the recruitment of DCs to the SCS by 3D multiphoton 
imaging and 3D electron tomography. In the first case, I injected PBS or CpG in the 
footpad of CD11c-YFP mice and 4 days later anti-CD169 was injected into the 
footpad of mice to label SCS macrophages in vivo. After 10 minutes, LNs were 
harvested and imaged by multiphoton microscopy. During steady state, a clear 
layer of macrophages (green) is observed below the collagen capsule (cyan) with 
no clear YFP+ cells (magenta) in this area. In contrast, after inflammation I 
observed an accumulation of YFP+ cells in the SCS, located inbetween the 
disrupted layer of macrophages (Figure 3.24A). Moreover, DCs with their 
characteristic convoluted cytoplasm and extended processes were found in the 
SCS of LNs from CpG-treated mice at high-resolution in electron microscopy 
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images examined with 3View (Figure 3.24B). In contrast, control animals did not 
exhibit any accumulation of DCs in the SCS region of the draining LN (Figure 
3.24B). 
 
  
Figure 3.24 3D analysis of DC accumulation in the SCS after inflammation 
(A) 3D multiphoton microscopy of explanted popliteal LNs from Cd11c-YFP 
animals injected in the footpad with either PBS or CpG (4 days) and anti-CD169 
antibody (green) 10 minutes before dissection. YFP signal is shown in magenta 
and second harmonic signal in cyan. Scale bar, 60µm. Histograms represent 
CD169 and YFP fluorescence measured from the outer edge of the LN to the inner 
areas. (B) Representative Z sections of 3View electron microscopy analysis of 
popliteal LN SCS after 4 days of PBS or CpG injection. Yellow stars indicate DCs 
located at the SCS. Scale bar, 5µm. All data are representative of two independent 
experiments with two mice per condition. 
 
 
In summary, after inflammation there is a substantial accumulation of 
migratory DCs in the SCS. Furthermore, direct sensing of CpG by DCs is 
absolutely necessary in inducing SCS macrophage layer disruption. These facts 
led me to investigate whether the arrival of migratory DCs from the periphery to the 
SCS could be potentially involved in altering the SCS macrophage distribution after 
inflammation. DC migration to the draining LNs is controlled by the main LN-
homing chemokine receptor CCR7 (Ohl et al., 2004). I therefore went on to analyse 
the macrophage disruption process in mice lacking CCR7. For this, I injected PBS 
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or CpG into either wild type or CCR7-/- mice and after 4 days, LNs were harvested 
and analysed by flow cytometry and confocal microscopy. A complete blockade in 
DC migration was observed in CCR7-/- deficient animals by flow cytometry (Figure 
3.25A). Moreover, the characteristic disruption of the SCS macrophage layer 
observed in wild type mice was abrogated in CCR7-deficient animals (Figure 
3.25B). This resulted in a significant decrease in both disruption and distance 
scores compared to wild type animals. These observations are consistent with the 
notion that DC arrival to the draining LNs is indeed necessary for the alteration of 
SCS macrophage organisation during inflammation.  
 
 
Figure 3.25 DC migration is necessary for SCS macrophage disruption 
(A) Flow cytometry analysis of popliteal LN cell suspensions 4 days after PBS 
(control) or CpG injection in the footpad of wild type or Ccr7-/- mice. Migratory DCs 
are gated as CD11cint MHCIIhi cells. Bar charts show the numbers of migratory DCs 
in each condition for an individual experiment. Each dot represents a different 
mouse. Mean± s.e.m. (B) Confocal images of popliteal LNs cryosections stained 
with mAbs to CD169 (green) and B220 (red) from wild-type and Ccr7-/- mice treated 
as in (A). Scale bars, 300 µm (top); 60 µm (bottom). Bar charts represent 
quantification of SCS macrophage disruption and distance of macrophages to LN 
border in each condition for an individual experiment. Each dot represents a distinct 
follicle. Mean ± s.e.m. Student t test, *p<0.05, ***p<0.001. Data are representative 
of three independent experiments with three mice per condition.  
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It is important to highlight that DCs are not the only cell population that 
express CCR7; B cells and T cells also express this chemokine receptor. However, 
these lymphocytes are not required for SCS macrophage disruption as this process 
occurs normally in Rag2 deficient animals, which lack both B and T cells (Figure 
3.18). I therefore propose that the lack of disruption of the SCS macrophage layer 
in CCR7-/- mice following CpG administration might be due to the inability of DCs to 
migrate to the LNs. I sought to obtain CCR7flox/flox CD11c-Cre+ mice in order to 
specifically delete CCR7 in the DC compartment, but unfortunately this strain has 
still not been generated. 
 
To formally test whether the arrival of DCs per se is sufficient in disrupting 
the layer of macrophages, I decided to transfer activated DCs to wild type animals 
and analyse the integrity of the macrophage layer. For this, CD45.2 BM-DCs were 
generated by treatment of bone marrow precursors with GM-CSF and then treated 
with PBS (control) or CpG for 16 hours. BM-DCs were then labelled with CFSE and 
adoptively transferred into the footpad of CD45.1 recipient mice. After four days, 
popliteal LNs were harvested and subjected to flow cytometry and 
immunohistochemistry. While a population of CD45.2+ CFSE+ cells was observed 
in popliteal LNs from mice receiving CpG-treated BM-DCs, almost no CD45.2+ 
CFSE+ cells were observed in LNs from mice receiving PBS-treated BMDCs 
(Figure 3.26A). This result indicates that activation of DCs is required in order to 
migrate to draining LNs. Interestingly, immunohistochemistry analysis showed a 
dramatic disruption of the SCS macrophage layer in the draining LNs of animals 
receiving CpG-treated BM-DCs but not control DCs (Figure 3.26B). CpG-treated 
BM-DCs were interspersed with SCS macrophages and located in the paracortex 
having gained entry into the LN interior (Figure 3.26B). On the other hand, the 
disruption of the SCS macrophage layer and the entry of DCs into the paracortex 
were severely reduced in mice receiving CpG-treated BM-DCs taken from a TLR9-
deficient donor (Figure 3.26A-B). This observation indicates that the disruption of 
SCS macrophages is not due to residual CpG remaining on the surface of BM-DCs 
but rather to the migratory effect that CpG induces on DCs.  
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Figure 3.26 DC migration is sufficient to induce SCS macrophage disruption 
(A) Flow cytometry analysis of popliteal LN after 4 days of footpad injection with 
3.106 CFSE-labelled CD45.2 control BM-DCs, CpG-treated wild type BM-DCs, 
CpG-treated Tlr9-/- BM-DCs or PGE2-treated wild type BM-DCs in CD45.1 recipient 
mice. Bar charts show the numbers of BM-DCs in popliteal LNs in each condition 
for a single experiment. Mean ± s.e.m. (B and C). Confocal images of popliteal LN 
cryosections 4 days after footpad injection with 3.106 CFSE-labelled (magenta) 
control BM-DCs, (B) CpG-treated WT BM-DCs, CpG-treated Tlr9-/- BM-DCs or (C) 
PGE2-treated BM-DCs. Sections were stained with mAb to CD169 (green). Bar 
charts represent quantification of SCS macrophage disruption and distance of 
macrophages to LN border in each condition for an individual experiment. Each dot 
represents a distinct follicle. Mean ± s.e.m. Student t test, *p<0.05, **p<0.01, 
****p<0.0001. All data are representative of at least two independent experiments 
with three mice per condition.  
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In order to establish that DC migration and not any other feature of DCs 
requiring MyD88 signalling is what disrupts SCS macrophages, I decided to induce 
DC migration independently of TLR signalling. To this end, I adoptively transferred 
CD45.2+CFSE+ BM-DCs previously treated with PGE2 (prostaglandin E2) in 
combination with TNF-α and IFN-α. Under these conditions BM-DCs were reported 
to migrate to draining LNs (Yen, Khayrullina and Ganea, 2008). After 4 days, a 
clear population of CD45.2+CFSE+ cells was detected in popliteal LNs by flow 
cytometry (Figure 3.26A), indicating that prostaglandin E2 treatment does induce 
DC migration. Importantly, the arrival of prostaglandin-treated DCs to the LNs also 
induces SCS macrophage disruption (Figure 3.26C), supporting the idea that DC 
migration and not any other feature of DCs requiring MyD88 signalling induces 
SCS macrophage disruption.  
 
Together, these results demonstrate that the CCR7-mediated arrival of 
mature DCs during inflammation is necessary and sufficient to trigger the disruption 
of SCS macrophages in the LNs.  
 
3.3.5 DC-mediated regulation of LN macrophage disruption 
How does the arrival of mature DCs to the LN induce the disruption of SCS 
macrophages? When DCs sense the presence of pathogens in the periphery they 
start a process of maturation that involves the up regulation of MHCII and CCR7, 
the down regulation of E-cadherins and the increased production of MMPs (matrix 
metalloproteases), especially MMP-9 (Hammad and Lambrecht, 2008). MMPs 
participate in tissue remodelling by degrading all kinds of proteins, helping DCs to 
detach from the skin and epithelia and to migrate to the draining LNs (Yen, 
Khayrullina and Ganea, 2008). I therefore wondered whether the secretion of 
MMPs by DCs would also induce a remodelling of the SCS extracellular matrix that 
would lead to a disruption of the macrophage layer during inflammation. To 
address this question, mice were injected i.p. with PBS (control) or the MMP 
general inhibitor GM6001 (Mirastschijski et al., 2004) every day during the course 
of the study. These animals were then injected in the footpad with CpG and four 
days later, popliteal LNs were collected. Cryosections were stained with anti-B220 
127 
and anti-CD169 and analysed by confocal microscopy. I observed an expansion of 
the B cell follicles in both groups of animals. Moreover, MMP inhibition did not 
prevent the disruption of the macrophage layer, suggesting that the disruption 
process is independent of extracellular matrix remodelling by MMPs (Figure 3.27).  
 
Figure 3.27 MMP activity is not involved in macrophage disruption  
Confocal microscopy of popliteal LN cryosections stained for CD169 (green) and 
B220 (red) from mice that were previously injected with PBS (control) or CpG in the 
footpad. Mice were also injected i.p. with PBS or GM6001 every day over the 
period of the experiment. Scale bars, 300µm (top); 60µm (bottom). Data are 
representative of two independent experiments with two mice per condition. 
 
Recently, several groups have shown that migratory DCs initiate the 
expansion of LNs during an inflammatory response. Migratory DCs express high 
levels of the C-type lectin CLEC-2, which interacts with the podoplanin expressed 
on the FRC network. This interaction between DCs and FRCs induces the 
relaxation of the FRC network and the consequent expansion of draining LNs. In 
fact, administration of CLEC-2 protein to immunised mice augments LN expansion, 
whereas selective ablation of CLEC-2 on DCs results in significantly smaller LNs 
(Acton et al., 2014, Astarita et al., 2015).  
 
I therefore wondered whether relaxation of the FRC network induced by the 
interaction between migratory DCs and FRCs would induce the scattering and 
disruption of the macrophage layer. To analyse this, I followed two different 
approaches. Firstly, I injected PBS or recombinant CLEC-2 protein in the footpad of 
mice and after 4 days popliteal LNs were harvested. Cryosections were stained 
Control CpG
CD169
B220
CpG + GM6001
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with anti-B220 and anti-CD169 and analysed by confocal microscopy. The 
macrophage layer remained intact after CLEC-2 injection, demonstrating that 
CLEC-2 by itself does not induce SCS macrophage scattering (Figure 3.28A). 
Secondly, I wondered whether specific deletion of CLEC-2 on DCs would interfere 
with the reorganisation process of the macrophage layer following inflammation. To 
this end, I injected PBS or CpG in the footpad of wild type and CLEC-2flox/flox 
CD11c-Cre+ mice, which do not express CLEC-2 in the DC compartment. After 4 
days popliteal LNs were harvested and cryosections stained with anti-B220 and 
anti-CD169. While an intact layer of macrophages was observed in non-immunised 
mice, a similar level of disruption was observed in wild type and CLEC-2flox/flox 
CD11c-Cre+ mice (Figure 3.28B). All together, these results indicate that the 
CLEC-2-mediated relaxation of the FRC network in the LNs is not involved in the 
disruption process of the macrophage layer.  
 
The exact mechanism by which migratory DCs induce the disruption of the 
macrophage layer remains to be elucidated. However, as the retention of CD169+ 
macrophages on the SCS requires chemokine signalling, it is tempting to speculate 
that migratory DCs would induce some changes on the steady state levels of 
chemokines after inflammation. These changes might result in the migration of 
macrophages towards the LN follicles and the subsequent alteration in the 
organisation of the SCS macrophage barrier. 
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Figure 3.28 Clec-2 expression by DCs is dispensable for macrophage disruption 
(A) Confocal images of popliteal LN cryosections 4 days after footpad injection of 
PBS or Clec2-Fc. Sections were stained with mAb to B220 (red) and CD169 
(green). (B) Confocal images of popliteal LN cryosections stained as in (A) from 
wild-type and Clec2flox/floxCD11c-Cre+ mice following 4 days of footpad injection with 
PBS or CpG. Scale bars, 300 µm (top); 60 µm (bottom). Data are representative of 
two independent experiments with two mice per condition. 
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3.4 Inflammation impedes acquisition of subsequent antigen 
by SCS macrophages and cognate B cells 
The strategic position of SCS macrophages at the lymph-tissue interface 
allows them to capture pathogens entering the LN and to present them to 
underlying B cells (Carrasco and Batista, 2007, Junt et al., 2007, Phan et al., 
2007). Therefore, the observed disruption to the integrity of the SCS macrophage 
layer during infection or inflammation raises the important question of the functional 
implications of this phenomenon for retention and presentation of antigen arriving in 
a subsequent wave.  
 
3.4.1 Macrophage layer disruption impedes retention of subsequently 
arriving antigen 
In order to investigate the consequences of either inflammation or viral and 
bacterial infection on the retention of a second incoming antigen to the LNs, mice 
were initially injected in the footpad with PBS (control), CpG, 104 PFU of VACV or 
106 CFU of GBS. Four days later, mice were challenged in the footpad with 108 
highly fluorescent microspheres as a surrogate antigen. These 0.2 µm 
microspheres, which are similar in size to a virus, allow visualisation and 
quantification of antigen retention by immunofluorescence (Carrasco and Batista, 
2007). Six hours after antigen challenge, popliteal LNs were harvested; 
cryosections were stained with anti-CD169 and anti-B220 and examined by 
confocal microscopy to reveal the distribution of the microspheres. Bead 
fluorescence in the LN compartments was quantifed using Image J (RBS). In line 
with previous reports, a considerable deposition of microspheres was observed at 
the SCS in draining LNs of control mice (Carrasco and Batista, 2007) (Figure 
3.29A–C). Moreover, a substantial number of beads also gained access to the 
underlying follicles (Figure 3.29A-C). In contrast, this accumulation of antigen in the 
SCS and in the follicles was dramatically diminished in the LNs of mice that had 
previously received CpG, VACV or GBS (Figure 3.29A–C).  
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Figure 3.29 Inflammation and infection hinder retention of subsequent antigen 
(A-C) Confocal microscopy images of popliteal LNs from mice injected in the 
footpad with PBS (control) or (A) 10µg of CpG, (B) 104 PFU of VACV or (C) 106 
CFU of GBS and 4 days later injected again with 8x108 polystyrene fluorescent 
microspheres (0.2 µm, white). Sections were labelled with antibodies to B220 (red) 
and CD169 (green). Scale bar, 60µm. Bar charts represent antigen fluorescence 
quantification in the SCS and follicles for a single experiment. Data are 
representative of three experiments. (D) Flow cytometry analysis of popliteal LNs 
from animals treated as in (A). Representative dot plots depict bead acquisition by 
B220-CD3- cells. Quantification of bead-positive cells from three independent 
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experiments is shown in the bar chart. In all panels, each dot represents a single 
LN. Mean ± s.e.m. Student t test, **p<0.01, ***p<0.001, ****p<0.0001.  
 
Taking an independent approach, I also analysed the extent of antigen 
retention in draining LNs by flow cytometry. Mice were injected in the footpad with 
PBS or CpG and 4 days later, challenged with 108 fluorescent beads. After 6 hours, 
popliteal LNs were harvested and single cell suspensions were stained with anti-
B220, anti-CD3 and DAPI in order to exclude dead cells and lymphocytes from the 
analysis. The percentage of cells that were positive for beads was quantified in 
control and CpG-treated mice. While around 2x104 cells had acquired fluorescent 
beads in LNs from control animals, this acquisition was severely impaired in LNs 
from mice receiving CpG (Figure 3.29D). Together, these results suggest that 
primary inflammation or infection severely impedes the capture of antigen coming 
on a subsequent wave to the LNs. 
 
3.4.2 Lymphatic flow is not altered during CpG-mediated inflammation 
I wondered whether this impairment in the capture of a second antigen was 
due to the loss of the integrity of the macrophage barrier or to a disruption of the 
lymphatic flow to the LN after inflammation. To test this, I looked at the drainage of 
a soluble dye in vivo with the assistance of Sophie Lutter and Angelo Castello. The 
chosen dye was ICG (indocyanine green), which binds tightly to soluble proteins 
and remains confined to the vascular system. The infrared absorbance and 
emission spectrum of ICG allows for deep tissue imaging with minimal signal 
scattering (Alander et al., 2012). Animals were injected with PBS or CpG in the left 
footpad, injected again with ICG 4 days after and imaged every 4 seconds using 
the IVIS Spectrum Whole Body Imaging System. The ICG signal progressively 
moved along the hind limb from the site of injection, with most of the fluorescence 
clearly restricted to the vascular compartment. After 60 seconds, fluorescence 
intensity peaked in the draining popliteal LNs (Figure 3.30). The progressive 
movement and accumulation of the soluble dye ICG in the draining LNs were 
similar in both mice receiving PBS or CpG four days before (Figure 3.30). Taken 
together these results suggest that the failure to capture a subsequent incoming 
antigen following primary inflammation is not due to a disruption in the lymphatic 
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flow. Instead inflammation is most likely to affect the antigen retention capacity of 
the LN by inducing the disruption of the macrophage barrier. 
 
 
Figure 3.30 Lymphatic flow is not affected by CpG administration 
Time-lapse whole body imaging of lymphatic flow in mice that were injected in the 
footpad with either PBS or CpG and injected again 4 days later with ICG dye. 
False-colour scale bar shows signal radiant efficiency. Data are representative of 
two independent experiments with two mice per condition.  
 
3.4.3 Antigen retention capacity is subsequently recovered  
 As shown in Figure 3.5, the macrophage layer is recovered at the SCS after 
around four weeks after the induction of inflammation. I therefore wondered if the 
recovery of the macrophage layer would restore the antigen retention capacity of 
the LN. To analyse this, mice were injected with PBS or CpG in the footpad and 
after 28 days, mice were re-challenged with 108 fluorescent 0.2 µm microspheres. 
Six hours after bead administration, popliteal LNs were harvested and cryosections 
stained with anti-CD169 and anti-B220. As observed in Figure 3.29, an extensive 
accumulation of fluorescent beads was detected in the SCS of draining LNs from 
control mice (Figure 3.31). Importantly, a similar extent of bead deposition was 
observed in the SCS of LNs harvested from mice that were injected with CpG four 
weeks previously (Figure 3.31). This demonstrates that the ability to retain antigen 
is restored around four weeks after the initiation of inflammation, a timeframe in line 
with the recovery of the SCS macrophage layer. 
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Collectively, these results show that the temporary disruption of the SCS 
macrophage layer during inflammation or infection has an important functional 
impact on the capacity of the LN to retain antigen arriving in a subsequent wave. 
 
 
Figure 3.31 Antigen retention is restored after macrophage layer recovery 
Confocal microscopy images of LN cryosections from mice treated with PBS or 
CpG and injected again 4 weeks later with 8.108 fluorescent microspheres (0.2 µm, 
white). Sections were labelled with antibodies to B220 (red) and CD169 (green). 
Scale bar, 60µm. Bar charts represent antigen fluorescence quantification in SCS 
and follicles for a single experiment. Data are representative of two independent 
experiments with three mice per condition. 
 
3.4.4 Macrophage layer disruption impedes acquisition of subsequent 
arriving antigen by cognate B cells 
As antigen retained by SCS macrophages can be presented to follicular B 
cells, I examined the impact of inflammation on the ability of cognate B cells to 
acquire antigen arriving to the node in a subsequent wave. To this end, I generated 
TLR9-/- MD4+ transgenic mice in order to obtain B cells that express a transgenic 
BCR with high affinity for HEL (hen egg lysozyme) and are unable to directly sense 
the presence of CpG. By using TLR9-/- B cells I could exclude any possible 
secondary effect on B cells of the CpG used to induce inflammation. Primary B 
cells from TLR9-/- MD4+ mice were isolated and labelled with SNARF, in order to 
track them during the experiment. 5x106 labelled TLR9-/- MD4+ primary B cells were 
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adoptively transferred into wild type recipient animals. The following day, these 
mice were injected in the footpad with either PBS (control) or CpG and four days 
later, they were challenged with either uncoated or HEL-coated fluorescent 
microspheres. After six hours popliteal LNs were harvested, cryosections stained 
with anti-B220 (blue) and analysed by confocal microscopy to quantify the extent of 
BCR-mediated antigen acquisition by adoptively transferred B cells in vivo. At this 
time, in LNs from control mice, around 50% of antigen specific MD4 B cells (red) 
had acquired between 1 and 5 HEL-coated microspheres (green) (Figure 3.32A). 
This uptake was dependent on the BCR as it was not seen upon administration of 
uncoated microspheres (Figure 3.32A). In contrast, after treatment with CpG, I 
observed that only 3% of MD4 B cells acquire HEL-coated microspheres and never 
more than one antigen particle per cell (Figure 3.32A).  
 
I also analysed the extent of B cell acquisition of cognate antigen following 
inflammation by flow cytometry. A similar adoptive transfer and immunisation 
protocol was followed. Briefly, CD45.2 TLR9-/- MD4+ B cells were transferred into 
CD45.1 recipient animals. This was useful in order to gate on CD45.2+ cells when 
analysing antigen retention by MD4 B cells. Then, mice were injected with PBS or 
CpG and challenged with HEL-coated fluorescent beads as before. Popliteal LNs 
were harvested after six hours, single cell suspensions were stained with anti-
CD45.1, anti-CD45.2, anti-B220 and DAPI and analysed by flow cytometry. 
CD45.1+ DAPI+ cells were gated out to exclude dead cells and cells from the host 
(Figure 3.32B). The percentage of CD45.2+ B220+ cells that were also positive for 
beads was then analysed. While around 15% of cognate B cells had acquired HEL-
coated beads in LNs from control mice, I observed a dramatic reduction in the 
amount of antigen acquisition by MD4 B cells in mice previously treated with CpG 
(Figure 3.32B). Thus, in line with the reduction of antigen retention by SCS 
macrophages, the acquisition of cognate antigen by B cells is reduced in draining 
LNs after inflammation. 
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Figure 3.32 Inflammation hampers acquisition of subsequent antigen by B cells 
(A) Confocal microscopy images of LN from mice that were adoptively transferred 
with 5x106 SNARF-labelled MD4+ Tlr9-/- B cells (red) on day 0, footpad 
administrated with PBS or CpG on day 1, injected again with 8x108 avidin 
fluorescent particles (green) coated or not with HEL on day 5 and sacrificed after 6 
hours. Sections were stained with B220 antibody (blue). Scale bar, 20µm. Bar 
charts represent the proportion of MD4 B cells loaded with different amount of 
particles for an individual experiment. (B) Flow cytometry analysis of popliteal LNs 
from CD45.1 animals that were treated as (A). Gating is on B220+ cells that have 
acquired HEL-beads. Quantification of beads-positive cells from a single 
experiment is shown in the bar chart. In all panels, each dot represents a single 
mouse. Mean ± s.e.m. All date are representative of at least three experiments. 
Student t test, **p<0.01, ***p<0.001, ****p<0.0001.  
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3.4.5 B cell response to 2nd incoming antigen is impaired after inflammation 
I then wondered whether this observed reduction in antigen acquisition 
during inflammation has an effect on the capacity of B cells to respond to 
subsequent antigenic challenge in vivo. When B cells capture antigen through the 
BCR, they receive the first activation signal. However to complete the activation 
and start producing antigen-specific antibodies, they need the help from T cells 
(Batista and Harwood, 2009). To analyse the formation of antibody secreting cells 
in response to antigen during normal or inflammatory conditions, I decided to use 
two different approaches in which B cells receive help from different T cell subsets.  
 
In the first approach, I used the MD4-OTII / HEL-OVA system. In this case, 
MD4 B cells capture HEL-OVA beads due to the high-affinity of their BCR for HEL. 
They then present OVA peptides in the context of MHCII and receive help from OT 
II CD4+ T cells, which express a transgenic TCR specific for OVA (Goodnow et al., 
1988, Barnden et al., 1998). This process maximizes the production of HEL-
specific antibodies by MD4 B cells. To this end, I adoptively transferred 5x106 
TLR9-/- MD4 B cells and 5x106 OT-II T cells into recipient wild type mice. These 
mice were then treated with either PBS (control) or CpG in the footpad, and six 
days later were challenged with 2.5µl of HEL-OVA coated microspheres in each 
footpad. After a further seven days, draining LNs were harvested and ELISPOTs 
were used to quantify the number of ASCs (antibody secreting cells). The LNs of 
control mice contained HEL-specific ASCs to the order of 103 (Figure 3.33A). In 
contrast, when local inflammation was induced with CpG before particulate antigen 
administration, the number of ASCs in the draining LNs was dramatically reduced 
(Figure 3.33A).  
 
For the second strategy, I used the MD4-NKT / HEL-αGalCer system. 
αGalCer is a glycolipid antigen that is presented by B cells in the context of CD1d. 
This allows the recruitment of endogenous NKT cells to complete B cell activation 
(Barral et al., 2008). Initially, 5x106 TLR9-/- MD4 B cells were adoptively transferred 
into wild type recipient mice. These mice were then treated with either PBS 
(control) or CpG in the footpad, and six days later received microspheres coated 
with both HEL and α-GalCer. After seven further days, popliteal LNs were 
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harvested and the number of ASCs was examined by ELISPOT. This analysis 
revealed that the number of HEL-specific ASCs formed in LNs from control mice 
was in the order of 102 (Figure 3.33B). However, in mice that had been previously 
treated with CpG, the formation of HEL-specific ASCs was significantly reduced 
(Figure 3.33B). In summary, these two approaches demonstrate that inflammatory 
signals do indeed have a direct effect on the extent to which B cells can acquire 
and respond to further antigenic challenge in vivo. 
 
 
Figure 3.33 Inflammation blocks B cell response to subsequent incoming antigen 
(A and B) ELISPOT analysis of HEL-specific ASCs (day 14) in popliteal LNs of 
animals that were adoptively transferred with (A) 5 x 106 MD4 Tlr9-/- B cells and 5 x 
106 OT-II T cells or (B) 2 x 106 MD4 Tlr9-/- B cells, footpad injected with PBS or 
CpG on day 1 and injected again with (A) OVA-HEL beads or (B) αGalCer-HEL 
beads on day 7. Bar charts represent the number of HEL-specific ASCs in each 
condition for an individual experiment. Data are representative of three 
independent experiments. Each dot in bar charts represents a single mouse. 
Mean± s.e.m. Student t test, *p<0.05, **p<0.01. 
 
All together these experiments demonstrate that the disruption of SCS layer 
by inflammatory signals have a direct effect on the extent to which B cells can 
acquire a subsequent incoming antigen as well as on their overall capacity to 
respond to further antigenic challenge in vivo. 
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3.5 Inflammation and primary infection shut down B cell 
responses to subsequent pathogens 
During a local infection or inflammation, there is a temporary disruption of 
the SCS macrophage barrier in the draining LNs. This process temporarily impairs 
the retention of a subsequent incoming antigen to draining LNs, resulting in less 
acquisition of antigen by B cells. I therefore next investigated the potential effect 
that this local and temporary disruption might have on the B cell responses to 
secondary pathogens.  
 
3.5.1 Inflammation dampens B cell response to subsequent viral infection 
Firstly, I analysed the effect of local inflammation on the B cell response to a 
subsequent viral infection. To this end, wild type mice were injected with PBS 
(control) or CpG in the footpad and seven days later locally infected with 104 PFU 
of VACV. After seven further days, popliteal LNs were harvested and the antiviral B 
cell response analysed. B cell differentiation into GCs was analysed by flow 
cytometry and immunohistochemistry. For flow cytometry, single cells suspensions 
were stained with anti-B220 and the GC markers: anti-GL7 and anti-CD95. 
Following VACV infection, LNs from PBS-treated mice exhibited a dramatic 
expansion of the GL7+Fas+ B cell population (Figure 3.34A). In contrast, this 
expansion was substantially impaired in popliteal LNs from CpG-treated mice 
(Figure 3.34A). I further analysed GC formation by the staining of cryosections with 
anti-B220 (red) and the GC marker Bcl6 (cyan) (Calado et al., 2012). Following 9 
days of VACV infection, the formation of Bcl6+ structures, corresponding to GCs, 
was observed in the B cell follicles of control mice (Figure 3.34B). However, the 
formation of GC structures was substantially impaired in the LNs from CpG-treated 
mice (Figure 3.34B). 
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Figure 3.34 Inflammation shuts down GC response to subsequent viral infection 
(A) Flow cytometry analysis of GC formation (day 14) in popliteal LNs from mice 
that were administered with PBS or CpG in the footpad and 7 days later infected 
with 104 PFU of VACV. Representative contour plots display the percentage of 
B220+ cells that are GL-7+Fas+. Bar charts display the quantification of GL-7+Fas+ B 
cells in the different conditions for a single experiment. (B) Confocal microscopy 
analysis of popliteal LNs from mice treated as in (A). Sections were stained with 
mAbs to B220 (red) and Bcl-6 (cyan). Scale bar, 60µm. Quantification of the GC 
area for an individual experiment is depicted on the right bar chart. Experiments 
were performed at least three times and each dot represents a different mouse. 
Mean ± s.e.m. Student t test, ***p<0.001 and ****p<0.0001. 
 
I went on to analyse the B cell differentiation into PCs (plasma cells) by flow 
cytometry and ELISPOT. For flow cytometry, single cell suspensions were stained 
with anti-B220, the PC marker CD138 and anti-IgD. PCs express high levels of 
CD138, intermediate levels of B220 and low or undetectable levels of IgD in the 
surface (Shi et al., 2015). After VACV infection, LNs from control mice display an 
expansion of the CD138+IgD- PC population (Figure 3.35A). In contrast, PC 
differentiation was severely decreased in popliteal LNs from CpG-treated mice 
(Figure 3.35A). I also analysed the formation of VACV-specific ASCs by ELISPOT. 
After 7 days of VACV infection, VACV-specific ASCs were detected in the order of 
103 in control mice (Figure 3.35B). In contrast, the formation of VACV-specific 
ASCs, both IgM and IgG secreting cells, was completely impaired in LNs from 
CpG-treated mice (Figure 3.35B). Collectively, these results show that local 
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inflammation impairs the B cell response to subsequent viral infections in the 
draining LNs. 
  
Figure 3.35 Inflammation blocks PC formation to subsequent viral infection 
(A) Flow cytometry analysis of PC formation (day 14) in popliteal LNs from mice 
that were administered with PBS or CpG in the footpad and infected 7 days later 
with 104 PFU of VACV. Representative contour plots show the percentage of B220+ 
cells that are also CD138+IgDlow. The quantification of CD138+IgDlow B cells for a 
single experiment is shown on the right bar charts. (B) ELISPOT analysis of total, 
IgM and IgG VACV-specific ASCs in popliteal LNs from mice that were treated as 
in (A). Bar charts represent the number of VACV-specific ASCs for an individual 
experiment. Experiments were performed at least three times and each dot 
represents a different mouse. Mean ± s.e.m. Student t test, **p<0.01,  ***p<0.001 
and ****p<0.0001. 
 
3.5.2 Antiviral B cell response is subsequently recovered 
As shown in Figure 3.5, the disruption of the SCS macrophage layer after 
inflammation is temporary and the layer is recovered around 4 weeks later. The 
recovery of the structural integrity of this barrier also restores the antigen retention 
capacity of the LN (Figure 3.31). Therefore I wondered whether the recovery of the 
macrophage layer and its antigen retention capacity after inflammation would 
restore the B cell response to following incoming virus to the LN. To analyse this, 
mice were injected in the footpad with PBS or CpG and after 4 weeks they were 
locally infected with 104 PFU of VACV. LNs were harvested 7 days later and GC 
response was analysed by flow cytometry and PC differentiation by flow cytometry 
and ELISPOT. Importantly, the formation of GL7+Fas+ GCs, CD138+IgD- PCs and 
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VACV-specific ASCs, were similar in both groups of mice (Figure 3.36A–C). The 
restoration of B cell responses towards the second wave of infection was 
consistent with the timeframe of recovery of the structural integrity of the SCS 
macrophage layer and its capacity to retain antigen four weeks after inflammation. 
 
 
 
Figure 3.36 Humoral response is restored following macrophage layer recovery 
(A and B) Flow cytometry analysis of GC and PC formation in mice injected with 
PBS or CpG and infected 4 weeks later with 104 PFU of VACV. Popliteal LNs were 
harvested 7 days after infection. Representative contour plots display the 
percentage of B220+ cells that are (A) Fas+GL-7+ or (B) CD138+IgDlow. The 
quantification of GCs and PCs in the different conditions for a single experiment is 
shown in the bar charts on the right. (C) ELISPOT analysis of total VACV-specific 
ASCs in popliteal LNs from mice that were treated as in (A and B). All data are 
representative of two independent experiments. Each dot represents a different 
animal. Mean ± s.e.m.  
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3.5.3 Chemical and genetic ablation of SCS macrophages hamper B cell 
immunity 
To formally establish that impaired responses to VACV result from SCS 
macrophage disruption after CpG treatment, I employed two alternative ways of 
depleting SCS macrophages in the LN. In the first, SCS macrophages were 
depleted by the use of clodronate liposomes. Macrophages are highly phagocytic 
cells that digest microorganisms and non-self particles. When macrophages 
phagocytose these liposomes, the clodronate inside the liposome vesicles is 
released and accumulates inside the cell. Once this soluble clodronate reaches a 
certain intracellular concentration, it induces apoptosis of the macrophages (van 
Rooijen, Sanders and van den Berg, 1996). I injected PBS-containing liposomes 
(control) or clodronate-containing liposomes in the footpad of mice. After 6 days, 
popliteal LNs were harvested and cryosections stained with anti-B220 and anti-
CD169 to assess the depletion efficacy. An almost complete depletion of SCS 
macrophages was observed in mice receiving clodronate-liposomes, but not in 
those receiving PBS-containing liposomes (Figure 3.37A). Importantly, medullar 
macrophages were also targeted by this technique. As this approach was 
consistently working, I went on to infect mice with 104 PFU of VACV in the footpad, 
six days after initial injection of PBS- or clodronate-containing liposomes. Popliteal 
LNs were harvested one week after viral infection and B cell response was 
assessed by flow cytometry and ELISPOT. While a considerable expansion of the 
GCs, PCs and VACV-specific ASCs was observed in mice receiving PBS-
liposomes, this process was significantly reduced in mice receiving clodronate-
containing liposomes (Figure 3.37B-D). The results suggest that the structural 
integrity of the macrophage barrier is essential for the development of the B cell 
response against an incoming virus to the LN. However, the local use of 
clodronate-containing liposomes, not only depletes SCS macrophages, but also the 
other phagocytic cells present in the draining LNs such as medullary macrophages, 
and to a lesser extent, DCs.      
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Figure 3.37 Clodronate treatment reduces antiviral B cell response   
(A) Confocal microscopy analysis of popliteal LNs 6 days after footpad injection of 
PBS- (control) or clodronate-containing (CLL) liposomes in wild type mice. Sections 
were stained with mAbs to B220 (red), and CD169 (green). Scale bars, 300µm 
(top); 60µm (bottom). (B and C) Flow cytometry analysis of (B) GC and (C) PC 
formation in wild type mice that were injected with PBS or CLL liposomes and 6 
days later infected with 104 PFU of VACV. Popliteal LNs were harvested after 7 
days of infection and analysed by flow cytometry. Representative contour plots 
display the percentage of B220+ cells that are (B) GL-7+Fas+ or (C) CD138+IgDlo. 
Quantifications of GCs and PCs in the different conditions for a single experiment 
are shown in the right bar charts. (D) ELISPOT analysis of total VACV-specific 
ASCs in popliteal LNs from mice that were treated as in (B and C). Data are 
representative of two independent experiments. Each dot represents a different 
animal. Mean ± s.e.m. Student t test *p<0.05, **p<0.01 and ***p<0.001. 
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I therefore considered using a more specific way of targeting SCS 
macrophages. To this end, I imported a mouse strain from the Riken Institute in 
Japan that expresses the human DTR (difteria toxin receptor) under the CD169 
promoter (Miyake et al., 2007). When DT is administered to these mice, it induces 
cell death in CD169-expressing cells by inhibiting the protein synthesis process. I 
injected PBS or DT in the footpad of CD169DTR/+ mice. After 6 days, popliteal LNs 
were harvested and cryosections stained with anti-B220 and anti-CD169 to assess 
the efficiency of this procedure. A near-complete depletion of SCS macrophages 
was observed in CD169DTR/+ mice following DT but not PBS administration (Figure 
3.38A). Importantly, in this case, medullar macrophages were not as reduced as in 
the case of clodronate-containing liposome injection. This could be due to the lower 
level expression of CD169 compared to their SCS counterparts. Moreover, DCs 
would not be affected in this procedure, as the great majority of them do not 
express CD169. With this technique I was mostly targeting SCS macrophages, so I 
proceeded to infect CD169DTR/+ mice with 104 PFU of VACV in the footpad, six days 
after initial administration of PBS or DT. As before, popliteal LNs were harvested 
one week after viral infection and the development of GCs and PCs was quantified 
using flow cytometry. The formation of both GCs and PCs was dramatically 
reduced in the CD169DTR/+ mice that received DT prior to infection with VACV 
compared to the ones that received PBS (Figure 3.38B-C). Together, these two 
approaches indicate that the presence of CD169+ macrophages in the LN SCS is 
important for the initiation of the B cell response during a viral infection.  
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Figure 3.38 CD169-DTR mice have reduced antiviral B cell response   
(A) Confocal microscopy analysis of popliteal LNs 6 days after footpad injection of 
PBS or DT in Cd169-DTR+ mice. Sections were stained with mAbs to B220 (red), 
and CD169 (green). Scale bars, 300µm (top); 60µm (bottom). (B and C) Flow 
cytometry analysis of (B) GC and (C) PC formation in Cd169DTR/+ mice that were 
injected with PBS or DT and 6 days later were infected with 104 PFU of VACV. 
Popliteal LNs were harvested after 7 days of infection and analysed by flow 
cytometry. Representative contour plots display the percentage of B220+ cells that 
are (B) GL-7+Fas+ or (C) CD138+IgDlo. Quantifications of GCs and PCs in the 
different conditions for a single experiment are shown in the right-hand bar charts. 
All data are representative of three independent experiments. Each dot represents 
a different animal. Mean ± s.e.m. Student t test **p<0.01 and ***p<0.001. 
 
3.5.4 Inflammation dampens B cell-mediated immunity to subsequent 
bacterial infection 
I then wondered whether this disruption of the SCS macrophage barrier 
during inflammation or its inducible depletion would also interfere with the B cell 
response during localised bacterial infections. To analyse this, I injected PBS, CpG 
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or clodronate-containing liposomes in the ear dermis. After seven days, cervical 
draining LNs were harvested and cryosections stained with anti-B220 and anti-
CD169 to assess the integrity of the macrophage barrier. After CpG treatment, 
cervical LNs were greatly expanded, with a substantial enlargement of the B cell 
follicles (Figure 3.39A). Importantly, the macrophage barrier was severely disrupted 
as observed in popliteal LNs following footpad injection of CpG (Figure 3.39A). In 
the case of clodronate treatment, cervical LNs were also somewhat expanded and 
a complete depletion of SCS and medullar macrophages was observed (Figure 
3.39A). I therefore moved to inject mice with PBS, CpG or clodronate in the ear 
dermis and after seven days locally infected them with 107 CFU of Staphylococcus 
aureus. Seven days after infection, cervical LNs were harvested and the B cell 
response was analysed by flow cytometry. A dramatic expansion of GCs and PCs 
was observed after S. aureus infection compared to non-infected mice (Figure 
3.39B-C). In contrast, a significant reduction in GC and PC formation was observed 
when mice received CpG or clodronate in the ear before infection with S. aureus 
(Figure 3.39B-C). Therefore, it does indeed appear that the local disruption of the 
SCS macrophage layer triggered by inflammation dramatically affects the ability of 
B cells to mount responses to viral or bacterial antigen arriving in a secondary 
wave.  
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Figure 3.39 SCS macrophage disruption reduces B cell response to S. aureus   
(A) Confocal microscopy analysis of superficial cervical LNs 7 days after ear 
administration of PBS, CpG or CLL-liposomes. Sections were stained with mAbs to 
B220 (red), and CD169 (green). Scale bars, 300µm (top); 60 µm (bottom). (B and 
C) Flow cytometry analysis of GC and PC formation in mice administered with PBS, 
CpG or CLL liposomes and infected 7 days later with 107 CFU of S. aureus. 
Superficial cervical LNs were harvested 7 days after infection. Representative 
contour plots display the percentage of B220+ cells that are (B) Fas+GL-7+ or (C) 
CD138+IgDlow. The quantification of GCs and PCs in the different conditions from 
three independent experiments is shown on the right-hand bar charts. Each dot 
represents a different animal. Mean ± s.e.m. Student t test **p<0.01 and 
****p<0.0001. 
 
3.5.5 Primary infection impairs B cell response to secondary pathogens 
Finally, I wondered whether SCS macrophage disruption during a primary 
infection hampers the ability of B cells to respond to a secondary pathogen. To 
address this, I set up a bacteria-virus double infection model. I first injected mice 
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with PBS (control) or 106 CFU of Group B Streptococcus in the footpad. After 7 
days, when a complete disruption of the macrophage layer was observed (Figure 
3.1B), mice were infected with 104 PFU of VACV. After a further 7 days, popliteal 
LNs were harvested and the formation of VACV-specific ASCs was measured by 
ELISPOT. The development of VACV-specific ASCs, both IgM and IgG-secreting 
cells, was significantly reduced in mice previously infected with GBS (Figure 3.40). 
This result is consistent with the idea that the loss of integrity of the SCS 
macrophage layer during primary local infections severely affects the capacity of B 
cells to respond to secondary pathogens. 
 
 
Figure 3.40 Primary infection shuts down B cell response to secondary pathogen 
ELISPOT analysis of total, IgM and IgG VACV-specific ASCs (day 14) from mice 
that were footpad-administered with PBS or 106 CFU of GBS and then infected with 
104 PFU of VACV on day 7. Bar charts represent the number of VACV-specific 
ASCs from three independent experiments. Each dot represents a different mouse. 
Mean ± s.e.m. Student t test, *p<0.05, **p<0.01, ***p<0.001.  
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3.6 Discussion 
 In recent years, SCS macrophages have been placed at the heart of anti-
pathogen responses due to their key role in antigen trapping and immune response 
initiation (Carrasco and Batista, 2007, Junt et al., 2007, Phan et al., 2007, 
Chtanova et al., 2008, 2009, Gonzalez et al., 2010, Coombes et al., 2012, Garcia 
et al., 2012, Kastenmüller et al., 2012). In this chapter, I have shown that after local 
infection or inflammation, draining LNs undergo a dramatic architectural 
reorganisation. This phenomenon not only involves an increase in the B cell 
follicles’ size but also a severe disruption of the SCS macrophage layer. Analysis of 
this process by a set of different imaging techniques revealed that this structural 
rearrangement of the macrophage layer is a result of both cell loss and the 
retraction of these cells from the SCS to inner follicular areas. This disruption 
process is initiated by the arrival of peripheral DCs into draining LNs after local 
inflammation and, importantly, it is a localised and temporary event, being 
restricted to draining LNs and lasting for a defined period of time. I found that the 
temporary loss of macrophage layer integrity has a severe impact on the ability of 
these LNs to retain and capture antigen from a subsequent wave of infection. This 
impairment has deep consequences in the ability of follicular B cells to acquire 
cognate antigen and to mount an appropriate immune response during subsequent 
secondary infections (Figure 3.41) (Gaya et al., 2015). 
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Figure 3.41 SCS macrophages: guardians of the B cell response    
Model proposed for (A) the effect of a primary infection or inflammation on the 
organisation of CD169+ macrophages at the SCS and (B) the consequences of this 
process on the B cell response to secondary pathogens.  
 
 
Early electron microscopy and more recent dynamic imaging studies have 
shown that during steady state conditions, CD169+ macrophages are a sessile 
population that lay longitudinally on the SCS floor, with their cell bodies projected 
into the SCS lumen and their nucleus located within the LN parenchyma (Farr, Cho 
and De Bruyn, 1980, Fossum, 1980, Szakal, Holmes and Tew, 1983, Carrasco and 
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Batista, 2007, Junt et al., 2007, Phan et al., 2007). The exact mechanisms dictating 
the placing and orientation of these cells however, is still poorly understood. Some 
reports have suggested that lymph-borne signals play an important role based on 
the observation that cessation of afferent lymphatic flow causes the inward 
movement and eventual disappearance of these cells (Mebius et al., 1990, 1991). 
In addition, B cell-derived lymphotoxin-a1b2 signalling is required for the 
establishment and differentiation of this macrophage population, as mice lacking 
lymphotoxin-a1b2 on B cells have reduced number of SCS macrophages, and 
those remaining have an immature phenotype (Phan et al., 2009, Moseman et al., 
2012). In this chapter, I have shown that the blockage of E-cadherin- but not 
integrin-mediated adhesions, results in the partial scattering of the SCS 
macrophages. Therefore, even though the maintenance of the SCS macrophage 
layer in steady state conditions is not dependent on integrin-mediated adhesions, it 
might involve E-cadherin-mediated interactions. Furthermore, I found that 
chemokine signalling is essential for the retention of CD169+ macrophages at the 
LN SCS in the steady state, as blockage of intracellular chemokine signalling with 
Pertussis toxin induces an almost complete disruption of this macrophage layer in 
the SCS. This effect could be due to direct inhibition of chemokine signalling in 
SCS macrophages or an indirect effect caused by the interruption of chemokine 
signalling in other LN cells. For example, the lack of specific chemokine receptors 
in LECs can hinder the migration of DCs from the SCS to the LN parenchyma, 
even though intrinsic signalling in DCs remains unaltered. This is due to the ability 
of some cells to regulate chemokine gradients in the different LN compartments 
(Ulvmar et al., 2014). In my case, as CXCR5 signalling in B cells induces 
lymphotoxin-a1b2 upregulation (Cyster et al., 2000), it could then be that pertussis 
toxin might inhibit the production of lymphotoxin-a1b2 by B cells, compromising in 
this way, the integrity of the macrophage layer. In the future, it would be important 
to define the mechanism by which chemokine signalling is involved in the 
maintenance of CD169+ macrophages at the SCS.  
 
 SCS macrophages are stably positioned in their location during steady 
state conditions. However, whether these macrophages change their distribution 
and organisation during the course of an immune response was not clear. A 
previous work by Ellen Robey’s group showed that neutrophil migration to the LN 
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after Toxoplasma gondii infection induces the clearance of SCS macrophages in 
the sites of neutrophil cluster formation (Chtanova et al., 2008). Although it is not 
clear what induces this cell loss, the authors suggest that it might be mediated by 
the secretion of matrix metalloproteinases by neutrophils arriving at the SCS. Here, 
I established that local infection with virus or bacteria, and the inflammation 
process associated with that infection, induces a general disruption of the SCS 
macrophage layer. This phenomenon is quite different from the one described 
above. Firstly, the loss of macrophage layer integrity covers the whole of the SCS 
and not just small, delimited areas. Moreover, this process is not only due to cell 
loss, as observed during parasite infection, but also because of a massive 
retraction of these macrophages to inner follicular areas. The differences may 
come from the nature of the pathogens used in the studies and by the effector 
immune responses elicited in each case.   
 
The local loss of the macrophage integrity after inflammation is a temporary 
process, as the layer is restored within three to four weeks of inflammation 
induction. The recovery could be due to the return of macrophages to their initial 
position after transiently moving inwards into the B cell follicles. An alternative is 
that macrophages remaining in the SCS undergo local proliferation to re-cover the 
whole area of the SCS, as observed with pleural macrophages following parasite 
infection (Jenkins et al., 2011). Thirdly, this recovery could be due to the 
recruitment of de novo peripheral macrophages to the SCS. In fact, a previous 
study showed that incoming macrophages could completely repopulate the 
popliteal LN within two to five months of their clodronate-mediated depletion 
(Delemarre et al., 1990). The faster recovery observed in my study could be due to 
inflammation triggering the initial disruption of the SCS macrophage layer and at 
the same time speeding up the recruitment of new macrophages to restore the 
original cell layer. Furthermore, clodronate-liposomes could also be depleting 
macrophage progenitors and therefore delaying the recovery of the macrophage 
layer.   
 
This loss of integrity of the SCS macrophage layer during inflammation 
could be occurring for several reasons: expansion of the LN SCS without 
expansion of local macrophages, inflammation-induced death of macrophages, 
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intrinsic signalling in these cells that induces migration and/or other immune cells 
extrinsically mediating this disruption. The first explanation implies that this 
phenomenon would be merely a passive process caused by the increase in LN 
dimensions. 3View electron microscopy showed that following inflammation, SCS 
lining cells stretch out to accommodate the increase in size. It might be that the 
macrophages, anchored to these SCS lining cells, are simply pulled apart in the 
expansion process. Although this could explain the lateral scattering of the cells, it 
fails to explain the inward movement of macrophages to the follicles. Furthermore, 
although MyD88flox/flox CD11c-Cre+ and CCR7-/- mice displayed enlarged LNs after 
inflammation, the SCS macrophage layer remained almost intact, suggesting that 
this disruption process is not just due to an increase in LN dimensions. The second 
hypothesis, which suggests that macrophage layer disruption is the result of 
inflammation-induced cell death, arose from a recent report showing that 
Pseudomonas aeruginosa infection induces IL-1β and IL-18 production by SCS 
macrophages. The synthesis of these cytokines is mainly dependent on 
inflammasome activation, which usually concludes with pyroptosis of the cells 
(Kastenmüller et al., 2012). However, the disruption of SCS macrophages is not a 
result of inflammasome-mediated pyroptosis, as genetic interference with the 
assembly of the inflammasome complex did not prevent the disruption of the 
macrophage layer. The third possibility implies that direct detection of inflammation 
by macrophages induces the migration of these cells from the SCS to the inner 
parenchyma. Although this could be a potential scenario to explain the disruption of 
the macrophage layer, I was not able to experimentally address it. This is due to 
the genetic targeting of components of the TLR-signalling pathway in these 
macrophages proving to be ineffective. I attempted to abrogate MyD88 expression 
on SCS macrophages by developing MyD88flox/flox Lyz2-Cre+, however, MyD88 
levels remain unchanged in these macrophages, probably due to their low 
expression of lysozyme (Phan et al., 2009). The generation of CD169-Cre mice 
would be valuable to enable genetic targeting of this macrophage population.  
 
To address the fourth hypothesis, I genetically and biologically targeted 
various immune cells. Even though B cells are required for SCS macrophage 
development and differentiation (Phan et al., 2009, Moseman et al., 2012), the 
prevention of B cell recognition of inflammatory signals or their absence does not 
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prevent SCS macrophage disruption. T cells are also not involved in this disruption 
as lymphocyte-deficient mice display a normal disruption of the macrophage layer 
after inflammation. NK cells and neutrophils are recruited to the LN SCS after 
infection: NK cells are known to mediate the lysis of infected cells and neutrophils 
have been shown to induce the localised clearance of SCS macrophages during 
parasite infection (Chtanova et al., 2008, Coombes et al., 2012, Garcia et al., 2012, 
Kastenmüller et al., 2012). However, biological depletion of NK cells or neutrophils 
did not prevent the disruption of the macrophage layer after the induction of 
inflammation. Therefore, even though the huge influx of neutrophils into the LN 
SCS after parasite infection mediates the localised destruction of SCS 
macrophages, this process seems not to be a general feature of inflammation. I 
found that the arrival of migratory DCs to the LN SCS during inflammation is 
involved in the disruption of the macrophage layer. In fact, inhibition of DC sensing 
of inflammatory molecules, or blockage of their migration to the LNs, results in a 
dramatic decrease of the macrophage layer disruption. Furthermore, local 
administration of mature BM-DCs induces similar structural rearrangements of the 
macrophage layer to those observed during inflammation. Importantly, these 
observations parallel the findings made by Förster and colleagues, who found that 
intralymphatic injection of mature BM-DCs induces profound changes in the SCS 
floor, with CD169+ macrophages elongated and aligned in parallel to immigrating 
DCs (Braun et al., 2011). The mechanism by which incoming DCs induce the 
disruption of the macrophage layer is not known. It could be possible that in order 
to gain access to the lymphoid tissue, DCs pass through the SCS inner wall 
fenestrations, pushing away the CD169+ macrophages that normally occlude these 
fenestrations (CLARK, 1962). However, if this event were simply a consequence of 
macrophage disturbance by incoming DCs as they traverse the SCS floor, then the 
disruption would be greater in the inter-follicular areas, where there is active 
transmigration of DCs (Schumann et al., 2010, Gerner et al., 2012). In contrast, the 
macrophage layer is equitably disrupted along the whole length of the SCS, 
suggesting that rather than displacing macrophages, incoming DCs might signal 
them to migrate as well (Hickman, 2015). As the retention of CD169+ macrophages 
on the SCS requires E-cadherin interactions and chemokine signalling, it might be 
possible that incoming DCs produce soluble factors that mediate the loosening of 
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E-cadherin interactions, such as IL-1 or TNF-α (Jakob and Udey, 1998), or which 
induce changes in the steady state levels of chemokines in the SCS. 
 
The loss of integrity of the macrophage layer during a primary immune 
response renders draining LNs temporarily blind to pathogens entering on a 
secondary wave. This phenomenon might not only affect the initiation of the B cell 
response to subsequent pathogens but also interfere with other processes that 
require a functional layer of macrophages. For example, Cyster and colleagues 
showed that the relay of immune complexes from SCS macrophages to non-
cognate B cells and then to FDCs plays a key role in the antibody affinity 
maturation process (Phan et al., 2009). It is conceivable then, that the transport of 
immune complexes from SCS macrophages to FDCs is also impaired during this 
period. Furthermore, several studies showed that SCS macrophages are essential 
to prevent systemic dissemination of pathogens (Iannacone et al., 2010, 
Kastenmüller et al., 2012). This temporary disruption might, therefore, result in the 
spreading of pathogens to other lymphoid organs, such as spleen and further LNs 
following local infection. It is feasible that these organs might take control of the 
secondary infection while local LNs focus the response on primary pathogens.  
 
 The temporary inability of local LNs to respond to subsequent challenges 
provides a potential explanation for the increased susceptibly of the organism to 
contract secondary bacterial infections, such as Streptococcus pneumoniae, during 
influenza pandemics and epidemics (Brundage and Shanks, 2008). Furthermore, 
the initial fragmentation of the SCS macrophage layer following primary infection 
might explain the suboptimal immune response induced by vaccines when children 
are unwell at the time of vaccination (Zepp, 2010). My findings are in line with 
previous observations which show that failure of host defences to counteract 
secondary infections results from the loss of lymphoid tissue integrity (Odermatt et 
al., 1991, Scandella et al., 2008). For example, systemic infection with LCMV and 
MCMV (mouse cytomegalovirus) induce downregulation of CCL19 and CCL21, 
leading to a temporary destruction of splenic T cell areas (Benedict et al., 2006, 
Mueller, Hosiawa-Meagher and Konieczny, 2007, Scandella et al., 2008). This 
process, which might be triggered by the cytokine storms accompanying acute 
infections (Heikenwalder et al., 2004, Mueller, Hosiawa-Meagher and Konieczny, 
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2007),  induces a transient loss of immunocompetence against secondary 
infections (Odermatt et al., 1991, Scandella et al., 2008). Studies performed by 
Medzhitov and colleagues offer an alternative view, where the increased 
susceptibility to secondary infections would be due to compromised innate host 
defence or impaired ability to tolerate further tissue damage after primary infection 
(Jamieson et al., 2010, 2013).  
 
The fact that the disruption of the macrophage layer temporarily reduces B 
cell responses to proximal secondary challenges raises the important question of 
the potential benefit of such phenomenon. At this stage, I can only speculate as to 
the answer, although it might help to focus the immune system on primary 
pathogens by favouring the development of the immune response. For instance, it 
is possible that the movement of macrophages away from the SCS may favour the 
entry of afferent lymph-derived immune cells directly through the SCS floor. Cells 
entering in this way may be better placed to encounter trapped cognate antigen 
and thus respond to it. In fact, morphological changes on the SCS floor allow 
lymph-derived T cells to entry the LN through the SCS floor (Braun et al., 2011). 
Alternatively, the retraction of macrophages from the SCS to the follicular interior 
might maximise the presentation of antigen to B cells or facilitate antigen relay to 
FDCs. These two scenarios, concomitantly with the processes of LN shutdown and 
lymphocyte clonal expansion, would enhance immune responses to primary 
infecting pathogens. In this way, SCS macrophages might function as a valve that 
detects inflammation within draining LNs, triggering the temporary suspension of 
humoral responses to secondary infections to prioritise the effective control of 
contemporaneous lymph-borne infecting pathogens.  
 
In the future it would be important to analyse the integrity of the macrophage 
layer in the case of chronic inflammation. This process is commonly observed 
during persistent infection with tuberculosis or HIV or during autoimmune diseases 
such as rheumatoid arthritis, lupus or multiple sclerosis (Marshak-Rothstein and 
Rifkin, 2007, Sasindran and Torrelles, 2011, Deeks, Tracy and Douek, 2013).  As 
inflammation per se can trigger SCS macrophage disruption and shut down 
antibody responses, this phenomenon may minimise autoimmune responses that 
develop after lymph drainage of self-antigens (Marshak-Rothstein and Rifkin, 
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2007). It will be also important to analyse this process in the context of cancer 
development, as cancer cells frequently use lymphatic vessels and lymph nodes to 
spread to other parts of the body (Stacker et al., 2014). Furthermore, it would be 
interesting to analyse the integrity of the macrophage layer in mesenteric LNs, 
which display a constant arrival of antigens from the intestine and spontaneous 
formation of GCs (Koni et al., 1997).  
 
I believe that the results presented here might have implications on the 
rational design of vaccination programs. For example, if children are vaccinated 
against pathogen A in one arm, then any vaccination against pathogen B, if 
performed shortly after the previous vaccination, should be applied on the other 
arm (and therefore different draining LNs) to induce a good immune response.   
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Chapter 4. BCR and TLR signalling in B cells induce 
ULK-independent autophagosome formation 
through the PLCγ2 pathway    
4.1 Introduction 
4.1.1 B cells and autophagy 
B cells are an essential part of the adaptive immunity as they provide 
specific protection from a variety of potential pathogens. B cells are activated after 
the recognition of specific antigens by the BCR, which induces intracellular 
signalling and the internalisation of antigen-loaded BCRs. Following internalisation, 
antigens are processed into small peptides or lipids followed by loading onto MHC 
II or CD1d molecules respectively, for presentation at the cell surface. The peptides 
are recognised by specific CD4+ T cells, and the lipids by NKT cells, both of which 
then stimulate B cell proliferation and differentiation into antibody-secreting cells 
(Batista and Harwood, 2009). 
   
Autophagy is an intracellular degradation system that delivers cytoplasmic 
constituents to the lysosome and is indispensable for the recycling of cell 
components and for the fulfillment of cell energy demands (Mizushima, 2007). In 
the present, it is believed to play an important role in the antigen-processing 
pathway. Different studies have established that tumor, viral and cytosolic self-
antigens can enter the MHC II compartments through autophagy for B cell 
presentation (Paludan et al., 2005, Schmid, Pypaert and Münz, 2007, Ireland and 
Unanue, 2011). However, the signals that induce this process in B cells and its 
contribution in the presentation of extracellular pathogens have not yet been 
investigated.  
 
4.1.2 Autophagosome formation 
Autophagy is a highly regulated pathway that can be differentially activated 
by energy deprivation, ER stress and immune signals, such as viral and bacterial 
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infection. This process results in the formation of double-membrane organelles 
called autophagosomes, which engulf macromolecular complexes and organelles 
for recycling, and pathogens for clearance. Autophagosomes then fuse with 
lysosomes and mature into autolysosomes, in which all the intravesicular 
components are degraded (Figure 4.1). In this way, the autophagy response 
contributes to survival under low-nutrient conditions and also provides protection 
against pathogens (Levine, Mizushima and Virgin, 2011).  
 
 The autophagosome formation involves the interaction between many 
different protein complexes. Upon autophagy induction, mTOR (mammalian target 
of rapamycin) complex is inactivated, inducing the translocation of the ULK1 
(unc51-like autophagy activating kinase 1) complex to the ER. This process 
mediates the activation of the ER-specific class III PI3K complex, which catalyses 
the production of PtdIns3P (phosphatidylinositol-3-phosphate) and recruits effector 
proteins such as DFCP1 (double FYVE-containing protein 1) and WIPI (WD-repeat 
protein interacting with phosphoinoside). DFCP1 and WIPI generate ER-associated 
isolation membranes, also known as omegasomes. The final step of the 
autophagosome formation involves the elongation and closure of these isolation 
membranes. This process is mediated by two ubiquitin-like complexes: the Atg12–
Atg5-Atg16L1 complex and the LC3 (microtubule-associated protein light chain 3)- 
phosphatidylethanolamine-conjugate complex (Mizushima, 2007).  
 
 The potential interrelation between the components of the different 
complexes, the mechanisms by which the different stimuli induce the formation of 
these double-membrane organelles and the origin of the isolation membranes are 
still very controversial subjects. In the latter case, while it was commonly accepted 
the isolation membrane was derived from the ER, it has been recently reported that 
the plasma, nuclear, and even mitochondrial membranes can contribute to the 
initiation of this process (Tooze and Yoshimori, 2010) . 
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Figure 4.1 Schematic overview of autophagy and its regulation 
The top left schematic shows a simplified model of the different steps involved in 
the autophagosome “life cycle”: membrane initiation, elongation and completion. 
The major membrane source is thought to be the ER, although several other 
membrane sources, such as mitochondria and the plasma or nuclear membrane, 
may contribute. The bottom right schematic shows a simplified model of the current 
understanding of the molecular events involved in membrane initiation. After 
induction of autophagy, the ULK1 complex translocates to the ER and activates the 
ER-localised autophagy-specific class III PI(3)K complex. The PtdIns(3)P formed 
on the ER membrane recruits WIPIs effector proteins. WIPIs and the Atg12–Atg5–
Atg16L1 complex are present on the outer membrane, and LC3–PE is present on 
both the outer and inner membrane of the isolation membrane.  
 
4.1.3 MHC II compartments receive antigens from autophagosomes 
Extracellular antigens are commonly internalised by antigen presenting cells 
and degraded in lysosomes. Subsequently, antigen-derived peptides, products of 
lysosomal proteolysis, are loaded on MHCII molecules and presented to CD4+ T 
cells. Although the main source of MHCII ligands comes from exogenous antigens, 
it has been shown that several intracellular peptides can gain access to MHCII 
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compartments through the binding of autophagosomes to these vesicles. This is 
the case for cytosolic viral peptides and also for citrullinated self-proteins, usually 
produced during autoimmune diseases (Paludan et al., 2005, Ireland and Unanue, 
2011). Thus, autophagy would not only strengthen immune responses to viral 
infections but also play an important role in the regulation of autoimmunity. 
Furthermore, coupling of extracellular antigens to LC3, targets antigens to 
autophagosomes, what leads to a substantial increase in MHCII presentation of 
extracellular antigens and CD4+ T cell proliferation (Schmid, Pypaert and Münz, 
2007). However, whether uncoupled extracellular antigens are delivered to 
autophagosomes or whether autophagy plays a role in their presentation on MHCII 
is not established.     
 
4.1.4 Autophagy in B cell responses 
Autophagy has recently been shown to be an important regulator of B cell 
responses. Following antigenic challenge, differentiating plasma cells, long-lived 
plasma cells and memory B cells display high levels of autophagy, with increased 
expression of genes that regulate autophagy initiation and autophagosome 
maturation (Pengo et al., 2013, Chen et al., 2014). Interestingly, B cell-specific 
ablation of autophagy proteins such as Atg5 or Atg7, results in reduced numbers of 
long-lived bone marrow plasma cells and memory B cells. This phenomenon 
results in defective primary or secondary antibody responses after infection with 
pneumococcus or influenza virus respectively (Pengo et al., 2013, Chen et al., 
2014). Autophagy is, therefore, an essential process for the survival of long-lived 
plasma cells and antigen-specific memory B cells and the maintenance of 
protective antibody responses required to combat infections. The specific signals 
that induce autophagosome formation in B cells, and the role of autophagy in the 
presentation of exogenous pathogens are far from being defined.  
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4.2 BCR and TLR signalling control autophagosome formation 
through the PLCγ2 pathway    
4.2.1 LC3II accumulation as an indicator of autophagy flux 
In order to investigate which signals induce autophagosome formation in B 
cells, I decided to follow the formation of autophagosomes after B cell stimulation 
with different stimuli. For this, I measured the accumulation of LC3, which is a 
specific marker for these double-membrane vesicles (Mizushima, Yoshimori and 
Levine, 2010). During autophagy, a cytosolic form of LC3 (LC3-I) is conjugated to 
phosphatidylethanolamine to form LC3-II conjugates; LC3-II is then recruited to 
autophagosomal membranes (Levine, Mizushima and Virgin, 2011). The detection 
of LC3 conversion (LC3-I to LC3-II) by western blot is one of the most widely used 
approaches to measure autophagosome formation, as the amount of LC3-II is 
directly correlated with the number of autophagosomes. Because of the 
degradation of cytosolic components and LC3-II during the formation of 
autophagolysosomes, the interpretation of LC3 levels by Western blot is somewhat 
problematic (Mizushima and Yoshimori, 2007). In order to measure the formation of 
autophagosomes independently of their degradation, lysosome inhibitors should be 
added to the system to prevent LC3-II degradation. The most common inhibitor 
used in this case is chloroquine, which inhibits the acidification of the lysosomes, 
leading to an inhibition in the lysosomal enzymes that require a low pH to work 
(Mizushima and Yoshimori, 2007).   
   
4.2.2 BCR signalling induces autophagosome formation 
Firstly, I wondered whether signalling through the BCR, the most important 
receptor on B cells, would induce formation of autophagosomes. To address this 
question, primary B cells were purified from the spleen of C57BL/6 mice and 
stimulated through the BCR with different concentrations of anti-IgM (0, 10 or 
20µg/ml) for 1 to 16 hours. In all the cases, PBS or chloroquine was added to the 
medium 30 minutes before the end of the time point. Cells were collected, lysed 
and the protein cell lysates were subject to electrophoresis. The samples were then 
transferred to PVDF membranes, which were incubated with primary antibodies 
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against LC3IIB and actin (used as loading control). After incubation with the 
corresponding secondary antibodies, membranes were developed using an ECL 
kit. The levels of LC3-II were increased after chloroquine addition even in the 
absence of stimulation (anti-IgM 0µg/ml, no chloroquine vs. chloroquine) (Figure 
4.2A). This reflects the basal rate of autophagosome formation in naïve B cells. 
Interestingly, BCR stimulation induces accumulation of LC3II levels since the first 
two hours of stimulation and these levels remained increasing after 3 hours of BCR 
crosslinking to overnight stimulation (anti-IgM 0µg/ml vs 10 or 20µg/ml)  (Figure 
4.2A). These results indicate that stimulation of B cells through the BCR leads to 
the formation of autophagosomes. 
 
Stimulation of B cells through the BCR in the absence of survival cytokines 
or co-stimulation molecules usually leads to apoptosis of these cells. In order to 
inhibit the apoptotic process, B cells were stimulated for 5 hours with anti-IgM  
(0, 10 or 20µg/ml) in the presence of IL-4, which protects primary B cells from 
entering into the apoptosis program (Wurster et al., 2002). Chloroquine was added 
to the system 30 minutes before the end point in order to induce autophagosome 
accumulation. Cells were collected, lysed and the protein lysates were subject to 
electrophoresis and Western blot as indicated before. IL-4 alone does not induce a 
significant accumulation of LC3-II (Figure 4.2B). In contrast, a massive increase in 
the levels of LC3-II was observed after BCR crosslinking in the presence of IL-4 
(Figure 4.2B). This result indicates that autophagosome formation in B cells after 
signalling induced through the BCR is not just a consequence of programed cell 
death. 
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Figure 4.2 BCR crosslinking induces autophagosome formation 
(A) Western blot analysis of cellular lysates derived from wild type B cells using 
anti-LC3IIB and anti-actin antibodies. B cells were stimulated with 0, 10 or 20µg/ml 
of anti-IgM for 1 to 16 hours and PBS or chloroquine were added to the culture 30 
minutes before lysing. Signal intensities were quantified with ImageJ and LC3-
II/actin signal ratios were normalised to non-stimulated samples (0 µg/ml anti-IgM 
plus chloroquine). Relative LC3-II/actin levels after different times of stimulation 
were plotted in the chart. (B) Western blot analysis of cellular lysates derived from 
wild type B cells using anti-LC3IIB and anti-actin antibodies. B cells were 
stimulated with 0, 10 or 20µg/ml of anti-IgM in the presence of IL-4 (5ng/ml) for 5 
hours and PBS or chloroquine were added to the culture 30 minutes before lysing. 
LC3-II/actin signals ratios were normalised to non-stimulated samples (0 µg/ml anti-
IgM minus Chloroquine). Relative LC3-II/actin levels following BCR stimulation 
were plotted in the bar chart. All data are representative of three independent 
experiments. 
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4.2.3 TLR signalling induces autophagosome formation 
B cells not only recognise and respond to pathogens through the surface 
BCRs, they also express a series of TLRs that allow them to recognise a variety of 
pathogen-associated molecular patterns (Pasare and Medzhitov, 2005). In 
particular, B cells express high levels of TLR9, which is located on intracellular 
endosomes and recognises CpG motifs and TLR4, which is located on the B cell 
surface and recognises LPS. The triggering of TLRs on B cells initiates an 
intracellular MyD88/TRIF-mediated signalling that results in proliferation, cytokine 
secretion and antibody production (Browne, 2012). Therefore, I wondered whether 
the stimulation of B cells through TLR9 or TLR4 would also induce the formation of 
autophagosomes as observed following BCR crosslinking.  
 
For this, I stimulated primary B cells for 3 or 5 hours with increasing 
concentrations of CpG (0, 0.5, 1 and 5µg/ml) or LPS (0, 0.1 and 1µg/ml). 
Chloroquine was added to the culture 30 minutes before harvesting the cells and 
protein cell lysates were subject to electrophoresis and Western blot to detect the 
levels of LC3II. CpG stimulation led to an increase in the levels of LC3II after 3 and 
5 hours of stimulation in a dose dependent manner (Figure 4.3A). Importantly, the 
accumulation of LC3II after CpG stimulation required signalling through TLR9, as 
the levels of LC3II remained similar to basal levels when primary B cells from 
TLR9-deficient mice were stimulated with CpG (Figure 4.3A). Moreover, stimulation 
of B cells with LPS also induced up regulation of LC3II levels, although this up 
regulation was not as strong as observed with CpG (Figure 4.3B). All together, 
signalling via BCRs as well as TLRs induces autophagosome formation in B cells.  
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Figure 4.3 TLR4 and TLR9 signalling induces autophagosome formation 
Western blot analysis of cellular lysates derived from wild type or Tlr9-/- B cells 
using anti-LC3IIB and anti-actin antibodies. B cells were stimulated with 0, 0.5, 1 
and 5µg/ml of (A) CpG or (B) LPS for 3 or 5 hours and chloroquine was added to 
the culture 30 minutes before lysing. Signal intensities were quantified and LC3-
II/actin signals ratios were normalised to non-stimulated samples. Relative LC3-
II/actin levels are plotted in the bar charts. All data are representative of two 
independent experiments. 
 
4.2.4 BCR and TLR signalling induces accumulation of LC3+ vesicles 
The previous results showed that stimulation of B cells through the BCR or 
TLRs induces accumulation of LC3II levels. To visualise the formation of these 
double-membrane organelles by confocal microscopy, primary B cells were 
stimulated in vitro with PBS (control), 10µg/ml of anti-IgM or 1µg/ml of CpG. After 3 
hours, B cells were washed with PBS, fixed and permeabilised with methanol and 
stained for LC3. Confocal analysis revealed a substantial accumulation of LC3-
containing vesicles after both BCR crosslinking and TLR9 stimulation (Figure 4.4A). 
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To quantify the number of LC3 foci per cell in the different conditions I used the 
spot detection tool in Imaris. Following stimulation with anti-IgM and CpG, an 
average of ten LC3 foci per B cell were observed (Figure 4.4B). On the other hand, 
most of non-stimulated B cells contained between zero to two LC3+ vesicles 
(Figure 4.4B). All together, the analysis of LC3II accumulation by Western blot and 
the quantification of LC3 foci by confocal microscopy show that stimulation of B 
cells through the BCR and TLR9 induce the formation of autophagosome vesicles. 
 
  
Figure 4.4 BCR and TLR9 signalling induces accumulation of LC3+ vesicles 
(A) Confocal images of primary B cells that were stimulated for three hours with 
PBS (control), 10 µg/ml of anti-IgM or 1 µg/ml of CpG, fixed, permeabilised and 
stained with anti-LC3 (green). (B) Quantification of LC3 foci per cell in B cells that 
were treated as in (A). Quantification was performed using the spot detection tool in 
Imaris. Data are representative of two independent experiments. Student t test, **** 
p<0.0001. 
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4.2.5 PLCγ2 is a central regulator of BCR and TLR-induced autophagy 
I moved on to analyse which molecules involved in BCR signalling are 
required for the formation of these autophagosomes. Crosslinking of the BCR after 
antigen recognition leads to a multitude of downstream signalling events. In short, 
BCR crosslinking leads to the early phosphorylation of the BCR complex and the 
recruitment of intracellular signalling molecules such as the kinase Syk, PLCγ2 and 
PI3K. Syk activates the E3 ubiquitin ligase c-Cbl, which is involved in BCR 
internalisation. PLCγ2 catalyses the production of the secondary messengers DAG 
and IP3 to ensure signal propagation. Finally, PI3K recruitment to the BCR by the 
protein adaptors BCAP and CD19 ensures the survival of B cells following 
activation (Harwood and Batista, 2009, Castello et al., 2013).  
 
To analyse the role of these different molecules in autophagosome 
formation after BCR crosslinking, primary B cells were isolated from wild type, c-
Cbl-/-, BCAP-/-, CD19-/- and PLCγ2-/- mice. B cells were stimulated for 5 hours with 
increasing concentrations of anti-IgM (0, 10 or 20µg/ml) and chloroquine was 
added to the medium 30 minutes before the end time point. Protein cell lysates 
were subject to electrophoresis and Western blot to detect the levels of LC3II. I 
observed an increase in the intensity of LC3II after BCR stimulation in both wild 
type and c-Cbl deficient B cells (Figure 4.5A). This indicates that c-Cbl is not 
required for the formation of these organelles following BCR stimulation. 
Surprisingly, the increase in the levels of LC3II after BCR crosslinking was also 
observed in CD19- and BCAP-deficient B cells (Figure 4.5B), indicating that PI3K 
recruitment to the BCR by these two adaptors is not necessary for the 
autophagosome formation. In contrast, the induction of LC3II up-regulation 
following BCR crosslinking was abrogated in PLCγ2-deficient B cells (Figure 4.5C), 
indicating that the PLCγ2 pathway is essential for the formation of these double 
membrane vesicles after BCR signalling. 
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Figure 4.5 PLCγ2 regulates BCR- and TLR-induced autophagosome formation 
Western blot analysis of cell lysates derived from wild type or (A) c-Cbl-/- (B) CD19-/-
or BCAP-/- and (C and D) PLCγ2-/- B cells using anti-LC3IIB and anti-actin 
antibodies. B cells were stimulated with (A to C) 0, 10 and 20µg/ml of anti-IgM or 
(D) 0,1 or 5µg/ml of CpG for 5 hours. Chloroquine was added to the culture 30 
minutes before lysing. Signal intensities were quantified and LC3-II/actin signal 
ratios were normalised to non-stimulated samples. Relative LC3-II/actin levels are 
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plotted in the bar charts. All data are representative of two independent 
experiments. 
 
I wondered whether PLCγ2 is also involved in the formation of 
autophagosomes following TLR stimulation. For this, primary B cells were isolated 
from wild type and PLCγ2-/- mice and stimulated for 5 hours with increasing 
concentrations of CpG (0, 1 or 5µg/ml). Chloroquine was added to the medium 30 
minutes before harvesting the cells, and cell lysates were subject to electrophoresis 
and Western blot to detect the levels of LC3II. As expected, the levels of LC3II 
were increased in wild type B cells after CpG stimulation (Figure 4.5D). In contrast, 
the up regulation of LC3II after TLR stimulation was dramatically decreased in 
PLCγ2-deficient B cells (Figure 4.5D). 
 
Together these results suggest that PLCγ2 could act as a central hub for the 
induction of autophagosome formation following recognition of pathogens by B 
cells, through the BCR or TLRs. The lipase activity of PLCγ2 cleaves PIP2 
(phosphatidylinositol 4,5-bisphosphate) into IP3 and DAG, which then function as 
secondary messengers. IP3 binds to IP3 receptors in the ER to induce the release 
of Ca2+ while DAG activates PKC, which phosphorylates other cytosolic proteins. 
Therefore, through Ca2+ and PKC, PLCγ2 could be controlling the formation of 
autophagosomes following antigen challenge. To directly assess the role of these 
two distinct pathways in the autophagy process, it would be important to analyse 
the formation of autophagosomes following BCR and TLR stimulation in PKC-
deficient or IP3 receptor deficient B cells. 
 
4.3 BCR- and TLR-induced autophagy is ULK1/2-independent 
4.3.1 BCR accumulates in autophagosomes after internalisation  
When BCR recognises antigen, the BCR-antigen complex is internalised 
inside the cell onto specific cellular compartments. These compartments are rapidly 
polarised towards the MTOC (microtubule organising centre) and are where 
antigen is loaded onto MHCII molecules for presentation to T cells (Thaunat et al., 
2012, Burbage et al., 2015). As autophagosome formation is induced following 
BCR crosslinking, I wondered whether these structures were localising near the 
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internalised antigen. To visualise the formation and localisation of 
autophagosomes, primary B cells were isolated from GFP-LC3 mice. Then, they 
were incubated with 10µg/ml of labelled anti-IgM for 0, 15 or 60 minutes at 37oC. 
The use of labelled anti-IgM not only allows the stimulation of B cells through the 
BCR but also serves as a labelled antigen that can be easily tracked after 
internalisation. At each time point, B cells were washed with PBS, and fixed and 
permeabilised with methanol. Cells were then stained with anti-α-tubulin, to stain 
the microtubules and the MTOC, and with anti-GFP to increase the signal of LC3.  
 
Confocal analysis revealed that in the steady state, BCR is detected on the 
surface of B cells and LC3 was seen diffuse in the cytoplasm (Figure 4.6A). After 
15 minutes of activation, BCR is no longer observed on the B cell surface and it is 
found in rounded intracellular vesicles. Moreover, LC3 is less diffuse than in steady 
state and starts accumulating on small vesicles. Interestingly, most of these LC3+ 
vesicles were co-localising with the antigen-loaded ones, suggesting that antigen 
could be delivered to LC3+ vesicles following internalisation (Figure 4.6B). After 1 
hour of stimulation, individual vesicles of antigen could not longer been observed. 
Instead, antigen is accumulated on big compartments polarised towards the 
MTOC, easily identified due to its bright staining with α-tubulin. Surprisingly, LC3 is 
also detected as a large cluster polarised towards the MTOC co-localising with the 
antigen (Figure 4.6C). These results suggest that following BCR internalisation, 
antigen is delivered to autophagosome compartments where it might be loaded 
onto MHCII molecules for antigen presentation. 
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Figure 4.6 BCR localises in autophagosomes after internalisation 
(A) Confocal 3D projections of primary B cells from GFP-LC3 mice that were 
stimulated with 10µg/ml of anti-IgM AF546 for 0 or 15 minutes, fixed, permeabilised 
and stained with anti-GFP (green). (B) Confocal single plane images of B cell 
treated as in (A). Histograms represent GFP and AF546 fluorescence measured 
across the dashed lines. (C) Confocal 3D projections of primary B cells from GFP-
LC3 mice that were stimulated with 10µg/ml of anti-IgM AF546 for 0 or 60 minutes, 
A
Fl
uo
re
sc
en
ce
 (A
U
)
2500
1250
0
BCR LC3 Merged
0 min
15 min
C
0 min
60 min
BCRLC3 MergedTubulin LC3 + Tubulin
B
0 min
15 min
BCR + LC3
BCR
LC3
0 min
4000
2000
0
15 min
'LVWDQFHȝP
0 6 12
174 
fixed, permeabilised and stained with anti-GFP (green) and anti-tubulin (blue). Data 
are representative of two independent experiments.  
 
4.3.2 PI3K inhibitors block antigen presentation by B cells 
As the BCR localises in autophagosome compartments following 
internalisation, I wondered whether autophagosome formation was necessary for 
the presentation of extracellular antigens by B cells. Autophagosome formation is a 
complex and tightly regulated process that requires the interaction of several 
different proteins. As detailed in the introduction, this process is initiated when the 
ULK1 complex translocates to the ER and activates the ER-specific class III PI3K 
that catalyse the production of PtdIns3P. PtdIns3P generate ER-associated 
isolation membranes which then mature into autophagosomes (Levine, Mizushima 
and Virgin, 2011) 
 
 As a first approach to block the formation of autophagosomes, I used two 
well-known autophagy inhibitors: wortmannin and 3-methyladenine. Both drugs are 
inhibitors of type III PI3K, which is required for the initial assembly of these double-
membrane organelles. However, wortmannin might also inhibit type I and type II 
PI3K (Ireland and Unanue, 2011). To test whether these drugs inhibit BCR-induced 
formation of autophagosomes, primary B cells were stimulated with 10µg/ml of 
labelled anti-IgM in the absence or presence of 10nM Wortmannin or 1mM 3-
methyladenine. After 15 minutes, cells were washed, fixed, permeabilised and 
stained for LC3. Following BCR crosslinking, both BCR+ and LC3+ vesicles were 
formed in control samples. In contrast, while antigen-containing vesicles could be 
observed in the presence of PI3K inhibitors, the formation of LC3+ vesicles was 
abrogated (Figure 4.7). As PI3K inhibitors inhibit BCR-induced formation of 
autophagosomes without affecting the internalisation of antigen, I went on to 
analyse the antigen presentation capacity of B cells in the presence or absence of 
these inhibitors. 
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Figure 4.7 Wortmannin and 3-methyladenine inhibit autophagosome formation 
(A) Confocal 3D projections of primary B cells that were stimulated with 10µg/ml of 
anti-IgM AF546 for 0 or 15 minutes in the presence of PBS (control), 10nM 
Wortmannin or  mM 3-methyladenine. Cells were fixed, permeabilised and stained 
for LC3. Data are representative of two independent experiments.  
 
To measure antigen presentation I performed the well-established technique 
of B-T cell co-culture. For this, I isolated primary B cells and labelled them with 
CFSE. B cells were then cultured with beads coated with anti-IgM and OVA in the 
absence or presence of 10nM Wortmannin or 1mM 3-methyladenine. In a normal 
situation, B cells internalise these beads, process the OVA and load OVA peptides 
on MHCII for presentation. Beads and inhibitors were washed from the culture after 
1 hour and B cells were co-cultured with OT II CD4+ T cells previously labelled with 
CellTrace™ Violet. As OT II T cells have a TCR specific for OVA, they recognise 
OVA peptides presented by B cells and proliferate and secrete IL-2. As the extent 
of T cell division is proportional to the amount of antigen presented by B cells, the 
measurement of T cell division by CellTrace™ Violet dilution and IL-2 secretion are 
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indicative of how much antigen is being presented by the B cells. B cell division can 
also be followed by measuring dilution of CFSE by flow cytometry. 
 
After 3 days of co-culture, B cell and T cell division were measured by flow 
cytometry and IL-2 secretion by ELISA. In the absence of inhibitors, B cells and T 
cells undergo several rounds of cell division after 3 days of co-culture, as judged by 
the dilution of CFSE and CellTrace™ Violet respectively (Figure 4.8A–B). 
Moreover, T cells actively secrete IL-2, as observed by ELISA (Figure 4.8C). In 
contrast, the proliferation of B cells and T cells, as well as the secretion of IL-2, 
were abrogated in the presence of Wortmannin or 3-methyladenine (Figure 4.8A–
C). This experiment indicates that type III PI3K and probably autophagosome 
formation might be necessary for antigen presentation.  
 
 
Figure 4.8 PI3K inhibitors interfere with B cell antigen presentation 
Flow cytometry analysis of (A) CFSE and (B) celltrace violate dilution from CFSE-
labelled primary B cells stimulated with anti-IgM and OVA-coated beads in the 
presence of PBS, 10 nM Wortmannin or 1mM 3-methyladenine and co-cultured 
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177 
with CellTrace™ Violet labelled-OT-II T cells for 72 hours. The percentage of 
divided B cells and T cells are depicted in the graphs. Red curve: no stimulated 
cells, blue curve: stimulated cells.  (C) IL-2 levels measured in co-culture 
supernatants from (A and B) by ELISA after 72 hours. Data are representative of 
two independent experiments.  
 
4.3.3 ULK1/2 are dispensable for B cell antigen presentation 
3-methyladenine can have off targets effects (Ito et al., 2007, Hou et al., 
2012) and wortmannin inhibits all three types of PI3K and not only the type III 
autophagy-specific one (Vanhaesebroeck et al., 2001). I therefore moved on to 
genetically target diverse components of the autophagosome complex machinery 
to directly assess the role of autophagy on the antigen presentation process. As 
mentioned previously, autophagosome formation is initiated by the recruitment of 
the ULK complex (ULK1 and ULK2) to the ER (Lee and Tournier, 2011). I therefore 
analysed the antigen presentation capacity of primary B cells derived from wild 
type; ULK1-deficient and ULK2-deficient mice using the B-T cell co-culture 
technique explained above. Increasing concentrations of OVA were used to coat 
the beads (from 0.001 to 1µM) in order to titrate the T cell response.  After 3 days 
of co-culture, B cell proliferation, T cell proliferation and IL-2 secretion were 
analysed.    
 
The rate of B cell and T cell proliferation and IL-2 secretion directly 
increases with the amount of OVA used to coat the beads (Figure 4.9A–C). 
However, no significant differences were observed in these parameters between 
wild type B cells and ULK1-deficient or ULK2-deficient B cells (Figure 4.9A–C). 
This result indicates that ULK1 and ULK2 are not required for B cell antigen 
presentation to CD4+ T cells. However, these proteins share 78% homology within 
their protein kinase domains and have redundant functions to mediate autophagy 
under nutrient-deprivation (Lee and Tournier, 2011). I therefore thought to analyse 
antigen-presentation on primary B cells from ULK1/ULK2 double-deficient mice.  
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Figure 4.9 ULK1 and ULK2 are dispensable for B cell antigen presentation 
Flow cytometry analysis of (A) CFSE and (B) celltrace violate dilution from wild 
type, ULK1-/- and ULK2-/- B cells stimulated with beads coated with anti-IgM and 
increasing amount of OVA and co-cultured with OT-II CD4+ T cells for 72 hours. 
The percentage of divided B cells and T cells are depicted in the graphs. Red 
curve: no stimulated cells, blue curve: stimulated cells.  (C) IL-2 levels measured in 
co-culture supernatants from (A and B) by ELISA after 72 hours. Data are 
representative of two independent experiments.  
 
ULK1/2-deficient mice die within one week after birth due to feeding-related 
problems (Cheong et al., 2011). As at this time the B cell compartment is still not 
fully developed, I thought to generate chimeras from fetal liver hematopoietic stem 
cells of ULK1/2 deficient embryos. For this, embryos were collected at day E14.5, 
genotyped using their tails, and liver cells from either wild type or ULK1/2-deficient 
embryos were injected into sub-lethally irradiated Rag2-/- mice. Eight weeks post-
transplant, primary B cells were isolated from wild type and ULK1/2-/- chimeras and 
the antigen presentation capacity of these cells was analysed using the B-T cell co-
culture technique. After 3 days of co-culture, B cell proliferation, T cell proliferation 
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and IL-2 secretion were analysed as before. Surprisingly, the rate of B cell and T 
cell proliferation and IL-2 secretion were similar independently of whether B cells 
originated from wild type or ULK1/2-/- chimeras (Figure 4.10A–C). These results 
indicate that ULK proteins are not involved in the presentation of antigen by B cells 
to CD4+ T cells.  
 
 
Figure 4.10 ULK complex is dispensable for B cell antigen presentation 
Flow cytometry analysis of (A) CFSE and (B) celltrace violate dilution from wild type 
and ULK1/2-/- B cells stimulated with beads coated with anti-IgM and increasing 
amounts of OVA and co-cultured with OT-II CD4+ T cells for 72 hours. The 
percentage of divided B cells and T cells are depicted in the graphs. Red curve: no 
stimulated cells, blue curve: stimulated cells. (C) IL-2 levels measured in co-culture 
supernatants from (A and B) by ELISA after 72 hours. Data are representative of 
two independent experiments.  
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B cells not only present antigen-derived peptides to CD4+ T cells, but they 
can also present lipid antigens to NKT cells in the context of CD1d (Barral et al., 
2008). I therefore wondered whether ULK proteins would be involved in the B cell 
presentation of lipids to NKT cells. To test this hypothesis, I performed a B cell-NKT 
cell co-culture. For this technique, I isolated primary B cells from wild type and 
ULK1/2-/- chimeras and stimulated them with beads coated with anti-IgM and 
increasing concentrations of α-GalCer-containing liposomes. In normal conditions, 
B cells internalise these beads and load α-GalCer on CD1d for presentation (Barral 
et al., 2008). After 1 hour, beads were washed from the culture and B cells were 
co-cultured with an NKT cell hybridoma (DN32.D3) that produces IL-2 after α-
GalCer recognition on CD1d (Bendelac et al., 1995). The extent of IL-2 production 
by the NKT cell hybridoma is proportional to the amount of α-GalCer presented by 
B cells. After 24 hours of co-culture, supernatants were collected and IL-2 
measured by ELISA. As observed in Figure 4.11A, IL-2 production increases with 
the amount of α-GalCer used to coat the beads. However, the production of IL-2 
was similar independently of NKT cells being cultured with wild type or ULK1/2 
deficient B cells. This result indicates that ULK proteins are not necessary for B cell 
presentation of lipids to NKT cells.  
 
I went on to measure the amount of α-GalCer loaded on CD1d in the 
surface of B cells by using a labelled antibody that recognises α-GalCer-CD1d 
complex. To test this, primary B cells from wild type and ULK1/2-/- chimeras were 
cultured with beads coated with anti-IgM and increasing concentrations of α-
GalCer-containing liposomes. After overnight culture, B cells were washed and 
stained with labelled anti-α-GalCer-CD1d complex. Flow cytometry analysis 
showed that the levels of α-GalCer loaded on CD1d are proportional to the amount 
of α-GalCer used to coat the beads (Figure 4.11B). However, α-GalCer 
presentation was similar in wild type and ULK1/2 deficient B cells (Figure 4.11B). 
This result, together with the B cell-NKT cell co-culture, demonstrates that ULK 
proteins are not necessary for the presentation of lipids in the context of CD1d to 
NKT cells. 
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Figure 4.1 The ULK complex is dispensable for B cell lipid presentation of CD1d 
(A) IL-2 levels measured by ELISA in supernatants from wild type and ULK1/2-/- B 
cells stimulated with beads coated with anti-IgM and increasing amounts of α-
GalCer and co-cultured with DN32.D3 hybridoma cells for 24 hours. (B) Flow 
cytometry analysis of the amount of α-GalCer loaded on CD1d from wild type and 
ULK1/2-/- B cells stimulated with beads coated with anti-IgM and increasing 
amounts of α-GalCer for 24 hours. The mean fluorescence intensity of α-GalCer-
CD1d for each concentration of α-GalCer used is depicted in the graph. Data are 
representative of three independent experiments. 
 
4.3.4 ULK1/2 are dispensable for BCR and TLR-induced autophagy  
While the treatment of B cells with PI3K inhibitors reduces the ability of B 
cells to present antigen to T cells, the deletion of ULK proteins does not affect the 
antigen presentation capacity of B cells. I wondered whether the formation of 
autophagosomes following BCR and TLR stimulation was blocked in the absence 
of ULK proteins. To analyse this, primary B cells from wild type and ULK1/2-/- 
chimeras were stimulated for 5 hours with increasing concentrations of anti-IgM  
(0, 10 and 20µg/ml) or CpG (0, 1 and 5µg/ml). Chloroquine was added to the 
culture 30 minutes before harvesting the cells and protein cell lysates were subject 
to electrophoresis and western blot to detect the levels of LC3II. Surprisingly, BCR 
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and TLR stimulation induced up regulation of LC3II in both wild type and ULK1/2-
deficient B cells (Figure 4.12A–B). In fact, the levels of LC3II were higher in 
ULK1/2-deficient compared to wild type B cells, not only after stimulation but also in 
steady state conditions (0µg/ml of stimulus).  
 
 
Figure 4.12 BCR- and TLR-induced autophagy are independent of the ULK 
complex 
Western blot analysis of cellular lysates derived from wild type or ULK1/2-/- B cells 
using anti-LC3IIB and anti-actin antibodies. B cells were stimulated with (A) 0, 10 and 
20µg/ml of anti-IgM or (B) 0, 1 or 5µg/ml of CpG for 5 hours. PBS or chloroquine was 
added to the culture 15 minutes before lysing. Signal intensities were quantified and 
LC3-II/Actin signals ratios were normalised to wild type non-stimulated samples. 
Relative LC3-II/actin levels are plotted in the bar charts. Data are representative of 
two independent experiments.  
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These results are striking as they demonstrate that ULK proteins, despite 
being essential for the induction of autophagy under nutrient-deprived conditions 
(Lee and Tournier, 2011), are dispensable for the formation of autophagosomes 
after B cell stimulation. Therefore, BCR and TLR-dependent formation of 
autophagosomes in B cells involves an ULK-independent pathway, different from 
the conserved one triggered during starvation. 
 
In summary, BCR and TLR signalling induces autophagosome formation in 
B cells through a non-conserved pathway where the ULK complex is dispensable. 
In contrast, PLCγ2 could act as a central regulator for the induction of 
autophagosome formation following recognition of pathogens by B cells. 
Importantly, antigens colocalise with autophagosomes following internalisation. 
However, as autophagy is not blocked in ULK1/2-deficient B cells, I cannot 
conclude whether autophagosome formation is important for the presentation of 
exogenous antigens by B cells. In the future, it would be important to analyse the 
requirement of other conserved components of the autophagy machinery, such as 
Atg5, Atg7 or Atg16L in the formation of autophagosomes following B cell 
stimulation. In that case, it would be interesting to assess their role on the 
presentation of exogenous antigens by B cells. 
 
4.4 Discussion 
Autophagy is the cellular process of degradation of the cell’s own cytoplasm 
and organelles to generate energy and build new proteins and membranes 
(Mizushima, 2007). In this chapter I have shown that signalling through the BCR or 
through TLRs induces autophagy in B cells. This process is strictly dependent on 
the PLCγ2 pathway and does not require the presence of the conserved proteins 
ULK1 and ULK2. Furthermore, antigen localises in close contact with 
autophagosome vesicles after internalisation, suggesting a potential role for this 
process in antigen presentation. 
 
Although B cells are small in size (10µm) and most of their cytoplasmic 
volume is occupied by the nucleus, they express high levels of the autophagy 
proteins Atg5, Atg7 and LC3 (McLeod, Jia and He, 2012). Autophagy might 
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therefore play an important role in the tightly-controlled organisation of organelles 
and the metabolic environment taking place in such a limited space. In this chapter 
I showed that even though B cells do not seem to display high levels of autophagy 
in the steady state, this process is increased after antigen recognition. BCR 
crosslinking results in up regulation of the autophagy flux, as already described for 
B cell lines and splenic B cells (Watanabe et al., 2008, Ireland and Unanue, 2011). 
Importantly, BCR signalling induces autophagy even in the presence of the co-
stimulatory molecule IL-4, which serves as a survival factor, suggesting that 
autophagy induction is not just the result of apoptosis. This observation differs 
somewhat from those made by Watanabe and collaborators, who suggest that 
BCR signalling in the presence of co-stimulatory molecules does not induce 
autophagy (Watanabe et al., 2008). The differences may come from the fact that in 
their study, they use transformed B cell lines instead of primary B cells. 
Furthermore, the recognition of PAMPS such as LPS and CpG through TLRs 
induces autophagosome formation to a similar extent as observed after BCR 
crosslinking. As activated B cells need to pass through several rounds of 
proliferation to expand, high levels of autophagy might support B cell energy 
demands to successfully complete this process. 
 
The autophagy pathway followed after BCR and TLR engagement seems to 
be quite unique compared to the conserved mechanisms present in many other 
systems (Levine, Mizushima and Virgin, 2011, McLeod, Jia and He, 2012). In B 
cells, this process is strictly dependent on PLCγ2 pathway and is independent of 
ULK1 and ULK2 factors. PLCγ2 is a central protein in the propagation of signals 
after B cell recognition of antigens. PLCγ2 catalyses the degradation of membrane-
bound PIP2 into DAG and IP3. While DAG activates the PKC pathway, IP3 binds to 
IP3 receptors in the ER and induces the release of intracellular Ca2+ (Weber et al., 
2008). Although a potential role of PKC in autophagy initiation remains undefined, 
the rise of free cytosolic Ca2+ has been shown to be a potent inducer of autophagy 
(Høyer-Hansen et al., 2007). Therefore, through PKC or most probably Ca2+-
signalling, PLCγ2 acts as a central hub for autophagy induction in B cells. It would 
be important, in the future, to define the importance of these two branches of 
PLCγ2-mediated signalling on the induction of the autophagy program.  
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ULK1 and ULK2 are conserved proteins involved in autophagosome 
formation in response to stress and nutrient starvation (Cheong et al., 2011, Lee 
and Tournier, 2011). Under such conditions, mTOR activity is inhibited, which 
results in ULK1/2 phosphorylation and activation of class III PI3K complex (Kim et 
al., 2011). Class III PI3K complex generates PtdIns3P, which induces the 
generation of phagophores that later mature into autophagosomes (Mizushima, 
2007). Even though ULK-deficiency renders cells unable to form autophagosomes 
under nutrient starvation (Cheong et al., 2011, Lee and Tournier, 2011, Russell et 
al., 2013), it does not interfere with the induction of autophagy in B cells after BCR 
or TLR stimulation. In fact, autophagosome formation is enhanced in the absence 
of ULK proteins. These results indicate that B cells undergo a non-conserved type 
of autophagy that occurs after the recognition of pathogens that does not require 
ULK proteins. In line with this idea, recent reports showed that autophagy induction 
in T cells after TCR engagement is independent of mTOR complex and class III 
PI3K (Jia and He, 2011, O'Brien et al., 2011). However, proteins that are involved 
in the later steps of the autophagosome formation, such as Atg5 or Atg7, are 
essential for autophagy induction in lymphocytes (McLeod, Jia and He, 2012, 
Pengo et al., 2013, Chen et al., 2014).  
 
BCR recognition of antigen induces mTOR activation though PI3K (Limon 
and Fruman, 2012). Triggering of mTOR might block the initial steps involved in the 
generation of isolation membranes from the ER (ULK1/2, type III PI3K, WIPIs) and 
at the same time, induce a non-conserved version of autophagy where isolation 
membranes are directly provided by BCR-containing endosomes. In fact, this 
seems to be the case, as BCR co-localises with LC3 in the same compartments 
shortly after BCR crosslinking. Therefore, the use of BCR-containing endosomes 
as isolation membranes would allow B cells to bypass the early conserved steps of 
autophagosome formation. As lymphocytes have a very limited cytoplasmic space, 
and they require a lot of energy for their massive proliferation, this short version of 
the autophagy machinery would allow them to rapidly generate autophagosomes 
and fulfil their energy demands. In the future, it will be interesting to analyse the 
role of different initiation, nucleation and elongation factors in the induction of B cell 
autophagy and assess whether BCR-containing endosomes can function as 
isolation membranes to form autophagosomes.    
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Regardless of the signalling pathways involved in autophagosome formation 
in B cells, it is important to understand the role of this process in B cell physiology. 
It has been shown that autophagy is necessary for the survival of long-lived plasma 
and memory B cells (Pengo et al., 2013, Chen et al., 2014). However, its 
importance in the early steps of B cell function is not clear. Antigen internalised 
through the BCR localises on autophagosome vesicles polarised towards the 
MTOC. This suggests that autophagosomes may serve as compartments for 
antigen processing and loading on MHC II molecules before presentation on the 
membrane. Interestingly, MHC II has been shown to co-localise with antigen in 
autophagosomes after B cell activation (Ireland and Unanue, 2011). I attempted to 
analyse the role of autophagosomes not only in MHC II but also in CD1d-
dependent antigen presentation through the use of ULK1/2 deficient B cells. 
However, as B cell autophagy is independent of these proteins, I was not able to 
address this question. It is interesting to analyse in the future, the antigen 
presentation capacity of B cells deficient in elongation factors, such as Atg5 or Atg7. 
 
As an alternative to roles in antigen presentation, autophagosomes might 
play part in connecting the BCR to other co-stimulatory receptors, such as TLR9, 
for antigens containing nucleic acids. TLR9 is an intracellular TLR, localised in 
endosome vesicles in the steady state. As B cells are poorly phagocytic, the only 
way TLR9 can make contact with nucleic acid containing antigens is through 
translocation to BCR-containing vesicles (Chaturvedi, Dorward and Pierce, 2008, 
Eckl-Dorna and Batista, 2009). In fact, after BCR engagement, TLR9 translocates 
to autophagosome-like structures together with the BCR, what amplifies B cell 
responses to nucleic-acid containing antigens (Chaturvedi, Dorward and Pierce, 
2008, Eckl-Dorna and Batista, 2009). Furthermore, this mechanism also has 
implications on the development of autoimmune responses, as BCR synergistic 
interaction with TLR9 or TLR7 has been shown to enhance the production of DNA- 
and RNA-specific autoantibodies (Marshak-Rothstein, 2006). A recent study 
showed that in a mouse model for SLE (systemic lupus erythematosus) where the 
RNA ligand for TLR7 is overexpressed, inhibition of B cell autophagy completely 
abrogates the production of autoantibodies through a blockage of TLR7 encounter 
with RNA ligands. Therefore, a tight regulation of the autophagy process is required 
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not only to fulfil energy demands or enhance antigen presentation, but also to 
prevent the development of autoimmune responses.  
 
 
Figure 4.13 Suggested model for autophagy in B cells  
The general mechanism of autophagosome formation is evolutionarily conserved 
and involves the stages of initiation, nucleation, elongation and closure, and 
degradation. In B cells, a non-conserved route of autophagy may bypass the 
initiation and nucleation steps through the provision of BCR-containing endosomes 
as a source of phagophores. This pathway is dependent on PLCγ2 and may 
participate in antigen presentation and BCR encounter with intracellular TLRs  
  
BCR
General autophagy
3/&Ȗ
Autophagy in B cells
mTOR
ULK 1/2
Class III 
PI3K
PtdIns3P
WIPIs
ATG5 ATG7
LC3
Initiation
Nucleation
Elongation
Autophagosome Autolysosome
Lysosome
Phagophore 
(from ER)
Phagophore 
(from BCR endosomes)
ATG5 ATG7
LC3
Autophagosome
Lysosome
Autolysosome
Elongation
Antigen presentation?
BCR encounter with TLRs
188 
Chapter 5. iNKT cell activation by CD103+ DCs 
regulates germinal centre response to viral infection   
5.1 Introduction 
NKT cells are a distinct subset of T lymphocytes that express an invariant 
CD1d-restricted TCR and NK cell lineage receptors (Bendelac, Savage and 
Teyton, 2007). NKT cells play a key role in the host defense against pathogens due 
to their ability to recognise special glycolipids present on the surface of a variety of 
microbes such as Borrelia sp., the causative agent of Lyme disease (Kinjo et al., 
2006), Sphingomonas sp., usually a hospital-acquired organism (Kinjo et al., 2005), 
and Streptococcus pneumoniae, the major cause of pneumonia (Kinjo et al., 2011). 
The recognition of exogenous glycolipids induces NKT cells to secrete a broad 
range of cytokines and provide cognate help to B cells, promoting both humoral 
and cell-mediated immunity (Brennan, Brigl and Brenner, 2013).  
 
Remarkably, the importance of NKT cells in the immune response against 
pathogens is not restricted to glycolipid-bearing organisms. In fact, NKT cells have 
the unique ability to recognise atypical lysosomal glycolipids produced by particular 
immune cells during an inflammatory process. This allows NKT cells to support the 
immune response against a broader spectrum of microorganisms even in the 
absence of pathogen-derived glycolipids, as in the case of viral infections (Mattner 
et al., 2005). The understanding of NKT cell biology during infection is an exciting 
and emergent field of research that has been relatively limited due to the lack of 
tools to address questions in vivo. For instance, the role that different antigen 
presenting cells play on the activation of NKT cells during infection and the 
potential role of these innate T lymphocytes in the modulation of antibody 
responses remain largely unexplored. 
 
5.1.1 NKT cell development and distribution  
There are two main subsets of NKT cells: type I NKT cells, also known as 
iNKT (invariant NKT) cells, which express a highly restricted TCR repertoire (Vα14-
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Jα18 combined with Vβ7, Vβ8 or Vβ2 chains) and type II NKT cells or non-iNKT 
cells which express a more diverse TCR repertoire (Benlagha et al., 2000). While 
both subsets are CD1d-restricted, iNKT cells are known to recognise glycolipid 
antigens while the ligands for non-iNKT cells are still not well defined. Some 
studies have demonstrated that sulphatides and sulphonates in the context of 
CD1d could stimulate non-iNKT cells, although only a subset (Blomqvist et al., 
2009). Non-iNKT cells are much less abundant than iNKT cells and their biology 
has not been studied in detail due to the lack of specific markers and agonistic 
antigens. For the rest of my thesis I will focus on the biology of iNKT cells.  
  
Both iNKT cells and conventional MHC-restricted T cells develop in the 
thymus from a common CD4- CD8- precursor (Pear, Tu and Stein, 2004). In this 
stage, double negative thymocytes rearrange the variable region of the TCRβ chain 
though VDJ recombination, a similar process to that described for B cells in 
Chapter 1. Those thymocytes that have successfully rearranged the TCRβ chain 
become CD4+ CD8+ thymocytes. These double positive progenitors undergo 
stochastic rearrangement of their TCRα chain and those expressing the specific 
Vα14-Jα18 rearrangement will give rise to the iNKT cell lineage. These cells will be 
positively selected following recognition of self-glycolipid antigens in complex with 
CD1d on the surface of other double positive thymocytes (Das, Sant'Angelo and 
Nichols, 2010). The nature of these self-antigens is quite controversial, although 
plasmalogen lysophosphatidyl-ethanolamine, a glycolipid present mainly in the 
peroxisomes, was recently identified as a candidate for positive selection in the 
thymus (Facciotti et al., 2012). The Vα14-Jα18 TCRα chain of iNKT cells 
associates with a restricted set of Vβ segments (Vβ7, Vβ8 and Vβ2), as only those 
TCR combinations are able to recognise lipids in the context of CD1d and generate 
a relatively strong TCR signal (Wei et al., 2006). This signal leads to expression of 
Egr1 and Egr2 (early growth response proteins) (Seiler et al., 2012), which direct 
the expression of the transcription factor PLZF (promyelocytic leukaemia zinc finger 
protein), the master regulator for iNKT cells (Kovalovsky et al., 2008, Savage et al., 
2008). It is important to mention that a recently described subset of iNKT cells 
residing in the adipose tissue does not require PLZF but the E4BP4 master 
transcription factor instead (Lynch et al., 2015). In addition to signals through the 
TCR, positive signals are provided to iNKT cells during positive selection through 
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SLAM (signalling lymphocytic activation molecule) proteins (Griewank et al., 2007) 
(Figure 5.1).  
 
Figure 5.1 Stages of iNKT cell development 
iNKT cell development occurs in the thymus from a pool of CD4-CD8-  double 
negative cells that differentiate into CD4+CD8+ double positive (DP) common 
precursors. Those thymocytes expressing an invariant TCR able to recognise 
glycolipids in the context of CD1d are selected and committed to the NKT cell 
lineage. After positive selection, immature iNKT cells undergo expansion and 
acquire a memory phenotype. They exit from the thymus while they are still 
immature and complete the maturation process in the periphery, where they might 
acquire NK cell lineage markers.   
 
 
Following positive selection, iNKT cells are believed to undergo negative 
selection to eliminate highly autoreactive cells. However, the existence of this 
process remains quite controversial and requires further study. Then, iNKT cells 
progress through different stages of maturation defined by the differential 
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expression of CD24, CD44 and NK1.1. The most immature iNKT cells are defined 
as CD24hiCD44loNK1.1− (Stage 0), followed by CD24loCD44loNK1.1− (Stage 1), 
CD24loCD44hiNK1.1− (Stage 2), and finally CD24loCD44hiNK1.1+ (Stage 3). The 
transition of iNKT cells from stage 0 to stage 1 is marked by a robust proliferation 
and the loss of CD4 marker in a subset of iNKT cells. As cells progress to Stage 2, 
they up regulate CD44 and acquire an activated phenotype. These cells leave the 
thymus during stage 2 and finish the maturation process in the periphery, where 
they can acquire NK cell-specific markers (Stage 3) or remain NK1.1 negative 
(Figure 5.1) (Das, Sant'Angelo and Nichols, 2010).  
 
iNKT cells have a particular distribution in the organism. They represent 
0.5% of total T cells in the blood and peripheral LNs and 2.5% of T cells in the 
spleen and mesenteric LNs (Bendelac, Savage and Teyton, 2007). iNKT cell 
localisation is highly strategic, as they are found in the inter-follicular areas of the 
LNs and the red pulp and marginal zone of the spleen, in close contact with the 
sites of pathogen arrival (Barral et al., 2012, Kastenmüller et al., 2012). 
Interestingly, iNKT cells can represent up to 30% of total T cells in the liver. The 
preferential location might be in part explained by their high expression of CXCR6 
that matches the expression of CXCL16 in the liver sinusoids. iNKT cells usually 
patrol liver sinusoids and they arrest to exert effector functions following activation 
by lipid antigens, specific cytokines or even by adrenergic signals produced during 
a stroke (Geissmann et al., 2005, Lee et al., 2010, Wong et al., 2011). In humans, 
iNKT cells are not highly enriched in the liver but they represent up to 10% of total 
T cells in the omentum, which is a double fold of the peritoneum connecting the 
stomach and other abdominal organs (Lynch et al., 2009). Furthermore, iNKT cells 
also reside in the lungs, skin, gastrointestinal tract and adipose tissue. Lung-
resident iNKT cells are located inside the vasculature and extravasate to the lung 
parenchyma after activation to support the inflammatory response (Scanlon et al., 
2011). In contrast, iNKT cells in the skin, intestine and adipose tissue seem to 
attenuate inflammation through the production of IL-10 (McKee, Mattarollo and 
Leggatt, 2014, Olszak et al., 2014, Lynch et al., 2015). 
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5.1.2 iNKT cell activation  
How are iNKT cells, with such limited TCR diversity, able to respond to 
different infectious pathogens? During the last decade, two mechanisms of iNKT 
cell activation have been delineated: direct, where iNKT cells directly recognise 
microbial glycolipid antigens through their TCR and indirect, where TCR recognition 
of pathogens is dispensable (Brennan, Brigl and Brenner, 2013).  
 
In the first mechanism, antigen-presenting cells, such as dendritic cells, 
macrophages or B cells, present processed lipids derived from the cell wall of 
specific bacteria in the context of CD1d molecules. These lipids include 
α-glycosphingolipids found in the cell wall of Sphingomonas sp., α-glycosylated 
diacylglycerols present in the cell wall of Borrelia sp. and Streptococcus 
pneumoniae and α-galactosylceramide (α-GalCer) isolated from marine sponge-
resident bacteria (Kawano et al., 1997, Kinjo et al., 2005, 2006, 2011). The α refers 
to the orientation of the glycosidic linkage between the carbohydrate head group 
and the lipid backbone. The α-linkage provides a potential foreign structural motif 
for antigenicity, as mammals do not usually attach carbohydrates to lipids in the α-
orientation (Kain et al., 2015). iNKT cells recognise these exogenous glycolipids 
presented in the context of CD1d by antigen-presenting cells and become activated 
(Figure 5.2A). The crystal structure of CD1d with α-GalCer revealed that CD1d has 
a hydrophobic antigen-binding cleft with two main pockets: the A’, where the acyl 
chain of α-GalCer is buried, and the F’, where the phytosphingosine chain is buried. 
In contrast, the α-galactosyl head group protrudes from the cleft, so it is directly 
available to make contact with the iNKT cell TCR (Koch et al., 2005) (Figure 5.3).  
 
In the second mechanism of iNKT cell activation, recognition of pathogen-
derived lipids is not required. In this case, the presentation of endogenous lipids 
and/or the production of cytokines by the antigen-presenting cells are sufficient to 
induce iNKT cell activation (Brigl et al., 2003, Paget et al., 2007). Antigen-
presenting cells can recognise a full range of pathogens through their TLRs; for 
example, they can recognise LPS from Salmonella sp. and Escherichia coli through 
TLR4 and microbial nucleic acids through TLR7 and TLR9. TLR signalling through 
MyD88 on the antigen presenting cells is sufficient to induce iNKT cell activation 
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This is due to the ability of antigen-presenting cells to produce IL-12 and present 
endogenous lipids in the context of CD1d after TLR signalling (Brigl et al., 2003, 
Mattner et al., 2005). (Figure 5.2B).  
 
 
 
 
Figure 5.2 Mechanisms of iNKT cell activation 
(A) Direct iNKT cell activation can occur via uptake of glycolipid-containing 
pathogens by antigen presenting cells and presentation of these exogenous lipids 
on CD1d to iNKT cells. (B) Indirect iNKT cell activation is triggered by recognition 
of pathogens through TLRs by antigen presenting cells, what induces IL-12 
secretion and presentation of endogenous lipids on CD1d to iNKT cells. 
 
 
The nature of these endogenous molecules is quite controversial. Initially, 
the lysosomal glycolipid iGb3 (isogloboside 3) was suggested as a potential 
endogenous lipid mediating iNKT cell development and activation (Zhou et al., 
2004). However, recent studies showed that mice deficient in iGb3 synthase 
display normal iNKT cell development and activation (Porubsky et al., 2007, 
Christiansen et al., 2008). Later, two studies analysed the lipidome of thymic and 
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antigen presenting cells by HPLC (high-pressure liquid chromatography) and MS 
(mass spectrometry) and found that β-anomers of glycosylceramides found in 
these cells are potent activators of iNKT cells (Brennan et al., 2011, Facciotti et al., 
2012). However, the significance of these β-glycosylceramides as self-antigens has 
been called into question by a study in 2014 that claims that the commercial β-
glycosylceramides used in those studies were contaminated with low amounts of α-
anomers (Kain et al., 2014). Surprisingly, this recent study revealed that immune 
cells are able to produce small quantities of α-glycosylceramides, such as α-GluCer 
and α-GalCer, and those are the major source of endogenous ligands for iNKT 
cells (Kain et al., 2014). The intracellular levels of α-GluCer and α-GalCer in 
immune cells are extremely low due to their constant degradation by the lysosomal 
enzyme α-galactosidase (GLA). In fact, GLA-deficiency induces increased amounts 
of self-ligands on the surface of thymocytes and antigen presenting cells, and 
hyper activation of iNKT cells. Interestingly, TLR stimulation on the antigen-
presenting cells inhibits the activity of this enzyme, leading to an increase in the 
accumulation and presentation of α-glycosylceramides on CD1d and induced 
activation of iNKT cells (Darmoise et al., 2010) (Figure 5.3).  
 
As mentioned, indirect activation of iNKT cells by antigen-presenting cells 
involves the presentation of endogenous lipids on CD1d molecules and the 
production of IL-12. However, some subsets of iNKT cells can become activated 
solely by cytokines, even in the absence of TCR engagement by CD1d. For 
example, iNKT cell activation during Pseudomonas aeruginosa infection is 
mediated by IL-12 and IL-18 produced by DCs and macrophages respectively. This 
capacity is due to the expression of IL-12R and IL-18R by some iNKT cells even in 
the steady state (Kastenmüller et al., 2012). 
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Figure 5.3 iNKT cell lipid antigens 
Structures of glycolipids involved or suggested to be involved in iNKT cell activation. 
The strongest activator of iNKT cells is α-Galactosylceramide (α-GalCer). Some 
pathogens also contain α-glycolipids, such as α-Glucosyldiacylglycerol (α-GluDAG) 
present in the cell wall of Streptococcus pneumoniae. The initial candidates for 
endogenous ligands isoglobotrihexosylceramide (iGb3) and β-Glucosylceramide 
(β-GluCer) are also shown. Structures extracted from (Brennan, Brigl and Brenner, 
2013).  
 
 
All these different mechanisms of activation and their strategic location in 
the peripheral and secondary lymphoid organs allow iNKT cells to rapidly respond 
to a variety of pathogenic threats.  
 
5.1.3 Outcome of iNKT cell activation: NKT cell effector subsets 
iNKT cells can recognise glycolipids present in the cell wall of Gram positive 
and negative bacteria and even in the absence of exogenous glycolipids, they can 
detect specific cytokines or endogenous lipids produced by microbe-activated 
antigen presenting cells. All these different mechanisms of activation allow them to 
respond to a broad range of infectious agents and can partially determine the 
resulting effector outcomes. For example, the activation of iNKT cells with a potent 
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exogenous glycolipid such as α-GalCer induces the production of IFN-γ and IL-4 
whereas the activation through endogenous ligands or cytokines usually leads to 
IFN-γ production only (Brigl et al., 2003). Regardless of the activation pathway, 
iNKT cells can differentiate into multiple phenotypically different subsets and 
modulate the activity of other immune cell types.  
 
iNKT cell subsets are defined by the transcription factors involved in their 
differentiation and by the cytokines they produce. Th1-like iNKT cells constitute the 
majority of iNKT cells in the liver and secondary lymphoid organs. They produce 
IFN-γ and IL-4, they can be CD4+ or CD4- and they need PLZF, GATA3 and T-bet 
for their differentiation. Th2-like iNKT cells are mainly found in the intestine and 
lungs, they are able to produce IL-4, IL-9, IL-10, IL-13 and GM-CSF after activation, 
are CD4+ and need PLZF and GATA3 for their generation. Th17-like iNKT cells are 
CD4-, reside in the LNs, lungs and skin, produce IL-17 and IL-22 and require PLZF, 
GATA3 and Rorγt for their differentiation (Watarai et al., 2012, Brennan, Brigl and 
Brenner, 2013). iNKTfh cells, as mentioned in chapter 1, express high levels of PD-
1 and CXCR-5, require Bcl6 for their differentiation, produce IL-21 and provide 
cognate help to B cells for GC formation (Chang et al., 2012, King et al., 2012). 
Recently, a population of regulatory iNKT cells that produce IL-2 and IL-10 has 
been described in the adipose tissue. These cells require E4BP4 (E4 promoter-
binding protein 4) for their differentiation but not PLZF or Foxp3 (forkhead box P3). 
Furthermore, they induce an anti-inflammatory phenotype in adipose-tissue 
resident macrophages and enhance the suppressor activity of regulatory T cells 
(Lynch et al., 2012, 2015).   
 
5.1.4 iNKT cell functions and interaction with other immune cells 
The production of cytokines by iNKT cells and the interaction with their 
CD1d-expressing cognate partners defines the ability of iNKT cells to control 
immune responses to a diverse spectrum of pathogens. I will discuss here the 
CD1d-mediated interaction of iNKT cells with different immune cells and the 
importance of these interactions in the development of an immune response 
(Figure 5.4).   
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The first immune cells described to interact with iNKT cells in a CD1d-
dependent manner are DCs (Fujii et al., 2004). DCs constitutively express CD1d 
and they mediate iNKT cell activation in the spleen and lungs after α-GalCer 
exposure (Scanlon et al., 2011, Barral et al., 2012). In vitro, it has been shown that 
TLR ligands induce DC-mediated presentation of endogenous lipids and the 
production of IL-12 to mediate iNKT cell activation (Mattner et al., 2005). The 
interactions established between DCs and iNKT cells not only involve CD1d-TCR 
contacts but also CD40—CD40 ligand interactions. Together, this leads to a strong 
IFN-γ production by iNKT cells and to further IL-12 production by DCs (Kitamura et 
al., 1999, Fujii et al., 2004). Both IFN-γ and IL-12 induce NK cell transactivation, 
enhanced responses by conventional CD4+ and CD8+ T cells and the licensing of 
dendritic cell cross-presentation (Fujii et al., 2003, Hermans et al., 2003, Semmling 
et al., 2010). Therefore, through bidirectional interactions, iNKT cells and DCs 
cooperate to amplify innate and adaptive immune responses (Figure 5.4).  
 
iNKT cells also interact with B cells through CD1d. Interestingly, splenic 
marginal-zone B cells express the highest CD1d levels of all antigen-presenting 
cells; however, whether these cells contribute to iNKT cell activation during 
infection remains unclear (Sonoda and Stein-Streilein, 2002). As described in 
chapter 1, a population of iNKT cells, iNKTfh cells, provide cognate help to B cells 
after B cell presentation of exogenous glycolipids on CD1d. This interaction results 
in fast immunoglobulin production and some affinity maturation, but does not lead 
to the generation of long-term B cell memory. Therefore, iNKT cell cognate-help 
might be important in enhancing early antibody responses during infection (Barral 
et al., 2008, Chang et al., 2012, King et al., 2012). Importantly, iNKT cells can 
provide non-cognate help to B cells through the production of IL-4, IL-5, IL-6, IL-13, 
IL-21 and CD40 ligand (Coquet et al., 2008) (Figure 5.4). 
 
Macrophages also interact through CD1d with iNKT cells in different organs. 
In the liver, where iNKT cells represent up to 30% of total T cells, different subsets 
of macrophages such as Kupffer cells and stellate cells, can present lipid antigens 
to mediate iNKT cell activation following Borrelia sp. Infection (Lee et al., 2010). In 
the LNs, SCS macrophages can present exogenous lipids on CD1d to resident 
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iNKT cells following particulate α-GalCer administration (Barral et al., 2010). 
Moreover, these macrophages can also mediate iNKT cell activation in the LNs 
through the secretion of IL-18 (Kastenmüller et al., 2012). These interactions are 
bidirectional, as iNKT cells can modulate the physiology of macrophages. For 
example, iNKT cell-derived IFN-γ can lead to iNOS production by SCS 
macrophages and enhanced phagocytosis by pulmonary macrophages 
(Nieuwenhuis et al., 2002, Kastenmüller et al., 2012). Moreover, iNKT cell-derived 
IL-10 can polarise macrophages to an anti-inflammatory phenotype in adipose 
tissue (Lynch et al., 2015) (Figure 5.4). 
 
Neutrophils also express CD1d and can interact with iNKT cells. During 
inflammation, levels of the acute phase protein SAA1 (serum amyloid A1) increase 
in the organism and induce the production of IL-10-producing neutrophils. 
Interestingly, under these conditions, neutrophils can mediate iNKT cell activation 
through CD1d presentation of endogenous ligands. iNKT cells are able to reverse 
the suppressive phenotype of these neutrophils and promote IL-12 production, 
which would be important to balance the frequencies of immunosuppressive 
neutrophils (De Santo et al., 2010). Moreover, iNKT cells can recruit neutrophils to 
infected tissues in a CD1d-independent manner through the production of CXCL2 
(Nieuwenhuis et al., 2002) (Figure 5.4).  
 
A population of CD11b+Gr1+ cells with immunosuppressive characteristics, 
defined as MDSCs (myeloid derived suppressor cells), also expresses high levels 
of CD1d. These cells display high-enzymatic activity of iNOS (nitric oxide synthase) 
and arginase 1, which limits the availability of arginine, and, therefore, T cell 
proliferation.  Following infection, CD1d-mediated interaction of MDSCs with iNKT 
can counterbalance the suppressive activity of these cells, enhancing the 
proliferation and formation of antigen-specific T cells (De Santo et al., 2008) (Figure 
5.4).  
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Figure 5.4 Interaction between iNKT cells and other immune cells 
The presentation of lipid antigens mediates cognate interactions between iNKT 
cells and CD1d-expressing cells. These interactions lead to the activation of iNKT 
cells and reciprocal modulation of CD1d-expressing cell activity through cytokine 
secretion and/or CD40-CD40L interactions.   
 
 NKT cells are now recognised as important participants in the linking of the 
innate and adaptive immune responses, and have been implicated not only during 
infection, but also during allergy, asthma, autoimmunity and tumour surveillance 
(Brennan, Brigl and Brenner, 2013). There are however, essential questions 
regarding iNKT cell biology that still remain unanswered. For example, which are 
the roles of the different CD1d expressing cells in the activation of iNKT cells during 
infection in the absence of exogenous glycolipids? Are iNKT cells able to regulate 
the antibody response in these situations? In this chapter, through the use of 
different genetically modified mice, I will attempt to answer these points.    
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5.2 iNKT cell activation following influenza infection in vivo 
requires MyD88 signalling in DCs  
In the last decade, several lines of research explored by different groups 
have shed light on the iNKT cell biology in the presence of exogenous bacteria-
derived glycosphingolipids. However, the vast majority of pathogens, particularly 
viruses, do not have these special glycolipids on their surface. This led me to 
investigate the role of iNKT cells in the immune response to pathogens in the 
absence of exogenous ligands; in particular, how iNKT cells get activated, and their 
ability to regulate the B cell response. 
 
5.2.1 NKT cell-deficient mice are more susceptible to influenza virus 
infection 
To understand the importance of iNKT cells, I compared the pathology and 
immune response of wild type and CD1d-/- mice during viral infections. CD1d-/- 
animals do not have iNKT cells in the periphery because of their impaired selection 
in the thymus during development (Mendiratta et al., 1997). Therefore, the use of 
these mice allowed me to understand the role of iNKT cells during an immune 
response against viral pathogens. Influenza A virus was chosen as an infection 
model for its importance in the clinic as it is responsible for annual epidemics that 
cause severe illness in around 5 million people worldwide. Influenza virus 
clearance from the organism is mainly mediated by cytotoxic CD8+ T lymphocytes 
and by neutralising antibodies secreted by B cells (Waffarn and Baumgarth, 2011). 
Interestingly, iNKT cells can sustain CD8+ T cell response to influenza virus by 
inhibiting the immunosuppressive activity of lung-resident MDSCs (De Santo et al., 
2008). However, the process of iNKT cell activation and the ability of these cells to 
regulate the B cell response following infection remain largely unknown.   
 
To assess whether iNKT cells play a role in controlling influenza virus 
infection, wild type and CD1d-/- mice were intranasally infected with a low dose (200 
PFU) of influenza virus PR8 (A/Puerto Rico/8/34). After six days of infection, the 
lungs, mediastinal LNs and spleen were harvested and RNA was extracted from 
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single cell suspensions to analyse influenza-specific viral RNA expression levels. 
Real-time RT-PCR was used to quantify the levels of influenza NP (nucleoprotein), 
using CPH (carboxypeptidase H) gene as a housekeeping gene for normalisation. 
While NP RNA was detected in the lungs six days after infection, no NP 
amplification was observed in non-immunised mice (Figure 5.5A). This clearly 
indicates that the NP primers used for the measurement of influenza virus levels 
are specific. Moreover, NP was not detected in mediastinal LNs or spleen following 
infection, indicating that the virus is mainly retained in the lungs (Figure 5.5A). 
Importantly, the NP RNA levels were significantly higher in the lungs of CD1d-/- 
mice, suggesting that iNKT cells might play a role in the clearance and protection of 
mice against influenza virus infection (Figure 5.5A).  
 
During the earliest stages of viral infection, there is a rapid release of IFN-α, 
IFN-γ, TNF-α, IL-1, IL-6 and IL-18 by innate immune cells such as neutrophils, 
eosinophils, monocytes, macrophages, DCs and NK cells. The levels of these 
inflammatory cytokines directly correlate with the magnitude of viral replication 
(Kaiser, Fritz and Straus, 2001). I therefore wondered whether higher titers of 
influenza in CD1d-/- mice would alter the cytokine expression pattern following 
influenza virus infection. To analyse this, wild type and CD1d-/- mice were infected 
with 200 PFU of influenza A virus, and six days after infection, the levels of several 
cytokines (IL-2, IL-4, IL-6, IFN-γ, TNF-α, IL-17A and IL-10) were measured in the 
blood using a cytometric bead array. High levels of IL-6 and IFN-γ were detected in 
the blood of infected mice while the levels of IL-2, IL-4, TNF-α, IL-17A and IL-10 
remained similar to basal levels in most cases (Figure 5.5B). Interestingly, the 
levels of IFN-γ in the blood were significantly higher in CD1d-/- mice compared to 
wild type animals (Figure 5.5B). Although, IL-6 levels seemed to be increased in 
CD1d-/- mice, this difference was not significant. The increase in IFN-γ levels 
observed in CD1d-/- mice following influenza virus infection was further 
recapitulated in the lungs by real time RT-PCR (Figure 5.5C). These results 
indicate that the ineffective clearance of influenza virus from the lungs in the 
absence of iNKT cells results in high titers of influenza virus and increased 
production of IFN-γ. 
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Figure 5.5 CD1d-/- mice are more susceptible to influenza virus infection 
(A) RT-PCR analysis of lungs, mediastinal LNs and spleen from wild type and 
CD1d-/- mice that were infected with 200 PFU of influenza virus 6 days previously 
or left untreated (not immunised). Relative RNA levels of viral NP1 were normalised 
to the housekeeping gene CPH and were plotted in the bar charts as expression 
levels relative to the mean level observed in wild type samples. (B) Cytometric 
bead array of serum from wild type and CD1d-/- mice treated as in (A). Mean 
fluorescence intensity for each cytokine was normalised to levels observed in non-
immunised samples and plotted in the bar charts. (C) RT-PCR analysis of lungs 
from mice treated as in (A). Relative RNA levels of IFN-γ were normalised to CPH 
and plotted as expression levels relative to the mean level observed in non-
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immunised samples. Each dot represents a different mouse. Mean± s.e.m. Data 
are representative of two independent experiments. Student t test, *p<0.05. 
 
5.2.2 iNKT cell activation results in CD69 up regulation and IFN-γ and IL-4 
secretion 
The previous results indicate that iNKT cells might be important for the 
regulation of the immune response against influenza virus. I therefore moved on to 
analyse the signals and components involved in the process of iNKT cell activation 
following infection. To analyse the kinetics of iNKT cell activation, mice were 
intranasally infected with 200 PFU of influenza virus and the lungs and mediastinal 
LNs were harvested after 1 to 6 days of infection. iNKT cells were identified by flow 
cytometry due to the expression of TCRβ and their ability to bind a PBS-57 loaded 
CD1d tetramer. PBS-57 is an analog of α-GalCer, a known ligand for iNKT cells 
(Kawano et al., 1997). Importantly, this TCRβ+ tetramer+ population is absent in 
CD1d-/- mice, confirming the specificity of the staining (Figure 5.6A). iNKT cell 
activation was followed by assessing the levels of the surface activation marker 
CD69 on the iNKT cell population. The levels of CD69 on iNKT cells increased from 
day 2 and were maintained at least until day 6 in the lungs and mediastinal LNs 
(Figure 5.6B). These results indicate that iNKT cells are activated very early during 
influenza infection.  
 
I further analysed the process of iNKT cell activation by assessing the 
production of cytokines after 72 hours of infection. For the measurement of 
intracellular cytokines, single cell suspensions of mediastinal LNs were stimulated 
ex vivo with PMA/ionomycin, and cytokine release was blocked using monensin, a 
protein transport inhibitor. LN suspensions were then stained with anti-TCRβ and 
PBS-57 CD1d tetramer, fixed, permeabilised and stained again with labelled 
antibodies against IFN-γ and IL-4. While IL-4 or IFN-γ production was not detected 
in iNKT cells from non-immunised mice, influenza infection results in the robust 
production of IL-4 and IFN-γ by iNKT cells (Figure 5.6C). These results indicate 
that the early activation of iNKT cells after influenza infection occurs in the lungs 
and draining mediastinal LNs and results in the up-regulation of CD69 and the 
production of IFN-γ and IL-4.     
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Figure 5.6 Early activation of iNKT cells results in IFN-γ and IL-4 secretion 
(A) Flow cytometry analysis of LN cell suspensions from wild type and CD1d-/- mice 
stained for TCRβ and PBS-57 tetramer. Representative plots are shown. (B) Flow 
cytometry analysis of lungs and LN  cell suspensions from wild type mice infected 
with 200 PFU of influenza virus 1 to 6 days before. The levels of CD69 on the 
TCRβ+ tetramer+ population are shown on the histograms. CD69 MFI (mean 
fluorescence intensity) in the TCRβ+Tetramer+ population was plotted. (C) Flow 
cytometry analysis of LN cell suspensions from wild type mice infected with 200 
PFU of influenza virus 3 days before. The percentage of IFN-γ+ and IL-4+ cells on 
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the TCRβ+ tetramer+ population is shown in the dot plots. Data are representative 
of two independent experiments with three mice per condition.  
 
5.2.3 Differential requirements of MyD88 and TLR7 for iNKT cell activation  
As explained before, in the absence of exogenous glycolipids, iNKT cells 
have the unique ability to recognise lysosomal glycolipids presented on the surface 
of antigen presenting cells. In vitro studies indicate that the production of these 
endogenous ligands in response to bacteria requires MyD88-mediated signalling 
on the presenting cells (Mattner et al., 2005). I therefore wondered whether 
MyD88-mediated signalling is required for in vivo iNKT cell activation after influenza 
infection. To this end, wild type and MyD88-/- mice were intranasally infected with 
200 PFU of influenza virus, and after 3 days, mediastinal LNs were harvested. 
iNKT cell activation was assessed by measuring CD69 levels and IFN-γ production 
as before. CD69 and secreted IFN-γ were up-regulated in iNKT cells from wild type 
animals in response to influenza infection, however, they were significantly reduced 
in iNKT cells from MyD88-/- mice (Figure 5.7). These results indicate that iNKT cell 
activation after influenza infection in vivo requires MyD88 signalling. 
 
 
Figure 5.7 iNKT cell activation following influenza infection is MyD88 dependent  
Flow cytometry analysis of lymph node cell suspensions from wild type and MyD88-
/- mice 3 days after infection with 200 PFU of influenza virus. The levels of CD69 in 
TCRβ+ tetramer+ cells are shown on the histograms and the percentage of IFN-γ+ 
iNKT cells is shown in the dot plots. Analysis of CD69 MFI and the percentage of 
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CD69+ and IFN-γ+ iNKT cells are shown on the bar charts. Each dot represents a 
single mouse. Data are representative of two independent experiments. Student t 
test, **p<0.01.  
 
 
MyD88 serves as a critical adaptor for signalling induced by TLRs, IL-1R 
and IL-18R, all of which contain an intracellular homology domain called TIR that 
recruits MyD88 adaptor for effective signalling (Adachi et al., 1998). As iNKT cell 
activation requires MyD88-mediated signalling during viral infection, I wondered 
whether signalling through TLR, IL-1R or IL-18R were involved in this process.  
 
Recognition of influenza single-stranded RNA by immune cells is restricted 
to TLR7 and TLR8 (Diebold et al., 2004). However, TLR8 is non-functional in mice 
because it lacks five amino acids, leaving TLR7 as the unique TLR capable of 
recognising influenza in mice (Kugelberg, 2014). To analyse the role of TLR 
signalling on NKT cell activation, wild type and Tlr7-/- mice were intranasally 
infected with 200 PFU of influenza virus, and mediastinal LNs were harvested 3 
days afterwards. iNKT cell activation was measured by up regulation of CD69 and 
secretion of IFN-γ and IL-4. Following infection, mediastinal LNs from Tlr7-/- mice 
were smaller in size and contained significantly fewer iNKT cells than their wild-
type counterparts. Surprisingly, iNKT cells from Tlr7-/- mice up regulate CD69 and 
secrete IL-4 and IFN-γ to the same extent of iNKT cells from wild type mice (Figure 
5.8). This result is key and demonstrates that even though MyD88-mediated 
signalling is required to activate iNKT cells after viral infection, this process is 
independent of TLR signalling. 
 
During influenza infection, there is an increased production of IL-1 and IL-18 
by lung-resident innate immune cells. This process is dependent on the activation 
of the inflammasome complex, as mice deficient in Caspase-1 or the adaptor ASC 
have dramatically reduced levels of IL-1 and IL-18 in the bronchoalveolar lavage 
(Thomas et al., 2009). As IL-1R and IL-18R signal through the MyD88 adaptor, the 
potential role of IL-1R and IL-18R on iNKT cell activation in vivo will be addressed 
in the future. For this, IL-1R and IL-18R-deficient mice were ordered from Jackson 
Laboratories and as of the time of writing I am still waiting for these strains. If iNKT 
cell activation were dependent on IL-1 or IL-18, it would be interesting to analyse 
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the contribution of the inflammasome complex on this process. For that, Caspase-1 
and ASC-deficient animals will be used to assess the extent of iNKT cell activation 
following viral infection.   
 
 
 
Figure 5.8 iNKT cell activation following influenza infection is TLR7 independent  
Flow cytometry analysis of LN cell suspensions from wild type and Tlr7-/- mice 3 
days after infection with 200 PFU of influenza virus. The levels of CD69 in TCRβ+ 
tetramer+ cells are shown on the histograms and the percentages of IFN-γ+ and IL-
4+ iNKT cells are shown in the dot plots. Analysis of CD69 MFI and the percentage 
of CD69+, IFN-γ+ and IL-4+ iNKT cells are shown on the bar charts. Each dot 
represents a single mouse. Data are representative of two independent 
experiments.  
 
5.2.4 iNKT cell activation requires MyD88-signalling in DCs  
Several immune cell populations in the lungs express MyD88. I therefore 
went on to analyse in vivo the requirement of MyD88 by different antigen 
presenting cells to mediate the activation of iNKT cells. For this, MyD88flox/flox mice 
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were crossed with mice expressing the Cre recombinase under different promoters: 
CD19, to specifically delete MyD88 on B cells (MyD88flox/floxCD19 Cre+), Lyz2 to 
delete MyD88 on neutrophils (MyD88flox/floxLyz2 Cre+) and CD11c, to delete MyD88 
on DCs (MyD88flox/floxCD11c Cre+). The analysis of MyD88 deletion in the different 
strains and immune cell populations was previously shown in Chapter 3. Wild type 
and these different transgenic mice were infected intranasally with 200 PFU of 
influenza virus and after 3 days mediastinal LNs were harvested. iNKT cell 
activation in these transgenic animals was assessed by the measurement of CD69 
up regulation and cytokine secretion. Influenza infection induced CD69 up- 
regulation by iNKT cells to the same extent in wild type, MyD88flox/floxCD19 Cre+ 
and MyD88flox/floxLyz2 Cre+ mice (Figure 5.9). These results indicate that MyD88-
mediated signalling in B cells or neutrophils is not required for the activation of 
iNKT cells following influenza infection. In contrast, iNKT cells from 
MyD88flox/floxCD11c Cre+ mice showed reduced up regulation of CD69 and impaired 
production of IL-4 and IFN-γ (Figure 5.9). This result demonstrates that iNKT cell 
activation in vivo following viral infection requires MyD88-mediated signalling in 
DCs. 
 
I wondered whether iNKT cell activation by DCs in vivo requires the 
presentation of endogenous lipids in the context of CD1d. To answer this question 
it would be necessary to specifically delete CD1d on the DC population. However, 
with the tools available at the initiation of this project, it was not possible to perform 
this kind of experiment. To address this and many other essential questions in the 
NKT cell biology, we thought it would be extremely useful to generate CD1dflox/flox 
mice to delete CD1d on specific immune cell populations.   
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Figure 5.9 iNKT cell activation requires MyD88-mediated signalling in DCs  
Flow cytometry analysis of LN cell suspensions from wild type, MyD88-/-, 
MyD88flox/floxCD19-Cre+, MyD88flox/floxLyz2-Cre+ and MyD88flox/floxCD11c-Cre+ mice 3 
days after infection with 200 PFU of influenza virus. The levels of CD69 in TCRβ+ 
tetramer+ cells are shown on the histograms. The percentages of IFN-γ+ and IL-4+ 
iNKT cells following infection of wild type and MyD88flox/floxCD11c-Cre+ mice are 
shown in the dot plots. Analysis of CD69 MFI and the percentage of CD69+, IFN-γ+ 
and IL-4+ iNKT cells are shown on the bar charts. Each dot represents a single 
mouse. Data are representative of two independent experiments. Student t test, 
*p<0.05, **p<0.01. 
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5.3 Generation of CD1d-floxed mice reveals CD1d requirement 
by DCs to complete iNKT cell activation in vivo 
5.3.1 Generation and selection of CD1d-floxed embryonic stem cells  
The conditional knockout strategy consists of genetically targeting a gene 
region of interest with 2 loxP sequences, one on either side. The loxP sites are 34-
nucleotide sequences recognised by Cre recombinase, an enzyme that excises 
any region of DNA placed between two loxP sites. The resulting mice contain the 
floxed allele (flanked by loxP sites) in all tissues but are phenotypically wild type. 
By crossing a floxed mouse with a specific Cre-expressing mouse, it is possible to 
delete the targeted gene only in cells that express Cre (Friedel et al., 2010). 
 
The initial step for the generation of a mouse with a targeted mutation is the 
construction of an efficient targeting vector. In my case, this vector was generated 
by Gene Bridges Co and is shown in Figure 5.10A. The two loxP sites (yellow) 
were inserted flanking exon 3 (blue) of CD1d, as this exon codes for an essential 
part of the CD1d protein. Both loxP sites were positioned in the introns of CD1d to 
avoid interference with the coding sequences or the promoter of the gene. A 
neomycin cassette (orange) surrounded by 2 FRT sites (green) was also added to 
the construct for future selection of cells that have taken up the vector. Moreover, a 
continuous length of homologous genomic sequence (6 kb) was added on each 
sided of the floxed exon to favor homologous recombination. The vector containing 
the targeted construct was introduced into C57BL/6 mouse ES (embryonic stem) 
cells by electroporation. Once inside the ES cells, homologous recombination 
between the mouse genome and the transfected vector occurs in a small 
percentage of cells. This strategy takes advantage of a cell’s own DNA repair 
machinery to replace a genomic sequence with a targeted genetic locus containing 
homologous sequences (Friedel et al., 2010). Since the transformation efficiency 
and the chances of recombination are very low, ES cells were cultured in medium 
containing Neomycin (a positive selection marker) to enrich clones that have the 
targeting vector inserted into their genome. 
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Figure 5.10 Strategy for the generation and selection of CD1d-floxed ES cells 
(A) Scheme showing the wild type and targeted CD1d locus containing two loxP 
sites flanking the exon 3 of CD1d as well as two FRT sites for the removal of the 
Neomycin resistance cassette. (B) Specific fragments amplified by long-range PCR 
for the 5’ end (7.1kb) and 3’ end (6.6kb) of the clones that correctly performed 
homologous recombination. (C) Electrophoresis gel of digested DNA with SacI 
restriction enzyme of the three positive clones. (D) Electrophoresis gel of 5’ 
Southern probe labelled with or without with Digoxigenin. (E) Southern blot of the 
three positive clones performed with the labelled 5’ Southern probe. The upper 
band corresponds to the WT locus (10.6kb) and the lower band to the targeted 
locus (7.3kb). (F) Southern blot of the three positive clones performed with a 
Wild type locus A
Targeted locus 
B Long range PCR strategy Southern blot strategy
B
E
C DNA digestion
Clones 1 2 3
D Probe labelling
+DIG -DIG
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labelled Southern probe against the Neomycin cassette. White arrows indicate the 
5.2kb band recognised by this probe.   
 
 
To identify those ES cell clones that have correctly inserted the targeted 
locus in the genome, I performed a thorough screening process by long-range PCR 
of 100 clones. For this strategy, I designed pairs of primers that amplify a fragment 
from the neomycin cassette to outside the homology arm in the 5’ direction 
(Primers 1-2, 7.1kb fragment) and from the neomycin cassette to outside the 
homology arm in the 3’ direction (primers 3–4, 6.6kb fragment). In this way, only 
those clones that have the correctly inserted targeted locus in both 5’ and 3’ 
directions will generate the 7.1 and 6.6kb fragments after PCR amplification. Only 
three out of a hundred clones generated these two fragments, indicating correct 
insertion in the genome (Figure 5.10B). I further confirmed the correct insertion in 
these three clones by Southern blot. For this, DNA from the three clones was 
digested with the restriction enzyme SacI. Successful digestion of the DNA was 
confirmed by electrophoresis, as a smear of DNA is obtained when DNA is properly 
digested (Figure 5.10C). Digested DNA was subject to Southern blot, where a DIG 
(digoxigenin)-labelled DNA probe was used for detection. Effective DIG-labeling of 
the probe was confirmed by a shift in the weight of the DNA probe in the 
electrophoresis gel (Figure 5.10D). When DNA is digested with SacI, this probe 
recognises a 10.6kb fragment in the wild type allele and a 7.3kb fragment in the 
targeted allele due to the insertion of a SacI restriction site in the Neomycin 
cassette. All these three clones produced the 10.6kb and the 7.3kb bands, 
confirming the correct insertion of the targeted allele (Figure 5.10E). Moreover, only 
one insertion event occurred in the genome of these clones as a single band of 
5.2kb is obtained when a DIG-labelled probe against the Neomycin cassette is 
used (Figure 5.10F).  
 
5.3.2 Generation of CD1d-floxed transgenic mice  
As the three positive clones have a single correct insertion of the CD1d 
floxed allele, a karyotype of them was performed to analyse the levels of euploidy. 
While clone 1 has only 50% of euploidy, clone 2 and 3 had more than 90 % of 
euploidy. Therefore, clone 1 was discarded, and ES cells from clone 2 and 3 were 
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used for injection into BALB/C blastocysts and transplanted into surrogate mothers. 
These C57BL/6 ES cells are totipotent so, when injected into BALB/c blastocysts, 
they can potentially differentiate into any of the cell types of the resultant chimaeric 
mouse. When litters were born, only those mice with more than 80% of chimerism, 
as judge by the coat color, were crossed with C57BL/6 mice. Mice with higher 
levels of chimerism were used to improve the chances of germ line transmission of 
the target gene. The black litters from the crosses between chimeras and C57BL/6 
mice were genotyped for the neomycin cassette, for detection of mice carrying the 
targeted gene. Those mice that were positive for the neomycin cassette were then 
crossed with FLPo mice, which express the flippase recombinase and excise the 
neomycin cassette flanked by two 34 bp sequences known as FRT sites. The 
removal of the positive selection marker is necessary to avoid interference with the 
final mutated gene. 
 
After the removal of the neomycin cassette, mice carrying the flox allele 
were crossed with mice expressing the Cre recombinase under the following 
promoters; CD19 and Mb1 to specifically delete CD1d on B cells, Lyz2 to delete 
CD1d on neutrophils and macrophages, and CD11c to delete CD1d on DCs. 
Finally, mice were crossed again with the same floxed mice to make them 
homozygous for the floxed allele. Deletion of CD1d in the different splenic immune 
cell populations for the different transgenic mice was analysed by flow cytometry. B 
cells were gated as B220+TCRβ-, DCs were gated as CD11c+MHCII+ and further 
subdivided into CD11b+ DCs and CD8+ DCs. Macrophages were gated as 
CD11bintF4/80hi and CD11bhiF4/80int. Neutrophils were gated as CD11bhiF4/80- 
(Figure 5.11A).  
 
In the CD1dflox/floxCD19-Cre+ mice, deletion of CD1d was observed in 
approximately 80% of B cells (Figure 5.11B). However, in CD1dflox/floxMb1-Cre+ 
mice, CD1d deletion in B cells was almost 100% (Figure 5.11C). These results 
indicate that Mb1-Cre is a more efficient system to delete CD1d in B cells than 
CD19-Cre. Importantly, no deletion of CD1d was observed in B220- TCRβ- cells, 
indicating that CD1d deletion is specific for B cells in these two strains (Figure 
5.11B-C).  
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Figure 5.11 Analysis of CD1d deletion in the different immune cell populations 
(A) Flow cytometry plots of spleen single cell suspensions showing the gating 
strategy for B cells (B220+TCRβ-), CD8+ DCs (MHCII+CD11c+CD8+), CD11b+ DCs 
(MHCII+CD11c+CD11b+), F4/80+ macrophages (CD11bintF4/80hi), F4/80- 
macrophages (CD11bhiF4/80int) and neutrophils (CD11bhiF4/80-). (B to E) 
Histograms displaying the levels of CD1d in WT, CD1d-/- and in the different CD1d-
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floxed lines in the populations gated in (A). Bar charts show CD1d deletion efficacy 
and specificity for the different CD1d-floxed transgenic lines. Each dot represents a 
single mouse. Data are representative of two independent experiments. 
 
 In CD1dflox/floxCD11c-Cre+ mice, complete deletion of CD1d was observed in 
both CD8+ and CD11b+ DCs (Figure 5.11D), showing that CD11c-Cre is an 
effective tool to delete CD1d from DCs. In this case, CD1d deletion was also 
observed in around 10% of MHCII+CD11c- cells, indicating that other MHCII+ cells, 
probably splenic macrophages, also deleted CD1d in these mice (Figure 5.11D).  
 
Finally, in CD1dflox/floxLyz2-Cre+ mice, CD1d deletion was almost complete in 
CD11bintF4/80hi macrophages while around 60% deletion was observed in 
CD11bhiF4/80int macrophages and neutrophils (Figure 5.11E). Almost no deletion 
was observed in CD11b-F4/80- cells, highlighting the specificity of this Cre-line.  
 
In brief, I was able to generate four different transgenic lines in which CD1d 
was targeted to different immune cell populations. The generation of these new 
transgenic tools is of great value for the iNKT cell field as they provide an elegant 
system to study the role of various immune cells on homeostasis of iNKT cells and 
their regulation during infection, inflammation or autoimmune diseases.    
 
5.3.3 iNKT cell activation during infection requires CD1d expression on DCs 
As I now had these transgenic lines available, I went on to analyse the 
requirement of CD1d-dependent endogenous ligand presentation for iNKT cell 
activation in vivo. To analyse this, wild type and the various CD1d-transgenic mice 
were intranasally infected with 200 PFU of influenza virus. After 3 days of infection, 
mediastinal LNs were harvested and iNKT cell activation was measured by up-
regulation of CD69. Similar levels of CD69 were observed in wild type, 
CD1dflox/floxCD19Cre+ and CD1dflox/floxLyz2Cre+ mice following infection (Figure 
5.12). These results suggest that CD1d is not required on B cells and neutrophils to 
activate iNKT cells after influenza infection. In contrast, the levels of CD69 in iNKT 
cells were substantially decreased in CD1dflox/floxCD11cCre+ mice (Figure 5.12). 
This result demonstrates that in vivo activation of iNKT cells by DCs requires the 
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presentation of endogenous lipids in the context of CD1d. In future work, the 
production of IL-4 and IFN-γ will be assessed in these lines after infection. 
 
 
Figure 5.12 CD1d expression by DCs is required to complete iNKT cell activation 
Flow cytometry analysis of LN cell suspensions from wild type, CD1dflox/floxCD19-
Cre+, CD1dflox/floxLyz2-Cre+ and CD1dflox/floxCD11c-Cre+ mice 3 days after infection 
with 200 PFU of influenza virus. The levels of CD69 in TCRβ+ tetramer+ cells are 
shown on the histograms. Analysis of CD69 MFI and the percentage of CD69+ 
iNKT cells are shown on the bar charts. Each dot represents a single mouse. Data 
are representative of two independent experiments. Student t test, *p<0.05. 
 
5.4 CD103+ DCs are essential for iNKT cell activation  
During influenza infection, lung-resident DCs up regulate co-stimulatory 
molecules and cell surface chemokine receptors. In particular, CCR7 up regulation 
is essential for the migration of lung DCs to mediastinal LNs. Two different subsets 
of lung-resident DCs have the ability to migrate to draining LNs after infection or 
inflammation: CD103+ DCs and CD11b+ DCs. While CD103+ DCs are important for 
the early cross-presentation and priming of CD8+ T cell response, CD11b+ DCs 
function as antigen presenting cells for CD4+ T cells (del Rio et al., 2007, Neyt and 
Lambrecht, 2013).  
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5.4.1 Impaired iNKT cell activation in Batf3-/- and Langerin-DTR mice 
iNKT cell activation following influenza infection requires MyD88 and CD1d 
expression by DCs as shown in the previous paragraphs. For this reason I wanted 
to find out whether any of these two different subtypes of migratory DCs would 
preferentially activate iNKT cells following viral infection. CD103+ DCs depend on 
the expression of Batf3 for their development while CD11b+ DCs require CSF1 for 
their development and maintenance (Hildner et al., 2008, Hashimoto et al., 2011, 
Naik et al., 2015). Making use of this differential requirement for transcription or 
survival factors, I assessed the relative contribution of these two DC subsets to 
iNKT cell responses. Batf3-/- mice were used to target CD103+ DCs, as these mice 
lack CD103+ DCs in the lungs (Hildner et al., 2008). Moreover, the administration of 
Diphteria toxin to Langerin-DTR mice specifically depletes CD103+ DCs from the 
lungs, while the levels of CD11b+ DCs remain unaffected (Helft et al., 2012). 
Alternatively, MaFIA mice will be used in the future to target CD11b+ DCs, as they 
have an inducible Fas suicide system under the CSF1R promoter that induces 
apoptosis of CSF1R+ cells when AP20187 is administrated (Burnett et al., 2004).  
 
To assess the importance of CD103+ DCs on iNKT cell activation, wild type, 
Batf3-/- and Langerin-DTR mice previously injected i.p. on day -2 and -1 with 200ng 
of Diphteria toxin, were intranasally infected with 200 PFU. After 3 days, 
mediastinal LNs were harvested and analysis of DC populations and iNKT cell 
activation was performed by flow cytometry. Migratory DCs were gated as 
CD11cintMHCIIhi and this population was further separated into CD103+ and 
CD11b+ populations. Although CD11b+ DCs were observed in wild type, Batf3-/- and 
Langerin-DTR mice, the CD103+ population was completely lacking from Batf3-/- 
and Langerin-DTR mice, indicating that these two transgenic models are suitable 
for assessing the importance of CD103+ DCs in vivo (Figure 5.13A). Notably, while 
iNKT cells from wild type mice secrete high levels of IFN-γ and IL-4, this was 
dramatically decreased in Batf3-/- and Langerin-DTR mice (Figure 5.13B). This is a 
key result and demonstrates that CD103+ DCs are essential to induce iNKT cell 
activation in mediastinal LNs following influenza infection. The importance of 
CD11b+ DCs on iNKT cell activation will be addressed in the near future with the 
help of the MaFIA mice.   
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Figure 5.13 CD103+ DCs are essential for iNKT cell activation during viral 
infection 
(A) Flow cytometry analysis of LN cell suspensions from wild type, Batf3-/- and 
Langerin-DTR mice 3 days after infection with 200 PFU of influenza virus. 
Migratory DCs were gated as MHCIIhiCD11cint and further subdivided into CD103+ 
DCs and CD11b+ DCs. The percentage of CD103+ DCs in each strain is 
represented in the bar chart. (B) Flow cytometry analysis of IFN-γ secretion by 
iNKT cells from wild type, Batf3-/- and Langerin-DTR mice treated as in (A). The 
percentage of IFN-γ+ iNKT cells in each strain is shown in the bar chart. Each dot 
represents a single mouse. Data are representative of two independent 
experiments.  
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5.4.2 CD103+ DCs express high levels of IL-12 following infection 
I went on to compare different parameters related to iNKT cell activation on 
CD103+ and CD11b+ DCs to understand why CD103+ DCs are essential for this 
process. Differential expression of CD1d by CD103+ and CD11b+ seems not to be 
the reason as flow cytometry analysis indicates that both subsets express similar 
levels of CD1d on the surface (Figure 5.14A–B). I went on to analyse the 
expression of the enzymes involved in the production of endogenous glycolipids 
(Hexb and A3Galt2) in both DC subsets. For this, CD103+ and CD11b+ DCs were 
sorted from mediastinal LNs 3 days after influenza infection and RNA was 
extracted from them. Real time RT-PCR showed that the levels of Hexb and 
A3Galt2 were similar in both subsets (Figure 5.14C). This result indicates that there 
is no differential transcriptional regulation of the enzymes involved in the production 
of endogenous glycolipids in CD103+ and CD11b+ DCs. On the other hand, CD103+ 
DCs express much higher levels of IL-12 p40 compared to CD11b+ DCs (Figure 
5.14C). IL-12 has been shown to be necessary for the activation of iNKT cells in 
the absence of exogenous ligands. Therefore, CD103+ DCs might be essential for 
the activation of iNKT cells due to their ability to secrete high levels of IL-12.  
 
In the future it will be interesting to test the necessity of having MyD88 and 
CD1d expressed by CD103+ DCs for the activation of iNKT cells following influenza 
infection. For this reason, I generated mixed BM chimeras, in which CD45.1 
recipient mice were sub-lethally irradiated and received a) 80% Batf3-/- BM + 20% 
wild type BM, b) 80% Batf3-/- BM + 20% MyD88-/- or c) 80% Batf3-/- BM + 20% 
CD1d-/- BM. In this way, while most of the immune cells from these three different 
subsets of chimeras are reconstituted from the Batf3-/- BM, CD103+ DCs are 
reconstituted from a) wild type BM, b) MyD88-/- BM or c) CD1d-/- BM. Eight weeks 
after BM transplant, what will be after the submission of this thesis, I will infect 
these chimeras with 200 PFU of influenza virus and assess iNKT cell activation in 
mediastinal LNs. 
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Figure 5.14 CD103+ DCs express high levels of IL-12 p40 
(A) Gating strategy for migratory DCs (MHCIIhiCD11cint) and further subdivision into 
CD103+ DCs and CD11b+ DCs. (B) Flow cytometry analysis CD1d expression by 
CD103+ DCs and CD11b+ DCs before, and 3 days after, infection with 200 PFU of 
influenza virus. (C) RT-PCR analysis of sorted CD103+ DCs and CD11b+ DCs from 
mLNs of wild type mice that were infected with 200 PFU of influenza virus 3 days 
previously. Relative RNA levels of A3GALT2, HEXB and IL-12 p40 were 
normalised to the housekeeping gene CPH and were plotted in the bar charts as 
expression levels in CD103+ DCs relative to the mean level observed CD11b+ DCs. 
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Each dot represents a single mouse. Data are representative of two independent 
experiments.   
 
In summary, in this first part of the chapter I showed that iNKT cells are 
important for the effective clearance of influenza virus. Moreover, I demonstrated 
that iNKT cell activation in vivo requires MyD88-mediated signalling in DCs. 
Despite being MyD88-dependent, this process is independent of TLR signalling, 
suggesting a potential role of inflammasome derived IL-1 and IL-18 on this process. 
By generating new CD1d conditional knock out mice, I was also able to show that 
in vivo iNKT cell activation by DCs requires CD1d-dependent presentation of 
endogenous lipids. This process might be performed by a particular subset of DCs, 
CD103+ DCs. 
 
5.5 iNKT cells regulate antiviral GC response 
iNKT cells have been shown to regulate the B cell response to sphingolipid- 
bearing antigens. After immunisation with αGalCer-coated particles, B cells 
internalise and present these exogenous lipids in the context of CD1d to iNKT cells. 
iNKT cells then provide the help required for stimulating B cell proliferation and 
differentiation into extrafollicular plasma cells. These plasma cells mediate the 
production of high titers of specific IgM and early class-switched antibodies (Barral 
et al., 2008, Chang et al., 2012). As iNKT cells are essential to induce humoral 
response in the presence of exogenous glycolipids, I wondered whether they could 
also regulate the B cell response in the context of viral infections. 
 
5.5.1 iNKT cells are important for GC formation during viral infection 
To analyse the role of iNKT cells on the B cell response during viral 
infection, wild type and CD1d-/- mice were infected with 200 PFU of influenza virus. 
Nine days after infection, mediastinal LNs were harvested and the differentiation of 
B cells into GCs and CD4+ T cells into TfH cells were measured by flow cytometry. 
GC cells were detected as CD19+GL-7+CD95+ cells and T follicular helper cells 
were recognised as CD4+PD-1+CXCR-5+ cells. A considerable expansion of these 
populations was observed in wild type mice following influenza infection compared 
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to naïve animals (Figure 5.15A). In contrast, the formation of GC cells and Tfh cells 
were significantly reduced in mediastinal LNs from CD1d-/- animals compared to 
their wild type counterparts (Figure 5.15A). GC reactions are important for the 
generation of high-affinity class-switched antibodies specific for invading pathogens 
(Victora and Nussenzweig, 2012). I therefore went on to measure the levels of 
influenza-specific IgG levels in the serum of mice 9 days after influenza infection. In 
line with the impaired formation of GC cells, the blood levels of influenza-specific 
IgG were significantly reduced in CD1d-/- mice compared to wild type animals 
(Figure 5.15B). These results demonstrate that iNKT cells are important in the 
development of the GC response during influenza infection. 
 
Figure 5.15 CD1d-/- mice have impaired GC formation to influenza infection 
(A) Flow cytometry analysis of GC and Tfh cell formation in mediastinal LNs of wild 
type and CD1d-/- mice that were intranasally infected with 200 PFU of influenza 
virus 9 days before. Representative contour plots display the percentage of B220+ 
cells that are GL-7+Fas+ and CD4+ T cells that are CXCR-5+PD-1+. Bar charts 
display the quantification of GC cells and TfH cells in the different mice for a single 
experiment. (B) Serum levels of PR8-specific IgG measured by ELISA in mice 
treated as in (A). Each dot represents a single mouse. Data are representative of 
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two independent experiments. Mean ± s.e.m. Student t test, **p<0.01 and 
****p<0.0001. 
 
I wondered whether the importance of iNKT cells in the induction of the GC 
response was specific for the influenza virus or was a general feature of viral 
infections. I therefore decided to analyse the GC response in wild type and CD1d-/- 
mice during infection with another type of virus. Vaccinia virus was chosen as an 
alternative infection model due to its importance in the development of vaccines 
against smallpox, as immune responses generated from a vaccinia virus infection 
protects a person against potentially lethal smallpox infections. The vaccinia virus 
is a member of the Poxviridae family and its genome is comprised of double 
stranded DNA, very distantly related to single strand RNA viruses such as influenza 
(Walsh and Dolin, 2011). To this end, wild type and CD1d-/- mice were intranasally 
infected with 200 PFU of vaccinia virus and after 9 days, mediastinal LNs were 
harvested. The formation of GCs and TfH cells was assessed by flow cytometry. 
Following vaccinia virus infection, an expansion of GC and TfH cells was observed 
in wild type mice compared to non-infected animals (Figure 5.16). However, the 
formation of GCs was dramatically reduced in CD1d-/- animals compared to wild 
type animals (Figure 5.16). In this case, TfH cell formation remained unaffected. 
These results indicate that iNKT cells are general regulators of the GC reaction 
during viral infections.    
 
The previous results show that in the absence of iNKT cells, the 
development of the GC reaction during viral infections is compromised. I therefore 
wondered whether impaired activation of iNKT cells during infection would interfere 
with the correct development of the GC response. I previously showed that cognate 
interaction between DCs and iNKT cells is necessary for the complete activation of 
the later immune cells, as CD69 up regulation by iNKT cells is severely reduced in 
CD1dflox/flox CD11c-Cre+ following influenza infection. To test this, CD1dflox/flox 
CD11c-Cre- and Cre+ mice were intranasally infected with 200 PFU of influenza 
virus and mediastinal LNs were harvested 9 days later. GC response was analysed 
as previously by flow cytometry. Although a considerable expansion of GC B cells 
was observed in CD1dflox/flox CD11c-Cre- mice, the formation of GC cells was 
significantly decreased in CD1dflox/flox CD11c-Cre+ animals (Figure 5.17). This result 
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shows that impaired activation of iNKT cells during influenza infection interferes 
with the normal development of the GC response.       
    
Figure 5.16 CD1d-/- mice have impaired GC formation to vaccinia virus infection 
Flow cytometry analysis of GC and TfH cell formation in mediastinal LNs of wild 
type and CD1d-/- mice that were intranasally infected with 200 PFU of VACV 9 days 
before. Representative contour plots display the percentage of B220+ cells that are 
GL-7+Fas+ and CD4+ T cells that are CXCR-5+PD-1+. Bar charts display the 
quantification of GC B cells and TfH cells for a single experiment. Each dot 
represents a single mouse. Data are representative of two independent 
experiments. Mean ± s.e.m. Student t test, **p<0.01. 
 
 
Figure 5.17 CD1dflox/floxCD11c-Cre+ mice have impaired GC formation  
Flow cytometry analysis of GC and TfH cell formation in mediastinal LNs of 
CD1dflox/floxCD11c-Cre- and Cre+ mice that were intranasally infected with 200 PFU 
of influenza virus 9 days before. Representative contour plots display the 
percentage of B220+ cells that are GL-7+Fas+ and CD4+ T cells that are CXCR-
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5+PD-1+. Bar charts display the quantification of GC B cells and TfH cells. Each dot 
represents a single mouse. Data are representative of two independent 
experiments. Mean ± s.e.m. Student t test, *p<0.05. 
5.5.2 Cognate interaction between B cells and iNKTs is dispensable for the 
GC response during viral infection 
The previous data demonstrated that iNKT cells are important players in the 
GC reaction. How, then, do these innate-like T cells regulate the GC response 
during a viral infection?  
 
My first hypothesis was that during a viral infection, B cells would detect the 
presence of influenza virus through TLR-MyD88 and this would induce the 
presentation of endogenous glycolipids on CD1d. The presentation of endogenous 
ligands in the context of CD1d would recruit iNKT cells to provide the second signal 
necessary to complete B cell activation, proliferation and differentiation into GCs. 
To address whether cognate interaction between B cells and iNKT cells was 
necessary for GC formation, I prevented this potential interaction by specifically 
deleting CD1d on the B cell population. This was achieved by crossing CD1dflox/flox 
mice with mice expressing the Cre recombinase under the promoter of CD19 or 
Mb1. Wild type, CD1dflox/flox CD19-Cre+ and CD1dflox/flox Mb1-Cre+ mice were then 
intranasally infected with 200 PFU of influenza virus and mediastinal LNs were 
harvested after 9 days of infection. The formation of GC cells and TfH cells was 
similar in wild type, CD1dflox/flox CD19-Cre+ and CD1dflox/flox Mb1-Cre+ mice (Figure 
5.18A-B). This result is key as it demonstrates that cognate interaction between B 
cells and iNKT cells is not necessary for the GC reaction during viral infection. 
Therefore, iNKT cells are important in the GC reaction in the presence of pathogen-
derived glycolipids (Chang et al., 2012, King et al., 2012) and in the absence of 
exogenous glycolipids, as shown here. However, the mechanism behind iNKT cell 
regulation of GC formation is different in both cases. While cognate interaction 
between B cells and iNKT cells is required for the correct development of GCs in 
the presence of exogenous glycolipids (Chang et al., 2012, King et al., 2012), this 
interaction is dispensable during viral infections.  
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Figure 5.18 CD1dflox/floxCD19-Cre+ and Mb1-Cre+ mice display normal GCs 
Flow cytometry analysis of GC and TfHcell formation in mediastinal LNs from (A) 
CD1dflox/floxCD19-Cre- and Cre+ mice or (B) CD1dflox/floxMb1-Cre- and Cre+ mice that 
were intranasally infected with 200 PFU of influenza virus 9 days before. 
Representative contour plots display the percentage of B220+ cells that are GL-
7+Fas+ and of CD4+ T cells that are CXCR-5+PD-1+. Bar charts display the 
quantification of GC B cells and TfH cells. Each dot represents a single mouse. 
Data are representative of two independent experiments. Mean ± s.e.m.  
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5.5.3 Interaction between neutrophils and iNKT cells is dispensable for GC 
response 
During inflammation, neutrophils can mediate iNKT cell activation through 
CD1d presentation of endogenous ligands. Once activated, iNKT cells are able to 
induce a pro-inflammatory phenotype on these neutrophils (De Santo et al., 2010). 
Furthermore, activated neutrophils have been shown to potentiate B cell responses 
by producing BAFF (B cell activation factor), APRIL (a proliferation-inducing ligand) 
and IL-21 (Puga et al., 2011). To address whether iNKT-cell mediated activation of 
neutrophils could regulate GC response, I infected CD1dflox/flox Lyz2-Cre- and Cre+ 
mice with 200 PFU of influenza virus and mediastinal LNs were harvested 9 days 
later. GC response was analysed by flow cytometry. Surprisingly, a similar 
expansion of GC B cells and TfH cells was observed in CD1dflox/flox Lyz2-Cre- and 
Cre+ animals (Figure 5.19). This result indicates that cognate interaction between 
iNKT cells and neutrophils is dispensable for GC formation following influenza 
infection. iNKT cells therefore seem to promote B cell differentiation independently 
of neutrophils’ regulatory activity.   
 
 
Figure 5.19 CD1dflox/floxLyz2-Cre+ mice display normal GCs to influenza infection 
Flow cytometry analysis of GC and TfH cell formation in mediastinal LNs from 
CD1dflox/floxLyz2-Cre- and Cre+ mice that were intranasally infected with 200 PFU of 
influenza virus 9 days before. Representative contour plots display the percentage 
of B220+ cells that are GL-7+Fas+ and CD4+ T cells that are CXCR-5+PD-1+. Bar 
charts display the quantification of GC B cells and TfH cells. Each dot represents a 
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single mouse. Data are representative of two independent experiments. Mean ± 
s.e.m.  
 
5.5.4 iNKT cells produce high levels of IL-21 during influenza infection 
As iNKT cells regulate the GC response during viral infection independently 
of cognate interaction with B cells or neutrophils, I wondered whether they would 
help B cells to differentiate into GCs by producing specific cytokines. GC 
differentiation requires the presence of IL-21 to maintain high-level expression of 
Bcl-6. IL-21 is usually secreted by T follicular helper cells during an immune 
response (Zotos et al., 2010). However, when mice are immunised with synthetic 
glycosphingolipids, 10% of iNKT cells produce IL-21 by day 5 of immunisation 
(Chang et al., 2012, King et al., 2012). Moreover, when iNKT cells are stimulated in 
vitro with anti-CD3, anti-CD28 and IL-12, they begin production of IL-21 much 
faster than conventional CD4+ T cells (Coquet et al., 2007). Therefore I wondered 
whether iNKT cells produce IL-21 during viral infections and if this production 
provides the first IL-21 wave to induce GC formation. Wild type mice were 
intranasally infected with 200 PFU of influenza virus and after 9 days mediastinal 
LNs were harvested. Single cell suspensions were incubated for 4 hours with 
PMA/ionomycin at 37oC. Cells were then collected and stained with anti-TCRβ and 
PBS-57 loaded CD1d tetramer, fixed, permeabilised and intracellularly stained with 
anti-IL-21 antibody. Flow cytometry analysis revealed that 9 days after influenza 
infection, around 20% of iNKT cells produce IL-21 (Figure 5.20A). To further 
confirm the production of IL-21 by iNKT cells, TCRβ+ tetramer+ cells were sorted 
from mediastinal LNs 9 days after intranasal administration of PBS (control) or 200 
PFU of influenza virus. RNA was extracted from sorted cells and real-time RT-PCR 
was performed to quantify the levels of IL-21. CPH gene was used as a 
housekeeping gene for normalisation. RT-PCR analysis revealed that IL-21 
production by iNKT cells increases around 16-fold following influenza infection 
(Figure 5.20B). All together, these results show that iNKT cells produce high levels 
of IL-21 after viral infection even in the absence of exogenous glycosphingolipids.    
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Figure 5.20 iNKT cells secrete IL-21 following influenza infection 
(A) Flow cytometry analysis of LN cell suspensions from control mice and mice that 
were infected with 200 PFU of influenza virus 9 days before. IL-21 secretion by 
iNKT cells is depicted in the dot plots. The percentage of IL-21+ iNKT cells before 
and after infection is shown in the bar chart. (B) RT-PCR analysis of sorted iNKT 
cells from mLNs of wild type mice that were left untreated or infected with 200 PFU 
of influenza virus 9 days previously. Relative RNA levels of IL-21 were normalised 
to CPH and were plotted in the bar charts as expression levels relative to the mean 
level of non-immunised mice. Each dot represents a single mouse. Data are 
representative of two independent experiments. Mean ± s.e.m. Student t test, 
*p<0.05.  
 
To analyse whether IL-21 secretion by iNKT cells is necessary for the 
development of GCs following influenza infection, I went on to generate mixed BM 
chimeras, where iNKT cells are IL-21-/- while other immune cells are able to 
produce IL-21. For this, Rag2-/- mice were sub lethally irradiated and injected with: 
a) 80% Jα18-/- BM + 20% wild type BM or b) 80% Jα18-/- BM + 20% IL-21-/- BM. As 
Jα18-/- BMs are not able to generate iNKT cells, all the iNKT cells from these 
chimeras would come from a) wild type or b) IL-21-/- donors. Eight weeks of after 
reconstitution these mice will be intranasally infected with 200 PFU of influenza and 
9 days later the formation of GCs will be assessed in mediastinal LNs. This 
experimental setup will allow me to dissect the importance of iNKT cell-derived IL-
21 on GC formation following viral infection. 
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5.6 Discussion 
iNKT cells influence the activity of many other cell types through the 
production of a broad range of cytokines, chemokines and surface molecules. 
Furthermore, the interactions between iNKT cells and their CD1d-expressing 
partners are at the core of the ability of iNKT cells to orchestrate immune 
responses (Brennan, Brigl and Brenner, 2013). In this chapter I have shown that 
iNKT cells are important for the clearance of influenza virus from the lungs. Early 
iNKT cell activation in mediastinal LNs is mediated by CD103+ DCs, a subset of 
pulmonary DCs specialised in cross-presentation. This process requires MyD88-
signalling in DCs and the subsequent presentation of CD1d-loaded endogenous 
lipids; however, it does not require TLR recognition of influenza. Importantly, the 
presence of iNKT cells and their correct activation are necessary to induce GC 
formation and virus-specific antibodies after infection. Even though this process 
does not require cognate interaction between B cells and iNKT cells through CD1d, 
iNKT cells might support the initial development of GCs through the production of 
IL-21 (Figure 5.21).   
 
The functional plasticity of iNKT cells, combined with their ability to modulate 
the activation of other immune cell subsets, makes them important in controlling the 
course of an infection (Juno, Keynan and Fowke, 2012). Here, I showed that iNKT 
cells are needed for the clearance of influenza virus, as iNKT cell-deficient animals 
display significantly higher levels of viral NP1 RNA levels in the lungs compared to 
wild type mice. This inability to control viral replication correlates with high levels of 
inflammatory cytokines (IFN-γ and IL-6) in the blood and lungs. These observations 
are in line with previous work by Cerundolo and colleagues, who showed that 
infection with high doses of influenza virus results in higher viral titres and 
increased mortality of iNKT cell-deficient animals (De Santo et al., 2008). 
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Figure 5.21 iNKT cells: linking innate and adaptive immunity to infection 
Proposed model for the activation of iNKT cells in mediastinal LNs by pulmonary 
DCs and their importance in GC formation and antibody production to viral 
pathogens. 
 
 
Due to the essential role of iNKT cells in not only the clearance of influenza 
but also of HSV (herpes simplex virus), MCMV (mouse cytomegalovirus) and RSV 
(respiratory syncytial virus) during infection (Juno, Keynan and Fowke, 2012), it is 
important to define the process of iNKT cell activation during viral challenges. The 
understanding of this process has been somewhat limited due to the restricted 
availability of tools to address these types of questions in vivo. I found that iNKT 
cell activation occurs very early during influenza infection and results in CD69 up-
regulation and the secretion of IFN-γ and IL-4. Through the generation of different 
transgenic lines, I determined that CD1d-mediated presentation of endogenous 
lipids by DCs is essential for iNKT cell activation in draining LNs. In contrast, CD1d 
expression by B cells or neutrophils is not necessary for this process. Importantly, 
the induction of endogenous lipid presentation by DCs requires MyD88-mediated 
signalling. The general concept is that TLR signalling through MyD88 in antigen 
presenting cells is necessary to induce iNKT cell activation (Mattner et al., 2005). 
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However, I found that even though MyD88 expression by DCs is required for iNKT 
cell activation, TLR recognition of the influenza virus is not necessary. These 
observations raise the possibility that other receptors that signal through MyD88 
might be involved in CD1d-mediated presentation of endogenous lipids in vivo. 
 
As previously mentioned, MyD88 is a common adaptor for TLRs, IL-1R and 
IL-18R (Adachi et al., 1998). After influenza infection, lung immune and 
parenchyma cells release high levels of the inflammatory cytokines IL-1 and IL-18 
through the activation of the inflammasome complex (Ichinohe et al., 2009, Thomas 
et al., 2009, Ichinohe, Pang and Iwasaki, 2010). It is conceivable, therefore, that IL-
1 or IL-18 signalling on lung-resident DCs may induce CD1d-mediated presentation 
of endogenous lipids to iNKTs independently of TLR7 recognition of influenza. 
Interestingly, IL-1R signalling in DCs was shown to replace TLRs in promoting 
CD8+ T cell responses to the influenza virus (Pang, Ichinohe and Iwasaki, 2013). It 
is therefore key to analyse iNKT cell activation in the absence of IL-1R and IL-18R 
signalling to understand their contribution to CD1d-mediated presentation of 
endogenous lipids by DCs. Furthermore, it would be interesting to analyse iNKT 
cell activation in the context of defective inflammasome activity in the lungs, which 
results in the abrogation of IL-1 and IL-18 production after influenza infection 
(Ichinohe et al., 2009, Thomas et al., 2009). To address these questions, I am in 
the process of acquiring IL-1R, IL-18R, Caspase-1 and ASC-deficient animals.  
 
After infection with influenza, DCs mediate the cognate activation of iNKT 
cells in mediastinal LNs. Two main subsets of pulmonary DCs, known as 
CD103+ and CD11b+ DCs, migrate to mediastinal LNs after influenza infection 
(Braciale, Sun and Kim, 2012). CD103+ DCs, which reach maximum numbers 
between two to four days after influenza infection, serve as the most potent antigen 
presenting cells for CD8+ T cells (Helft et al., 2012). In contrast, CD11b+ DCs reach 
peak numbers at later time points, between five to seven days after influenza 
infection, and may act to expand the pool size of previously activated effector 
CD8+ T cells (Ballesteros-Tato et al., 2010). Both DC subsets also efficiently 
activate naive virus-specific CD4+ T cells (Braciale, Sun and Kim, 2012). In this 
chapter, I showed that CD103+ DCs are essential to induce early IFN-γ production 
by iNKT cells. Importantly, as the transgenic mouse lines used to target CD103+ 
233 
DCs, Batf3-/- and Langerin-DTR, also affect LN resident CD8+ DCs, it will be 
important for future studies to compare the contribution of migratory CD103+ DCs 
versus resident CD8+ DCs. In this case, the use of CCR7-/- mice would be useful to 
discern the importance of both populations as in the absence of CCR7, CD103+ 
DCs do not migrate to the LNs (Ohl et al., 2004). Furthermore, to analyse the role 
of CD11b+ DCs on iNKT cell activation I will use MaFIA mice, which express an 
inducible Fas suicide system under the CSF1R promoter that induces apoptosis of 
CSF1R+ cells (Burnett et al., 2004).  
 
The reason why CD103+ DCs play an essential role in iNKT cell activation 
remains to be investigated; although, it might be due to their early migration to the 
LNs (Ballesteros-Tato et al., 2010). While this first wave of CD103+ DCs arrival is 
essential for the early activation of iNKT cells, the later arrival of CD11b+ DCs might 
serve to provide further signals and expand the previous pool of cells as occurs 
with CD8+ T cells (Ballesteros-Tato et al., 2010). Furthermore, it could be possible 
that CD103+ DCs are specialised in presenting endogenous lipids on CD1d by 
expressing high levels of the enzymes involved in their biosynthesis. I measured 
the RNA levels of different enzymes involved in this process; however, their levels 
did not differ between CD103+ and CD11b+ subsets. In the future, it will be 
interesting to measure the activity of these enzymes in these two subsets and not 
only their RNA or protein levels. Even though both subsets express the same levels 
of surface CD1d, CD103+ DCs produce higher levels of IL-12 compared to CD11b+ 
DCs. As IL-12 is key for iNKT cell activation in the absence of exogenous 
glycolipids (Brigl et al., 2003), this would explain why CD103+ DCs are so important 
for iNKT cell activation. Interestingly, CD103+ DCs do not express TLR7; the only 
TLR involved in the recognition of influenza in mice (Diebold et al., 2004). This 
might explain why iNKT cell activation is independent of TLR signalling after 
influenza infection. It is then possible that IL-1 and/or IL-18 signalling through 
MyD88 in CD103+ DCs induces the presentation of lipid antigens to iNKT cells in 
the context of CD1d. 
 
The presence of iNKT cells and their correct activation by DCs in 
mediastinal LNs are important for B cell formation of GCs and the production of 
influenza-specific antibodies. Importantly, the ability of iNKT cells to regulate GC 
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responses is not specific to influenza virus but seems to be a general characteristic 
of viral infections, as GC formation in response to VACV infection is severally 
impaired in iNKT cell-deficient mice. Previous studies showed that after 
immunisation with α-GalCer, iNKT cells support GC development by providing 
cognate help to B cells through CD1d—TCR direct interaction and the production of 
IL-21 (Chang et al., 2012, King et al., 2012). However, the help provided by iNKT 
cells to B cells during influenza infection is non-cognate, as specific deletion of 
CD1d in B cells does not interfere with the GC development.  
 
The mechanism by which iNKT cells regulate GC development in response 
to viral infection remains to be defined. I found that iNKT cells produce high levels 
of IL-21 after influenza infection. As the production of cytokines by iNKT cells is 
faster than the conventional CD4+ T cells (Coquet et al., 2007), they might provide 
the first wave of IL-21 to induce B cell differentiation into GCs. Furthermore, it is 
possible that iNKT cells relocate to GCs after infection, where they might provide 
surviving signals such as BAFF or APRIL (Coquet et al., 2008) to support the GC 
response. In fact, a previous study showed the presence of iNKT cells in the GC 
after immunisation with glycosphingolipids (Chang et al., 2012).  
 
It is also conceivable that iNKT cells regulate GC response in an indirect 
way. For example, iNKT cells inhibit the suppressor activity of MDSCs after 
influenza infection, supporting T cell proliferation (De Santo et al., 2008). It is then 
possible that the inhibition of MDSCs by iNKT cells may also support the high 
levels of B cell proliferation in the GCs. Furthermore, regulatory iNKT cells have 
been shown to induce an anti-inflammatory phenotype in adipose tissue- 
macrophages through the production of IL-10 (Lynch et al., 2015). This anti-
inflammatory phenotype includes the production of arginase-1, which resembles 
the suppressor activity of MDSCs. It might be then possible that the IFN-γ 
production by iNKT during influenza infection would turn SCS macrophages 
towards an inflammatory phenotype instead of an anti-inflammatory one. As SCS 
macrophages are in close contact with B cells, their production of inflammatory 
signals may support B cell proliferation and differentiation into GCs. In the future, it 
would be interesting to analyse the regulation of MDSCs and SCS macrophages by 
iNKT cells and the importance of these axis in the regulation of the B cell response. 
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Concluding remarks 
B cells are key players of the immune system due to their exceptional ability 
to produce pathogen-specific antibodies. These antibodies mediate the clearance 
of infectious agents through neutralisation or induction of different effector functions. 
The activation of B cells and their differentiation into antibody-producing cells are 
highly regulated processes. Therefore, many factors can shape the outcome of the   
B cell response during infection.  
 
In the present thesis I found that an intact layer of macrophages at the LN 
SCS is required to initiate B cell responses after localised infection. Importantly, the 
integrity of this layer in draining LNs is compromised after primary infection or 
inflammation, resulting in the impairment of B cells to respond to subsequent 
incoming pathogens. This temporary shutdown of the B cell response increases the 
organism’s susceptibility to secondary infections. Furthermore, I found that B cell 
recognition of pathogens through the BCR or TLRs induces the formation of 
autophagosomes. Interestingly, the induction of this process in B cells is unique, as 
it is strictly dependent on the PLCγ2 pathway and does not require ULK proteins, 
as other cell types do. These organelles might play an important role in antigen 
presentation, as antigen localises in close contact to autophagosomes after 
internalisation. Finally, I found that iNKT cell activation is required for GC formation 
and antibody production after respiratory viral infection. Early iNKT cell activation in 
the LNs is mediated by pulmonary CD103+ DCs, which present CD1d-loaded 
endogenous lipids to iNKT cells after induction of MyD88-signalling. 
 
I believe that the data presented here contribute to the understanding of how 
B cells operate in vivo during pathogenic challenges. 
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